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General introduction 
 
 
 
 
 
 
 
 
     Figure 1:  DNA-Zinc finger complex (Pavletich, N. P.,  et al., Science 1991, 252, 809; Sera, T., et al. Biochemistry 2002, 41, 7074). 
 
Constructing Functional Molecules by Using Biopolymers  
The production system employed by living organisms is the most basic system for supplying the 
materials that we utilize, yet the efficiency, the variety and the versatility of this system remain 
untapped. Attempts to harness these systems directly or to imitate, reproduce and improve them by 
means of artificial materials is one of the world’s supreme propositions; various strategies for 
constructing the requisite functional molecules have been developed.
1-37
 In particular, a number of 
unique methods with the capability to utilize the features of bio-systems have been already established 
in the construction of functional biopolymers, in which the “life phenomenon” is controlled by the 
function of the biopolymer. This system has been applied to the field of energy and material production 
as well as the medical and food production fields by exploiting the catalytic activity of enzymes and the 
chemical properties of nucleic acids that bear the preservation and the mediation of genetic codes. 
Natural biopolymers utilize the individual function of thousands of enzymes and behave as an 
organization by the cooperation of each supermolecule, even though the constituent molecules are 
constructed by very simple elements and monomers based on carbon, hydrogen, nitrogen, oxygen, 
phosphorus and sulfur.  In other words, there is the potential for constructing various molecules with 
excellent functionalities by assembling very simple elements and components.  
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Methods for constructing functional biopolymers  
The substrate selectivity and the specificity of enzymatic reactions are important parameters that are 
difficult to design and reproduce using artificial catalysts and attempts to obtain feedback based on the 
information garnered by clarification of the structure-activity relationship of the native enzymes have 
been applied to the design of the desired functional materials. Site-specific mutation of the native 
enzyme based on the insight provided by molecular chemistry and three-dimensional structural 
information is often utilized as a representative method for the construction of functional biopolymers 
(structure-based design). Moreover, construction of functional biopolymers or ligands by 
computational design, including de novo design, which utilizes a simulation based on molecular 
dynamics calculations and information from a database of the relationship between the amino acid 
sequence and the folding of the native protein has been performed. However, the applicability of  these 
methods is still limited because of the database restrictions on the structure of biopolymers and the 
calculation method; consequently, the constructed molecule often does not have the originally designed 
function. On the other hand, there is a method in which the improvement and modification of the 
enzymatic activity of the native enzyme can be achieved by introducing a random mutation into the 
part of the enzyme that is difficult to design based on the structural information (directed evolution 
method).
4-9
 This method does not require structural information for the part of the molecule where the 
random mutation is introduced, moreover, mutations that are burdensome to be estimated from the 
structural set of information may be obtained. However, in many cases, it is challenging modifying the 
activity of the original enzyme dynamically and, nowadays, the application of this method is limited. In 
addition, another approach has been developed, in which the target molecule is isolated based on some 
indexes, such as the affinity for the target molecule or the activity of the target reaction, from a library 
composed of various molecules constructed by introducing the randomized component (combinatorial 
chemistry). In vitro selection or SELEX (systematic evolution of ligands by exponential enrichment) 
that utilizes a nucleic acid library,
10-11
 phage display,
12
 ribosome display,
13
 mRNA display,
15-18
 as well 
as emulsion techniques (in vitro compartmentalization)
19-22
 that operates using protein and peptide 
libraries, the split and mix method,
23-26
 which employs solid phase synthesis by the use of resins, have 
been established as representative methods for realizing this concept. Nevertheless, it is difficult to 
decide in advance what setup of the selection biases enables construction of the molecule that has the 
desired function and restriction of the library size compared to the ideal diversity of molecules that can 
be estimated. Besides, en efficient method for the sequential construction of polymers by means of 
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organic synthesis is necessary when the artificial materials are utilized as components. It is very 
difficult selecting the relevant synthetic approaches and solving the issues related to the purity of 
products and the design of the template molecule or monomer that becomes the scaffold for the library 
construction. Biopolymers represent a potential means of solving these problems considering that they 
have the advantage of being more adaptable to library construction and selection compared to artificial 
molecules, thanks to the limited number of monomers in the biopolymer and the high purity level of the 
product as a result of the reaction specificity of enzymes. In addition, the characteristic of amplification 
that cannot be achieved in a conventional artificial molecule can be conveniently realized. 
Conventional methods mainly utilize the affinity for the target compound as an index, but when the 
activity is assumed as an index, it becomes necessary to edit other design parameter individually. These 
methods ultimately lead to the concept in which the entire envisioned molecule is constructed and the 
functions evaluated one by one. However, an exceptional technical breakthrough would be necessary 
for the achievement of this concept because the exhaustive examination of all the possibilities is 
laborious to be executed. Recently, the development of the single molecule and single substance 
measurement technique has emerged. For example, the use of the micro flow channel of the cell sorter, 
affords a novel selection method.
27-30
 Though only just burgeoning, and although a number of 
evaluations will be necessary in order to achieve generality and practicality, the creation or the 
maturation of a novel method for constructing functional molecules by using measurements or 
detection and chemical synthesis technologies, that differ from the currently employed concepts, is 
anticipated.
31,32
  
Objectives of this work of thesis 
In the work of my thesis I attempted making a new step forward a better knowledge of protein-nucleic 
acid biopolymers, focusing on two complexes of strong interest. One of the important factors for 
determining the expression of the function is the structure of the biopolymer. Clarification of the 
relationship between the structure and the function of biopolymer is of crucial importance to the 
development of methods for constructing tailor-made functional molecules. The first goal of my thesis 
focalized on the obtainment of a structural model of a well-known protein-DNA complex: Maf DNA 
binding domain and it DNA target (T-MARE was used in this study) with the aim of outlining a 
strategy for the obtainment of activity modulators. Both in silico simulations and experimental studies 
were carried out leading to the definition of a modus-operandi based on a disorder-order transition of 
the complex which is commendatory for the protein activation. On the other hand, a number of 
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artificial enzymes have been recently constructed by using the molecular design based on structural 
information, screening methods that utilize libraries or by a combination of these two methods. 
However, the above mentioned approaches use single proteins or single nucleic acid as the structural 
unit, and the activity of the constructed artificial enzymes is remarkably lower in many cases, than that 
of the native enzymes. The construction of functional complexes (rather than a single biopolymer) as 
scaffold can be considered as one potential solution to these drawbacks. Further in my studies, using 
the HIV-Rev peptide and RRE (Rev Responsive Element) RNA complex as a scaffold, for which the 
tridimensional structure was fully characterized, the assemble of ribonucleopeptidic fluorescent sensors 
was accomplished in a stepwise manner.
 
In this method, a randomized nucleotide sequence was 
introduced into the RNA subunit of RNP to construct a RNP library on which the in vitro selection 
method was applied.
33-38
 In the second step, the Rev peptide was modified with the fluorophore without 
altering the affinity and specificity of the RNP receptor.
39
 In the absence of a ligand for RNP, 
fluorescence emission was effectively quenched in the RNP complex, but recovered upon ligand 
binding. RNP sensors were thus created, as the ligand-binding event can be monitored by measurement 
of the fluorescence signals. 
  
 
 
 
 
 
 
 
 
 
 
11 
 
References 
1) Damborsky, J., and Brezovsky, J., Curr. Opin. Chem. Biol. 2009, 13, 26-34. 
2) Chica, R. A., Doucet, N., and Pelletier, J. N., Curr. Opin. Biotech. 2005, 16, 378.384. 
3) Bolon, D. N., Voigt, C. A., and Mayo, S. L., Curr. Opin. Chem. Biol. 2002, 6, 125-129. 
4) May, O., Nguyen, P.T., and Arnold, F. H., Nat. Biotech. 2000, 18, 317-320. 
5) Moore, J. C., and Arnold, F. H., Nat. Biotech. 1996, 14, 458-467. 
6) Altamirano, M. M., Balckburn, J. M., Aguayo, C., and Fersht, A. R., Nature 2000, 403, 417-468. 
7) Xia, D., Chen, L., Sera, T., Fa, M., Schults, P.G., and Romesberg, F. E., Proc. Natl. Acad. Sci. USA 
2002, 99, 6597-6602. 
8) Bittler, J. A., Le, B. V., Liu, J. M., and Liu, D. R., Proc. Natl. Acad. Sci. USA 2004, 101, 7011-
7016. 
9) Schmidt-Dannert, C., Umeno, D., and Arnold, F. H., Nat. Biotech. 2000, 18, 750-753. 
10)  Elligton, A. D., and Szostak, J. W., Nature 1990, 346, 818-822. 
11) Tuerk, C., and Gold, L., Science 1990, 246, 505-510. 
12) Smith, G. P., Science 1985, 228, 1315-1317. 
13) Mattheakis, L. C., Bhatt, R. R., and Dower, W. J., Proc. Natl. Acad. Sci. USA 1994, 91, 9022-9026. 
14) Hanes, J., and Plückthun, A., Proc. Natl. Acad. Sci. USA 1997, 94, 4937-4942. 
15) Nemoto, N., Miyamoto-Sato, E., Husimi, Y., and Yanagawa, H., FEBS Lett. 1997, 414, 405-408. 
16) Roberts, R. W., and Szostak, J. W., Proc. Natl. Acad. Sci. USA 1997, 94, 12297-12302. 
17) Keefe, A. D., and Szostak, J. W., Nature 2001, 410, 715-718. 
18) Tabuchi, I., Soramoto, S., Nemoto, N., and Husimi, Y., FEBS Lett. 2001, 508, 309-312. 
19) Tawfic, D. S., and Griffiths, A. D., Nat. Biotechnol. 1998, 7, 652-656. 
20) Agresti, J. J., Kelly, B. T., Jaschke, A., and Griffiths, A. D., Proc. Natl. Acad. Sci. USA 2005, 102, 
16170-16175. 
21) Bernath, K., Hai, M., Mastrobattista, E., Griffiths, A. D., Magdassi, S., and Tawfik, D. S., Anal. 
Biochem. 2004, 325, 151-157. 
22) Doi, N, and Yanagawa, H., FEBS Lett. 1999, 457, 227-230. 
23) Furuka, A., Sebestyen, F., Asgedon, M., and Dibo, G. J., Pept. Protein Res., 1991, 37, 487-493. 
24) Lam, K. S., Salmon, S.E., Hersh, E. M., Hruby, V. J., Kazmierski, W. M., Knapp, R. J., Nature 
1991, 354, 82-84. 
12 
 
25) Houghten, R. A., Pinilla, C., Blondelle, S. E., Appel, J. R., Dooley, C. T., Cuervo, J. H., Nature 
1991, 354, 84-86. 
26) Tabuchi, I., Soramoto, S., Ueno, S., and Husimi, Y., BMC Biotech.2004, 4, 19-26. 
27) Sepp, A., Tawfik, D. S., and Griffiths, A.D., FEBS Lett. 2002, 532, 455-458. 
28) Ohuchi, S., Nakano, H., and Yamane, T., Nucleic Acids Res. 1998, 26, 4339-4346. 
29) Nakano, H., Koyabashi, K., Ohuchi, S., Sekiguchi, S., and Yamane, T. J., Biosci. Bioeng. 2000, 90, 
456-458. 
30) Granieri, L., Barnet, J. C., Griffiths, A. D., and Merten, C. A., Chem. Biol. 2010,17, 229-235. 
31) Mendousa, S. D., and Bowser, M. T., J. Am. Chem. Soc. 2004, 126, 20-21. 
32) Wassenaar, J., Jansen, E., Zeist, W. J., Bickelhaupt, F. M., Siegler, M. A., Spek, A. L., Reek, J. N. 
H., Nature Chemistry, 2010, 2, 417-421. 
33) Morii, T., Hagihara, M., Sato, S., and Makino, K., J. Am. Chem. Soc. 2002, 124, 4617-4622. 
34) Sato, S., Fukuda, M., Hagihara, M., Tanabe, Y., Ohkubo, K., and Morii, T., J. Am. Chem. Soc. 2005, 
127, 30-31. 
35) Hagihara, M., Fukuda, M., Hasegawa, T., and Morii, T., J. Am. Chem. Soc. 2006, 128, 12932-
12940. 
36) Hasegawa, T., Hagihara, M., Fukuda, M., Nakano, S., Fujieda, N., and Morii, T., Nucleosides 
Nucleotides Nucleic Acids 2007, 26, 1277-1281. 
37) Hasegawa, T., Hagihara, M., Fukuda, M., Nakano, S., Fujieda, N., and Morii, T., J. Am. Chem. Soc. 
2008, 130, 8804-8812. 
38) Hasegawa, T., Ohkubo, K., Yoshikawa, S., and Morii, T., e-J. Surf. Sci. Nanotech. 2005, 3, 33-37. 
39) Battiste, J.L., Mao, H., Rao, N. S., Muhandiram, D. R., Kay, L. E., Frankel, A. D.,  and Williamson, 
J. R., Science 1996, 273, 1547-1551. 
 
 
 
 
 
 
13 
 
Chapter 1: 
Maf proteins: an insight into their DNA binding 
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1.1. Introduction 
 
1.1.1. Disorder-order transitions in transcription factors 
A deeply understanding of how transcription factors interact with genomic target sites is crucial for 
reconstructing transcriptional networks in vitro. In particular, in recent years, great attention has been 
paid to structural and functional intrinsic disorder inside the cell.
1
 The occurrence of unstructured 
regions of significant size (>50 residues) is surprisingly common in functional proteins.
2,3
 In addition, 
the existence of functional unstructured proteins, for example, polypeptide hormones,
4
 has been 
recognized for many years, and unstructured proteins were observed in intact cells in early proton 
NMR experiments.
5
 However, the functional role of intrinsically disordered proteins in crucial areas 
such as transcriptional regulation, translation and cellular signal transduction
6-9
 has only recently been 
recognized, as a consequence of the use of new paradigms in biochemical methodology.
10
 Intrinsic 
disorder (ID) regions promote molecular recognition primarily through four features.
11
 ID proteins of 
ID regions are characterized by the unique combination of high specificity and low affinity in their 
interactions with functional partners, which is very important for transient protein-protein and protein-
nucleic acids interactions, such as those that frequently occur during the signal transduction, 
recognition, and regulation events. Intrinsic plasticity enables a single ID protein or region to recognize 
and bind many biological targets with high specificity.
12-15
 The ID protein or region have the propensity 
to form large interaction surfaces allowing them to wrap-up or surround their binding partners.
12, 16,17
 
The rapid turnover and reduced lifetime of ID proteins in cells might represent an important regulatory 
mechanism.
18
 These observations have particular importance to the basic leucine zipper (b-LZ) class of 
transcription factors, whose activity relies on disorder–order transitions of their DNA binding domains 
(DBD) for speciﬁc dimerization and DNA binding.19 The basic leucine zipper (bZIP) proteins form one 
of the largest families of eukaryotic transcription factors and play roles in a wide variety of biological 
phenomena, from responding to endoplasmic reticulum (ER) dysfunction to regulating immune 
responses and oncogenesis.
19
 Members of this superfamily contain a positively charged DNA binding 
region composed of basic residues linked to a leucine zipper sequence and homo- or hetero-dimerize 
via this leucine zipper. Although considered to be the simplest known protein-DNA recognition motif, 
crystal structures of bZIP domains bound to DNA have revealed functional variability in how these 
conserved residues contact DNA, and no universal code linking basic region sequence with target DNA 
preferences has been developed. Within b-LZs, Maf proteins represent a new paradigm for DNA 
binding speciﬁcity as they recognize a long palindromic DNA sequence (known as Maf recognition 
15 
 
element, MARE) which is composed by a core and a ﬂanking region.1,20 In order to acquire a deeper 
knowledge regarding b-LZ proteins disorder-order transitions, in this chapter we will focus on the in 
silico conformational studies performed on c-Maf, obtained generating first an homology model and 
subsequently, carrying out molecular dynamics simulations.  
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1.2. Maf proteins: discovery, functions and structural motifs 
 
1.2.1. Physiological roles of Maf proteins 
The Maf transcription factors belong to the AP1 super-family of basic leucine zipper (bZIP) proteins, 
which also includes Fos, Jun, CREB and ATF families (Figure 2).  
 
 
 
 
 
 
 
 
 
Figure 2: An unrooted phylogenic tree of the AP1 family of proteins. The tree was drawn using a CLUSTALW alignment algorithm at 
the National Laboratory for Computational Science and Engineering at the University of California, San Diego. Where 
available, Caenorhabditis elegans and Drosophila  melanogaster orthologues were included. 
 
The Maf family derives its name from the founding member, v-maf, that was originally discovered as 
the transduced transforming component of avian musculoaponeurotic fibrosarcoma virus, AS42.
1
 
Subsequent studies identified the cellular homolog of this gene, c-maf, from which the v-maf oncogene 
was originally transduced
2
 but in addition, C-maf was found to be but one member of an extended 
multigene family.
3
 Nowadays, the codifying genes for Maf family members has been isolated both in 
vertebrates (mammals, birds, frogs, fishes) and in invertebrates (drosophila)
3,4
 (Figure 3). 
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                                                           Figure 3:    Maf family members identified in different species 
Products of the maf proto-oncogene and related family members (the Maf family proteins) share a 
common, relatively well-conserved basic region and leucine zipper (b-Zip) motif which mediate DNA 
binding and dimer formation (Figure 4).
5
  
 
 
 
 
 
 
 
 
 
                                                                             Figure 4: b-ZIP motif of Maf family members. 
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Seven members of the Maf family have been reported and were subdivided into two groups depending 
on their molecular weight: large Mafs (MafA, MafB, C-Maf and NRL, 26-39kDa) which have a 
putative transactivation domain at their N-termini, and small Mafs (MafF, MafG and MafK, 17-18kDa)  
which lack of such a domain (Figure 5).
5-8
  
 
Figure 5: A comparison of large and small Maf transcription factors. The modular structure of the large and small Maf bZIP transcription 
factors with their respective functional domains is shown.  
 
Mafs family proteins play important roles in cellular differentiation and morphogenesis, and their 
unique functions seem to be determined by their selective dimerization and DNA-binding specificity.
9
 
Large Maf proteins can activate transcription by recruiting the co-activators p300 (EP300), CRE 
binding protein (CBP, also known as CREBBP)
10
 and P/CAF (also known as KAT2B)
11
 or the TATA 
binding protein TBP.
12
  Lacking the transactivation domain, small Mafs homodimers are not able to 
activate transcription, nevertheless, they are known to repress transcription
13,14
 by competing, notably 
with large Maf proteins, for binding to target gene promoters.
15
 Therefore, the ratio between small Maf 
homodimers and large Maf-containing complexes might have important biological consequences.
9,16
 
On the other hand, small Mafs can form heterodimers with other LZP transcription factors. For 
example, they are known to dimerize with p45 (the large subunit of the nuclear factor-erythroid 2, NF-
E2) to activate erythroid cell-specific transcription. In addition, as dimeric partners of the bZIP NF-
E2/Nrf family, small Maf proteins might contribute to oncogenic processes by participating in 
antioxidant response (Figure 6).
5-8 
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 Figure 6: Small Maf protein network. The small Maf proteins are embedded in a regulatory network that is essential for various cellular 
functions, including the response to stress. The expression of small Maf genes can be modified by diverse reagents or conditions. The 
proteins may be modified post-translationally through acetylation or sumoylation (shown for MafG only). The small Mafs are able to 
dimerize with CNC or other bZIP factors via their leucine zipper domain. The resulting hetero- and homodimers bind to MARE 
sequences or similar motifs regulating, for example, stress response genes. The small Mafs have been shown to interact with Hox proteins, 
but the functional significance of these interactions is not known. 
 
The large Maf genes display a restricted expression pattern
15,16
 and, in contrast to JUN, Fos and other 
nuclear oncogenes, Maf genes do not behave as immediate early genes.
17
 The expression of large Maf 
genes is tightly regulated in a spatio-temporal manner during development,
18,19
 and, although these 
genes display some overlap in their expression profile, different members can be expressed in a specific 
window of time in a developing tissue.
9
 This is exemplified in the lens and pancreas, where a cascade 
of expression of large Maf genes is observed. Therefore, the expression of the preceding gene could be 
21 
 
directly involved in the expression of the next gene in the cascade. Loss of function mutations in mice 
showed that large Maf genes are involved early in tissue specification,
20
 and later in terminal 
differentiation (Table 1). within a given tissue, their roles appear to be highly specific. Although in 
some instances they can negatively regulate cell proliferation, their major role is not to control essential 
cellular functions such as cell cycle, apoptosis or migration, but rather to regulate the expression of 
tissue-specific genes involved in terminal differentiation (Table 1). In agreement with this, MAF and 
NRL are mutated in diseases such as pulverulent cataract, clumped pigmentary retinal degeneration 
and retinitis pigmentosa.
18,19
 Interestingly, in virtually every case their ability to regulate gene 
expression depends on their synergy with other transcription factors, some of which are direct binding 
partners (Table 1), and they often control the expression of a set of genes that are expressed at high 
levels, such as insulin in β-cells or crystallins in lens fibre cells.9 
Maf Organ, 
tissue, cell 
type 
Biological 
response(s) 
Target 
gene(s) 
Cooperating 
factor(s) 
KO Phenotype(s) 
MafA Pancreas 
β-cells 
Insulin transcription 
and production in 
β-cells 
Insulin (Ins) PDX1, 
NeuroD 
Diabetes mellitus 
MafB Rhomben-
cephalon 
Rhomboemeres 5 
and 6 identity 
Hoxa3 and 
Hoxb3 
KROX20, Ets Hindbrain segmentation 
problems in the Kreisler (Kr
ENU
) 
mutant; fatal apnea at birth to 
lack of neurons from the 
PreBötC complex in the 
knockout mutant. 
 Myeloid 
progenitors 
Macrophage 
differentiation 
Unknown Unknown Altered actin-dependent 
macrophage morphology; F4/80 
expression suppressed in non-
adherent macrophages 
 Kidney 
podocytes 
Podocyte 
differentiation 
Unknown Unknown Aberrant podocyte foot process 
formation and proteinuria in the 
kr
ENU 
mutant; tubular apoptosis 
and renal dysgenesis in the 
knockout mutant  
 Pancreas Pancreatic 
endocrine cell 
commitment and 
maturation 
Glucagon (Gcg) PAX6 Reduced number of cells 
expressing insulin and glucagon 
in both kr
ENU 
and knockout 
mutants 
Maf T cells T helper 2 cell 
differentiation 
Il4 NFAT Lack of IL4 production 
(embryonic and perinatal 
lethality) 
 Lens Lens differentiation Crystallins, 
Cryaa, Cryab, 
Crybb1 and 
Crygf 
PAX6, CREB, 
SOX1, SOX2, 
PROX1 
Microphtalmia due to defect in 
lens fibre elongation 
 Endochondral 
bone 
Chondrocyte 
differentiation 
Collagen type II 
Α1 (Col2a1) 
SOX9 Decreased fetal bone length, 
abnormal terminal 
differentiation of hypertrophic 
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chondrocytes 
Nrl Neuroretina Rod differentiation Rhodopsin 
(Rho) 
CRX Lack of  rods 
 
Table 1: CREB, cAMP responsive element binding protein; CRX, cone-rod homeobox containing gene; Il, interleukin; KO, knockout; 
NFAT, nuclear factor of activated T cells; PAX, paired Hox; PDX1, pancreatic and duodenal homeobox factor 1; PROX1, prospero 
homeobox 1; SOX, sex-determining region y (SRY) box. 
 
1.2.2. DNA binding domain 
The Maf transcription factors are a unique family among b-ZIP factors, characterized by the presence 
of three specific regions located on the C-terminal side: the Maf extended homology region (EHR), the 
basic region and the Leucin Zipper region (Figure 7).  
 
 
 
 
 
Figure 7: Schematic of deduced hMafA amino acid sequence shows various structural [serine/proline/threonine (S/P/T)-rich acidic 
domain, glycine (G)- and histidine (H)-rich regions, extended homology region (EHR); basic leucine zipper (L-LZP)] and functional 
(transcriptional actrivation, DNA-binding, and protein dimerization) domains. Schematic of ∆N-hMafA shows lack of the putative 
transcriptional activation domain.  
 
The Leucin Zipper region consists of a repetition of hydrophobic residues in particular leucine. The 
leucine zipper domain allows the formation of homodimers or heterodimers, a prerequisite for DNA 
binding, and it is completely conserved within Maf family members (Figure 8). 
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Figure 8: Structures and DNA recognition sequences of Maf family transcription factors. Schematic representation of the structure of 
human (MafA, MafB, c-Maf and Nrl) and chicken (L-Maf) large Maf factors and their amino acids identities (%) with MafA are shown. 
 
The Maf family is defined by the presence of an additional homologous domain called the extended 
homology region (EHR) or ancillary domain, which also contacts DNA. The EHR region is rich in 
hydrophobic residues which, intramolecularly, interact determining the amphipathic α-helix 
conformation on the N-terminal side. The Maf extended homology region is conserved only within the 
Maf family and, together with the basic region, defines the DNA binding specific to Mafs. Recent 
NMR studies on MafG,
9
 a small Maf, clarified the solution structure of the well conserved Mafs DNA-
binding domain (residues 1-76).  The analysis revealed the presence of three α-helices, H1 (residues 26 
to 30), H2 (residues 35 to 39), and H3 (residues 46 to 99), in MafG. The Maf-specific structural 
element EHR consists of H1, H2, and the N-terminal region of H3 (Figure 9).  H3 (residues 46 to 99) 
corresponds to the bZip structure.
21 
 
24 
 
 
 
 
 
 
 
Figure 9: Ribbon diagram of the energy-minimized average structure of MafG (1-76). The α-helices are shown in purple and labelled 
 
H1 and H2 within the EHR interact with the basic region (residues 46 to 62 in H3 of MafG) through 
both hydrophobic and hydrophilic interactions. The helices are stabilized by hydrophobic interactions 
among H1, H2 and the basic region. In particular these interactions involve the following residues: Leu 
24 from the N-terminal region; Leu 29 and Val 30 from H1; Met 32 from a turn between H1 and H2; 
Leu 37 and Leu 41 from H2; Leu 44 from a turn between H2 and H3; Ile 49, Leu 52 and Leu 59 from 
H3. Conservation of these hydrophobic residues and the N-terminal capping boxes among Mafs 
indicates that there is a similarity in the 3D structures of their DNA-binding domains. Most of the basic 
amino acid residues reside on one side of the protein surface: Arg 35 from H2 and Lys 46, Lys 53, Arg 
56, Arg 57 and Lys 60 from H3 (Figure 10).
9
 In addition, loss of DNA binding was reported for the 
R57E mutant of MafG and the corresponding mutants of MAfK, MafF and MafB.
23,24 
 
 
 
 
 
                      
                    
                 Figure 10: Elrctrostatic potential surfaces of MafG (1-76). Positive and negative potentials are in blue and red, respectively. 
25 
 
Therefore the basic cluster on the protein surface is probably involved in the interaction with target 
DNA sequences. MafG contains a helix-turn-helix (HTH) motif between H2 and H3. The HTH motif is 
one of the most common DNA-binding motifs and is found in many eukaryotic and prokaryotic 
transcriptional regulatory proteins. The second helix of the motif usually binds to the major groove of 
DNA and, therefore, is mainly involved in recognition and interaction with specific DNA sequences.
22
 
In MafG the interhelical angle between the H2 and H3 (149
◦
) is considerably larger than the typical 
value for the common HTH motif (~110
◦
). Thus, MafG may have a protein-DNA interaction mode 
distinct from that of the ordinary HTH-type DNA-binding domains.
8
 All large Maf proteins have an N-
terminal serine/proline/threonine-rich acidic activation domain that is absent in the "small Maf" 
proteins. However, both large and small Maf proteins have a high degree of similarity in the C-terminal 
basic and leucine zipper domains (Figure 11).
23 
 
 
 
 
 
 
 
 
Figure 11: The EHR of Maf proteins, the basic regions, and the partial CNC domains of the CNC family are boxed. H1, H2, and H3 
along the top indicate the α-helical regions. The amino acid sequences of the EHR and CNC domains are aligned to each other according 
to structural correspondence. The amino acid positions in the lucine heptad repeats are indicated at the bottom, and amino acids at 
position “d” are highlighted in green. 
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1.2.3. DNA target recognition mode 
The AP1 super-family is characterized by the ability to bind TRE (12-O-tetradecanoyl phorbol 13-
acetate (TPA)-responsive element) or CRE (cAMP- responsive element) DNA sequences (Figure 12) 
through their bZIP domain. 
 
 
 
 
 
Figure 12: Members of the AP1 family have different DNA recognition sequences: TRE (12-O-tetradecanoyl phorbol 13-acetate (TPA)-
responsive element), CRE (cAMP-responsive element) and MAREs (Maf recognition elements). Maf proteins can bind to a T-MARE 
(containing a TRE core), a C-MARE (containing a CRE core), a degenerated MARE or a half MARE flanked by AT-rich sequences. 
 
However, of the various bZip transcription factors, only the Maf family members recognize the 
exceptionally long cis-acting DNA sequence of the MARE. A TRE or CRE core flanked on each side 
by GC sequences constitutes the MARE (TGCTGACTCAGCA or TGCTGACGTCAGCA) (Figure 
13). No other member of the bZip family requires the GC flanking sequence adjoining the core.
21
  
 
 
 
 
 
 
Figure 13: Consensus DNA sequences recognized by bZip transcription factors. The TRE and the CRE lie within the T-MARE and the 
C-MARE, respectively, and act as the established core sequences of these MAREs. Three bases on each side of the core form the flanking 
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sequence, which is critical for the recognition of the MARE by the Maf protein family. The NF-E2 binding site and ARE are symmetrical 
sequences composed of half of the TRE site and half of the MARE site with one flanking sequence. The core and flanking regions are in 
red and blue, respectively, cAMP, cyclic AMP. 
 
Although the TGC motif is crucial for Maf binding, the TRE or CRE core can be more degenerate. It is 
noteworthy that many natural Maf target genes contain only half of a MARE palindromic site. 
However, as homodimers, Maf proteins can also bind half MARE sites if they are flanked by 5-AT-rich 
sequences. Alternatively, but not exclusively, some of these Maf target genes might be controlled by 
Maf- containing heterodimers, with the Maf protein binding to the half MARE site.
9 
Previous reports suggested that at least two structural elements are responsible for the unique DNA 
recognition property of the Maf proteins. One is a tyrosine residue in the basic region, and the other is 
the EHR domain localized on the N-terminal side of the basic region, both of which are highly 
conserved in Maf proteins. To explore the structural basis by which Maf proteins recognize the unique 
DNA sequence of the MARE, Kurokawa et all. performed X-ray crystallography of a MafG 
homodimer in complex with its cognate DNA as previously mentioned. They obtained the crystal of 
MafG bound to a 15-bp MARE sequence termed MARE25. Kurokawa et all. also compared the crystal 
structure of the MafG homodimer with the crystal structures of Fos-Jun and Skn1, both of which do not 
demand the GC flanking region for DNA binding, and found that a single α-helix of one monomer 
grips the half-site of the DNA in the major groove in all three cases. Surprisingly, Maf-specific 
structural elements, including Tyr64 and Thr58 residues in the basic region and EHR en bloc, were not 
involved in the base recognition of the extended region. However, in sharp contrast to the case of Fos-
Jun, invariant Asn61 in the basic region of MafG has a distinct side-chain orientation enabling the 
recognition of the extended MARE sequence, and another invariant residue, Arg57, contacts with the 
flanking guanine base. Thus, the Maf-specific elements appear to stabilize the unique side-chain 
orientations of conserved Asn61 and Arg57 toward the extended GC bases through indirect interactions 
involving DNA backbone phosphates.
21 
The MARE25 contains the NF-E2 binding site, which is critical for erythroid-specific gene regulation 
and was previously shown to bind the Maf homodimer tightly. Since MARE25 contains one nucleotide 
deviation from the GC-(TRE core)-GC consensus sequence, it is possible to assess the singular DNA 
recognition of each MafG monomer. The asymmetric unit includes two MafG fragments and one 
28 
 
double-stranded 15-bp DNA. Each MafG monomer in the dimeric MafG-DNA complex recognizes a 
slightly different DNA sequence but displays a similar overall structure. The asymmetry of the DNA 
sequence used in the crystallization allows a distinction to be made between the two MafG monomers 
(called subunit A and subunit B). Subunit A is in contact with the GA flanking region and subunit B is 
in contact with the GC flanking region. The structural differences between subunits A and B of MafG 
appear to be due simply to the different crystal packing. Like GCN4 and Fos-Jun, the MafG 
homodimer embraces the major groove of the DNA via its two long H3 helices akin to a pair of 
chopsticks (Figure 14).
21
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Figure 14: Main-chain structure of MafG in complex with MARE DNA. (A and B) Orthogonal views of MafG in complex with its 
cognate DNA. MafG consists of three helices: H1 and H2 in the EHR and H3 in both the basic region that recognizes DNA and the 
leucine zipper region that forms a dimer with the other subunit. The sequence of the duplex oligonucleotide MARE25 that was used for 
cocrystallization is shown (A). Subunit A (in green) is in contact with the GA flanking region, and subunit B (in cyan) is in contact with 
the GC flanking region. (C) Comparison with Fos (in red)-Jun (in purple) in complex with DNA. (D) Comparison of MafG with Skn1 (in 
orange). The protein regions are used for superimposition. Structural alignment yields rmsd57Cα of 2.4 Å when the AP1 half-cores are 
superimposed and 1.8 Å when only the protein regions are superimposed. 
 
The DNA in the complex is in a straight B form and has an average helical rise and twist of 3.2 Å and 
34.6°, respectively. Furthermore the MafG H1 and H2 region is essentially similar to Skn1 H1 and H2 
region. Showing very good agreement with the case for AP1-type bZip factors, conserved Ala65 
residue of MafG create Van der Waals contacts with the T base at positions +1 and -3. Arg69 of 
subunit B forms a hydrogen bond with the G base at position 0 through a water molecule. A series of 
salt bridges is formed between Arg62 and the phosphate backbone of thymine at position +1, between 
Arg69 and the phosphate backbone of adenine at position -1, and between Lys71 and the phosphate 
oxygen of thymine at position -3. Arg56 of subunit B interacts with the phosphate backbone of thymine 
at position -7. Asn61 of MafG subunit A forms a direct hydrogen bond with adenine (position -4) in the 
GA flanking sequence (Figure 15B) and an indirect hydrogen bond with cytosine (position +2) of the 
opposite sequence (Figure 15A) in the core region of MARE25. Asn61 of MafG subunit B creates van 
der Waals forces with cytosine (position -4) in the GC flanking region of MARE25 (Figure 15C). Thus, 
MafG Asn61 recognizes mainly the flanking region, although it forms weak indirect hydrogen bonding 
with the TRE core region. In stark contrast to MafG, the invariant Asn511 of Skn1 interacted only with 
cytosine (position +2) in the TRE region (Figure 15D).
21
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Figure 15: MARE recognition by the basic region of MafG and comparison with AP1-type bZip factors. (A) The phosphate groups of 
MARE25 engaged by the MafG protein are shown. Chain C and chain D are the bottom and top strands of MARE25, respectively. The 
figure was drawn by NUCPLOT. (B to F) The conserved amino acid side chains of the motifs that make direct contacts with the DNA 
bases of the consensus sequence are shown for MafG subunit A (B), MafG subunit B (C), Skn1 (D), Pap1 (E), and C/EBP (F). Hydrogen 
bonds and van der Waals contacts are shown as solid and broken lines, respectively. PDB accession numbers 1SKN for Skn1 (D), 1GD2 
for Pap1 (E), and 1GU4 for C/EBP (F) were used to estimate the DNA base recognition mode. 
 
Arg57 in MafG subunit A forms critical hydrogen bonds with the O6 of guanine at position -5 and the 
O4 of thymine at position +4 (Figure 15A and B), while Arg57 in MafG subunit B forms hydrogen 
bonds to the O6 of guanine at position -5 and the O6 of guanine at position +4 (Figure 15A and C). It 
should be noted that Arg57 of MafG participates in DNA base recognition by changing its side-chain 
orientation; Arg57 in MafG shows a distinct side-chain orientation compared to the corresponding 
arginine residues of AP1-type and CNC-type factors. In fact, Arg507 and Arg143 residues are the 
residues corresponding to Arg57 of MafG in Skn1 and Fos, respectively, but the side chain of Arg507 
in Skn1 interacts with a backbone phosphate of DNA, and that of Arg143 in Fos is exposed to 
solvent,
24 
and these side chains are not involved in DNA base recognition (Figure 16).  
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Figure 16: Interactions of the DNA binding domain of MafG with DNA. Van Deer Waals forces between Maf-specific Thr58 and the 
DNA backbone phosphate. The hydrogen bond between Gln54 and Thr58 fixes the Thr58 side chain in an optimal orientation against the 
backbone phosphate. B) The DNA backbone phosphate referred to above interacts with Arg507 of Skn1. Arg507 corresponds to ARG57 
of MafG and forms indirect contacts with the invariant Asn511 via water molecule, thereby stabilizing the orientation of the Asn511 side 
chain for recognition of the code TRE half-region. 
 
Utilization of Arg57 for DNA recognition makes the Maf subfamily possess a unique and exceptionally 
long consensus protein sequence for DNA base recognition (13 residues, Rxxx NxxYAxxCR) (Figure 
15B and C). In contrast, those of AP1-type/ CNC-type factors (NxxAAxxC/SR) and the yeast AP1-
type factor Pap1 (NxxAQxxFR) contain a 9-residue sequence, and the arginine residue corresponding 
to Arg57 of MafG is not included in the interaction with DNA (Figure 15D and E). Another 
characteristic protein sequence is RxxNxxAVxxSR for the C/EBP subfamily, where the arginine 
residue involving DNA recognition is 1 amino acid closer to the asparagine residue than in MafG. The 
arginine residue of C/EBP at the position corresponding to Arg57 of MafG in the consensus sequence 
does not participate in DNA base recognition (Figure 15F). Thus, it is likely that the distinct side-chain 
orientation of Arg57 and Asn61 explains why MafG requires the flanking region for binding and 
recognizes the TRE core with specificity relatively broader than that of AP1-type and CNC-type 
transcription factors.
21
 An interesting achievement in Maf folding knowledge was obtained examining 
the effect of DNA binding on the conformation of the Maf bZIP domain and ancillary DNA-binding 
region using circular dichroism (CD). Comparison of the CD spectra of free Maf and Maf in the 
presence of a consensus binding site oligonucleotide reveals a large change in ellipticity at 208 and 222 
nm (Figure 17). 
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Figure 17: Comparison of the CD spectra of free Maf (green), the oligonucleotide containing a consensus Maf-binding site M (blue) and 
the Maf-M complex (purple). 
This change is consistent with an increase in the α-helicity of Maf upon binding the optimal recognition 
sequence. In the absence of DNA, Maf homodimers have a α-helix content that is consistent with 
folding of the leucine zipper prior to DNA binding. It is therefore likely that the ancillary DNA-binding 
region adopts a conformation of high α-helix content upon Maf binding to the consensus recognition 
sequence.  
Maf family members recognize a DNA sequence element that is almost twice as long as elements 
recognized by other bZIP proteins. Substitution of a single base pair in one of the extended recognition 
elements (position -6) reduces the change in Maf α-helicity induced by DNA binding by approximately 
half (Figure 18).  
                                                    
Figure 18: Comparison of Maf conformations at different recognition sites. The mean residue ellipticity of maf241-369 bound to 
different recognition sites (solid symbols) was calculated by subtraction of the ellipticity of each oligonucleotide from the ellipticity of the 
complex formed by Maf at each site, and was compared with that of free Maf241-369 (open symbols). There were no significant 
difference between the spectra of the oligonuclotides alone. 
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Substitution of the same base pair in both half-sites (positions ±6) abolishes the induced α-helical 
conformation of Maf ( Figure 18, blue line). This base pair is therefore essential for Maf to undergo a 
conformational change upon binding to DNA. Other base substitutions within the extended recognition 
elements (positions ±5 and positions ±7) have smaller effects on Maf conformation. Base substitutions 
within the CRE (position ±4) do not influence the α-helix content of Maf  (Figure 18, red line). In 
contrast, these base substitutions eliminates the coil-to-helix transition of Fos-Jun heterodimers (Figure 
19). 
                                                        
Figure 19: Comparison of Fos-Jun conformations at different recognition sites. The mean residue ellipticity of Fos 139-200--Jun257-318 
free and bound to different recognition sites was plotted as in B. 
 
No increase in the α-helix content of either Maf or Fos-Jun is observed in the presence of a GC co-
polymer oligonucleotide. Consequently, base substitutions in the core and extended recognition 
elements have reciprocal effects on the conformational changes of Maf and Fos-Jun. 
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1.3. Mafs and multiple myeloma 
 
1.3.1. Introduction 
Large Maf genes are bona fide oncogenes as highlighted from their initial isolation to their involvement 
in human cancer. Maf proteins can transform primary cells
1,2-4
 and their oncogenic activity has been 
validated in vivo both in birds and mammals: the As42 avian retrovirus, expressing v-Maf, induces 
tumours in chickens,
5,6
 and transgenic mice expressing Maf in the lymphoid compartment develop T 
cell lymphomas.
7
 In humans, Maf genes are overexpressed in 60% of human angioimmunoblastic T-
cell lymphomas (AITLs)
7,8
 and in 50% of cases of multiple myeloma (MM), and contribute directly to 
cancer progression.
9
 The oncogenic activities of the large Maf proteins have all been tested in vitro 
except for that of NRL, the only member that has not yet been found to be deregulated in human cancer. 
In contrast to small Maf proteins, MAF, MafB and MafA can efficiently transform primary fibroblasts 
in vitro,
1,2-4
 and, interestingly, this does not require an activating mutation (no such mutations have 
been found within large Maf genes in human cancers), although it can be enhanced by point 
mutation.
2,10
 MafA and MAF display the strongest oncogenic activity, whereas MafB is less effective at 
transforming cells.
3,4
 This weaker activity of MafB correlates with its reduced expression level 
compared with the other large Maf proteins, and possibly reflects the fact that MafB is a more unstable 
protein.
4
 Indeed, a threshold level of Maf expression might be required for transformation as only mice 
carrying a high copy number of the MAF transgene develop T-cell lymphoma.
7
 Moreover, Maf genes 
are also overexpressed in human cancers, suggesting that transformation requires a high level of Maf 
expression. The transforming activity of the Maf proteins depends on their ability to act as transcription 
factors.
2-4,10,11
 Accordingly, some of their target genes, such as those that encode cyclin D2, integrin β7 
and ARK5 (also known as NUAK1), have deregulated expression in MM,
9,12-15
 AITL and in Maf 
transgenic mice.
7
 However, the capacity of the large Maf genes to induce transformation does not 
strictly correlate with their transactivation strength, as measured using a reporter luciferase gene under 
the control of synthetic MARE sequences.
3,10
 In summary, when expressed at high levels, unmutated 
large Maf genes display oncogenic activity in cell culture, animal models and in human cancer.
16
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1.3.2. Multiple myeloma 
Multiple myeloma (MM) is a malignant disorder characterized by the clonal proliferation of plasma 
cells (PCs) in the bone marrow (BM). It constitutes about 10% of all hematologic cancers and its 
annual incidence, age-adjusted to the 2000 United States population, is 4.3 per 100,000.
17
 Occurrence 
of the disease is more common in men than women and twice as high in African-Americans compared 
to Caucasian.
18
 The frequent invasion of the adjacent bone by malignant PCs causes osteolytic bone 
lesions and fractures; anemia occurs in 70% of patients at diagnosis, and renal dysfunction and 
hypercalcemia in 50% and 25% of patients, respectively.
18
 The clinical course of MM is quite 
heterogeneous: frequently the tumor can be preceded by a condition known as monoclonal 
gammopathy of undetermined significance (MGUS), a pre-malignus disorder of the plasma cells 
characterized by a decrease in the number of plasma cells (<10%) and monoclonal proteins in the bone 
marrow, in the absence of osteolytic lesions, anemia, hypercalcaemia or depletion of  kidney functions. 
Multiple myeloma is usually confined in the bone marrow (intramedullary MM) where the myeloma 
cells strictly depend on the marrow microenvironment that assures them growth, survival, and 
resistance to conventional drug therapies. The final and more aggressive stage of the myeloma is called 
plasmacellular leukemia (PCL) and it is characterized by the presence of cancerogenic plasma cells in 
extramedullary sites such as blood vessels and skin  (Figure 20).  
 
 
 
 
 
 
 
Figure 20: Progression of multiple myeloma. MM lacks pathognomonic genetic lesion(s) that could account for all MM cases, and is 
instead characterized by a marked interpatient heterogeneity in its genetic background.19  
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1.3.3. Large Mafs and MM 
Genes encoding “large” Maf proteins, c-Maf, MafB and MafA, are involved in three chromosomal 
translocations representing primary oncogenic events in MM. These translocations involve the 
immunoglobulin heavy chain locus (IGH@), at chromosome 14q32, and are mostly mediated by errors 
in one of the three B-cell specific DNA modification mechanisms: VDJ recombination, IGH switch 
recombination, and somatic hypermutation. The effect of these translocations is the juxtaposition of 
strong Ig enhancers to non-random oncogene-harboring chromosomal loci, with the consequent 
deregulation of their expression; one of the three groups of recurrent IGH translocations in myeloma is 
represented by MAF (16q23), MAFB (21q12) and MAFA (8q24.3) genes, that are partners of IGH 
locus respectively in 5, 2 and less than 1% of MM cases. The chromosomal translocation t(14;16) was 
associated with a poor prognosis,
20,21
 and its presence is considered sufficient to place patients in the 
high risk category based on stratification models proposed by the Mayo Clinic
22
 and the International 
myeloma Working Group,
23
 which recommends the molecular cytogenetics analysis in routine clinical 
practice for an adequate prognostic characterization.  
Although a recent retrospective analysis of a large number of patients does not confirm the adverse 
prognostic impact of t(14;16),
24
 there is no doubt that the deregulation of MAF genes plays an 
important pathogenetic role in the context of the genetic heterogeneity characterizing myeloma. 
Transcriptional activation of CCND2 is probably the mechanism through which oncogenic Maf 
proteins induce cell proliferation; it was in fact observed that MM Maf group is characterized by high 
proliferative index. XBP is a bZIP family member involved in the differentiation of plasma cells. It is 
abundantly expressed in multiple myeloma and it could contribute to the expression increase of c-Maf. 
Indeed, knock-out mice show that an increasing in XBP expression in the lymphoid compartment is 
correlated with altered expression levels both of MafB and c-Maf. The mechanism that subtends the 
alteration of the expression profile of large Mafs remains unclear as the evidence that XBP is able to 
bind Maf proteins promoter. Nevertheless, these observations support the hypothesis for which other 
events, independently from chromosomal translocations, could lead to an increment of large Mafs gene 
expression. In the multiple myeloma, the principal c-Maf gene targets are: cylinD2, integrinβ7, CCR1 
(Chemokine receptor C-1) and ARK5 (protein kinase AMP-activated kinase-related 5) (Figure 21).  
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                                                             Figure 21: c-Maf oncogene targets in multiple myeloma. 
 
The over-expression of other genes belonging to Maf signature gives to myeloma cells a greater ability 
of invasion. Another fundamental pathogenetic aspect on which Maf deregulation acts is the interaction 
between tumor cells and stroma, which is favored by over-expression of integrin B7. This molecule 
allows myeloma cells to adhere more effectively to bone marrow stromal cells expressing on cell 
surface the integrin-binding protein E-cadherin. These cell-cell interactions induce the expression of 
pro-angiogenic cytokine VEGF, which helps to create a more favorable environment to the tumor 
(Figure 22).  
40 
 
 
 
Figure 22: Overexpression of large Maf proteins is involved in multiple myeloma (MM) progression by deregulating several cellular 
processes through the regulation of distinct gene expression. Large Maf proteins promote MM cell proliferation through inducing 
expression of CCND2, pathological interactions between bone marrow stromal and tumor cells by inducing expression of ITGB7 and cell 
migration and invasion by inducing expression of ARK5. MAREs (Maf-recognition elements) are present in the promoter of these genes. 
 
 
 
 
 
 
41 
 
1.3.4. References 
1) Kataoka, K., Fujiwara, K. T., Noda, M., Nishizawa, M., Moll. Cell. Biol. 1994, 14, 7581-7591. 
2) Kataoka, K., Nishizawa, M., Kawai, S., J. Virol. 1993, 67, 2133-2141. 
3) Nishizawa, M., Kataoka, K., Vogt, P. K., Oncogene 2003, 22, 7882-7890. 
4) Pouponnot, C, Oncogene 2006, 25, 1299-1310. 
5) Nishizawa, M., Kataoka, K., Goto, N., Fujiwara, K. T., Kawai, S., Proc. Natl. Acad. Sci. USA 1989, 
86, 7711-7715. 
6) Kawai, S., et al., Virology 1992, 188, 778-784. 
7) Morito, N., et al., Cancer Res. 2006, 66, 812-819. 
8) Murakami, Y., et al., J. Surg. Pathol. 2007, 31, 1695-1702. 
9) Hurt, E. M., et al., Cancer Cell 2004, 5, 191-199. 
10) Kataoka, K., Noda, M., Nishizawa, M., Oncogene 1996, 12, 53-62. 
11) Kataoka, K., Shioda, S., Yoshitomo-Nakagawa, K., Handa, H., Nishizawa, M., J. Biol. Chem. 2001, 
276, 36849-36856. 
12) Mattioli, M., et al., Oncogene 2005, 24, 2461-2473. 
13) Suzuki, A., et al., Oncogene 2005, 24, 6936-6944. 
14) Zhan, F., et al., Blood 2006, 108, 2020-2028. 
15) Monteiro, P., et al., Biochem. Biophys. Res. Commun. 2007, 358, 442-448. 
16) Eychène, A., Rocques, N., Pouponnot, C., Nature Reviews 2008, 8, 683-693. 
17) Kyle, R. A., Rajkumar, S. V., The New England Journal of Medicine 2004, 351, 1860-1873. 
18) Rajkumar, S. V., Curr. Probl. Cancer 2009, 33, 7-64. 
19) Mitsiades, C. S., Mitsiades, N., Munshi, N. C., Anderson, K., Cancer Cell J. 2004, 6, 439-444. 
20) Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M. M., Kyle, R. A., Gordon, W., Dewald. 
W., Van Ness, B., Van Wier, S. A., Henderson, K. J., Bailey, R. J., Greipp, P. R., Blood 2003, 101, 
4569-4575. 
21)   Zhang, F., Huang, Y., Colla, S., Steward, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., 
Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., Van Rhee, F., 
Walker, R., Zangari, M., Crowley, J., Barlogie, B., Shaughnessy, J., Blood 2006, 15, 2020-2028. 
22) Dispenzieri, A., Rajkumar, S. V., Gertz, M. A., Lacy, M. Q., Mayo Clinic Procc. 2007, 82, 323-341. 
23)  Fonseca, R., Bergsagel, P. L., Drach, L., Shaughnessy, J., Gutierrez, N., Steward, A. K., Morgan, 
G., Van Ness, B., Chesi, M., Minvielle, S., Neri, A., Barlogie, B., Kuehl, W. M., Liebisch, P., 
42 
 
Davies, F., Chen-Kiang, S., Durie, BGM., Carrasco, R., Sezer, O., Reiman, T., Pilarski, L., Avet-
Loiseau, H., Leukemia 2009, 23, 2210-2221. 
24) Munshi, N. C., Anderson, K. C., Bergsagel, P. L., Shaughnessy, J., Palumbo, A., Durie, B., Fonseca, 
R., Stewart, A. K., Harousseau, J. L., Dimopoulos, M., Jagannath, S., Hajek, R., Sezer, O., Kyle, R., 
Sonneveld, P., Cavo, M., Rajkumar, S. V., San Miguel, J., Crowley, J., Avet-Loisseau, H., Blood 
2011, 117, 4696-4700. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
1.4. Construction of a DNA binding domain (DBD) structural model for Mafs 
 
Large Mafs, as described in chapter 1.2, are proteins of considerable dimension (300 amino acidic 
residues), we focused on the DNA binding domain (DBD) as potential biological target for the 
obtainment of modulators. This domain corresponds to a 75 mer sequence and harbors the LZP region 
combined to a unique and conserved N-terminal motif called extended homology region (EHR) as 
shown in Figure 23. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Structure of the dimeric DBD of Mafs. From crystallographic data of Maf-G it is evicted that the EHR region is characterized 
by a H-T-H motif which comprehends three helices (H1, H2, H3). 
 
The comprehension of the DBD/ciclyn D2 promoter interaction (Figure 24) is an important task for the 
development of a structural model, as in the literature it is available only the model between MafG (a 
small Maf which is not involved in the pathogenesis of MM) and a TRE containing MARE. will be of 
importance in order to define the key amino acids (AA) and sequences responsible for the interaction 
with DNA.  
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                                                             Figure 24: DBD/Cyclin D2 promoter schematic illustration. 
 
In this work we focused on the study of two large Mafs, c-Maf and MafA, approaching the issue from 
two complementary directions. From an experimental point of view, carrying out the total chemical 
synthesis of MafA and performing folding and DNA target interactions studies using circular dicroism 
(CD); this work is material of an article published in 2012 (Amino Acids 2012, 43,1995–2003). A 
theoretical study was also performed with the aim of creating an homology model of c-Maf.  In a 
second time the design of DBD peptidic modulators was accomplished. C-Maf was appointed as 
biological target for the realization of modulators considering that its over-expression is strictly related 
the malignant progression of multiple myeloma, currently untreatable. In particular peptides were 
designed to interact with the LZP moiety in order to inhibit dimerization which is required for Mafs 
activation and DNA binding. LZP aminoacidic sequence is the most variable portion of DBD, that 
could guarantee a fine target modulation. Combining Molecular Mechanics Poisson Boltzmann Surface 
Area strategy with Computational Alanine Scanning method a small library of peptides (Figure 25) as 
LZP dimerization inhibitors was outlined. Starting from the LZP wild type aminoacidic sequence, two 
different classes of peptides were studied which bound respectively, or the N-termini region or the C-
termini region of LZP.  
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                                                  Figure 25: c-Maf LZP inhibitors outlined.  
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1.5. Chemical synthesis of MafA 75mer DNA binding domain  
 
1.5.1. Microwave assisted solid phase synthesis strategies 
The chemical synthesis of the 75mer peptide from MafA DBD represented a tough challenge, not being 
available previous reports on the preparation of such domain using conventional SPPS protocols. 
Furthermore, this sequence is particularly rich in Arg residues, which are somewhat difﬁcult to couple. 
As the usefulness of microwave irradiation was recently demonstrated for the preparation of long 
peptides and, particularly, for difﬁcult sequences,1 we planned to use automated MW-SPPS for 
obtaining 75mer MafA DBD and its different domains (i.e., the EHR, the basic region BR, and the 
dimerization domain; Figure 26).
2
  
 
 
 
 
 
                                                                                   Figure 26: MafA DBD sequence. 
 
We also planned the synthesis of shorter fragments corresponding to H1–H2, to the N-terminus of H3 
(named H3 short) and to the sequence H2-H3 short in order to perform circular dichroism (Table 2). 
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Table 2: A)Standard MW assisted single coupling; B) standard MW-assisted single coupling up to 35 residue, then double coupling; 
MALDI-TOF mass analyses; csee text for analytical HPLC gradient; dpurified peptides. 
Rink amide PEG MBHA resin (0.35 mmol/g loading) was chosen for its higher swelling efﬁciency 
with respect to Rink amide polystyrene. All the peptides were prepared using Fmoc/tBu methodology 
and entirely assembled using automatic MW-SPPS, applying different microwave protocols to the 
coupling steps depending on the amino acid type and the chain length (Table 2). In the standard 
protocol, which was applied to peptides up to 28 residues, couplings were performed using a ﬁvefold 
excess of Fmoc-amino acids, HOBT/HBTU (5 equiv., 0.45 M in DMF) as activators and DIPEA (10 
equiv., 1 M in NMP) as base and with a 5 min microwave irradiation at 75ºC. Fmoc deprotection was 
achieved using piperidine (20 % in DMF) with a 3 min microwave irradiation at 75ºC. In order to avoid 
cysteine and hystidine racemization, their couplings were performed at 50ºC. For arginine, which 
possesses a low reactivity toward peptide couplings, we adopted a double coupling approach (ﬁrst 
coupling: 30 min at 75ºC without microwave energy; second coupling: 5 min at 75ºC with microwave 
energy). This last protocol was used in the elongation of longer peptides starting from the 35th residue, 
regardless of the amino acid type. All the peptides were N-terminally acetylated (tenfold excess Ac2O 
and DIPEA in DCM) and cleaved from the resin using TFA and scavengers. The crude HPLC traces 
indicated a good homogeneity for all compounds (Fig. 2), which were then puriﬁed with preparative 
HPLC and identiﬁed using mass spectrometry. It should be underlined that in a relatively short time (70 
h) it was possible to obtain 50mg of pure 75mer DBD, thus demonstrating the effectiveness of stepwise 
MW-SPPS technique also for peptides with a chain length higher than 50 residues.
2 
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1.5.2. Circular dicroism experiments 
1.5.2.1. Folding properties studies 
The CD technique is particularly useful for examining macromolecular structures which in solution 
lack a well-ordered tertiary structure, as well as for determining dynamic protein/DNA interactions.
3,4
 
In phosphate buffer (0.1M, pH7.5), the entire 75mer peptide showed a negative band close to 200 nm 
(amide π          π* transition) and a negative shoulder near 222 nm (amide n          π* transition) (Figure 
27). 
 
 
 
 
 
 
                                          Figure 27: CD spectra of synthesized peptides in phosphate buffer (20μM solution). 
 
The absence of a positive band below 200 nm and the blue shift of the π        π* one indicated the 
presence of different conformations. This behavior was independent from sample concentration (data 
recorded from 5 to 50M, while at higher concentration, the DBD was not soluble). Accordingly, 
secondary structure analysis of the CD spectrum with the CONTIN algorithm
5,6
 indicated the presence 
of 46% unordered fraction together with a helix and, surprisingly, β sheet structure (Table 3).  
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                                                                  Table 3: CD spectra analyzed using CONTIN algorithm. 
 
By analyzing the CD spectra of different DBD fragments (Figure 28), it was found that the LZ 
fragment contained lesserβsheet contribution (α/β ratio, 2:1) than the other peptides. The entire DBD 
and the EHR-H3short (227–263) sequence possessed an α/β ratio of 1:1, while for other fragments this 
ratio was in favor of β sheet. These ﬁndings suggest that the presence of both the EHR and LZ is 
crucial for the stabilization of a helix structure. Nevertheless, in all cases the addition of 50% TFE led 
to the increase of the helix conformation indicating that β sheet structure is favored by a hydrophilic 
environment (Table 3). EHR domain is a peculiarity of Maf proteins and, from the literature data on 
MafG, hydrophobic interactions between residues from H1 and N-terminus of H3 (H3short) are 
evicted.
7 
 In order to ascertain if they are fundamental for the folding, we performed interaction studies 
between EHR-H3short (227–263) peptide and H1H2 (227–243) and H3short (248–263) fragments. In 
order to minimize the contribution of β sheet conformation, the experiments were carried out in 20% 
TFE. Under these conditions, all the three peptides were found almost helical (EHR-H3short: 61%, 
H1H2: 48 %, H3short: 76 %; helix percentage was estimated using the procedure of Chen et al.
8
; 
Figure 29).  
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                                                               Figure 28: CD spectra in 20% TFE (20μM solution). 
 
As shown in Figure 24A, the CD spectrum of the mixture containing EHR-H3short and H3short 
peptide was not superimposable to the arithmetic sum of the CD spectra of the single components. The 
same behavior was observed also for the mixture of EHR-H3short and H1H2 (Figure 29B), indicating 
that in both cases an interaction was effective.  
  
 
 
 
 
 
 
  
                                            Figure 29: Interaction between EHR-H3short with H3short (A) and H1H2 (B). 
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In particular, a blue shift of the π          π* band was observed, suggesting that an increase of unordered 
fraction, probably, occurs for all peptides. From these ﬁndings, we postulated that, when single H1H2 
or H3short fragments were added to EHR-H3 short, they could act as folding disrupter interfering in 
the formation of intramolecular interactions within EHR-H3short. 
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1.5.2.2. DNA target interaction studies 
The interaction of MafA DBD with a DNA sequence of 26 bp from human insulin enhancer containing 
MafA MARE (CGGAAATTGCAGCCTCAGCCCCCAGC)
9
 was studied. First, the CD spectrum of 
the DNA duplex was recorded in phosphate buffer (0.1M, pH7.5; Figure 30), showing a B-DNA 
conformation characterized by the presence of a positive peak at 270 nm and two negative ones, at 250 
and 210 nm, respectively.
10 
The CD spectrum of 75mer DBD alone was compared with the spectrum 
derived from a mixture with human insulin MARE (DBD/DNA, 2:1) by subtracting DNA contribution: 
an increase of α-helical content was observed (62% helix content found), indicating that an interaction 
was effective (Figure 30).  
 
 
 
 
 
 
 
 
                                                       Figure 30: CD spectrum of 26bp DNA sequence from human insulin enhancer. 
 
In order to investigate if the binding to DNA was 
Sequence speciﬁc, we also studied the interaction of DBD with a scrambled DNA sequence 
(GATCAGTACCACGCGCTC CACGCCGA). As expected, we obtained no speciﬁc con- formational 
changes in the CD spectrum of DBD (Figure 31).  
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Figure 31: Comparison between DBD spectrum alone and then spectrum derived from the 2:1 mixture with insulin MARE (on the left) 
and scrambled DNA (on the right). 
 
In order to gain an insight in the binding of MafA to insulin MARE which, as reported above, is 
uncommon with respect to standard ones,
9
 CD studies were also performed using shorter sequences 
from DBD. In the presence of DNA, a structural change (20% helix structure in CD spectrum) was 
only observed for the peptide corresponding to EHR–BR sequence (227–278) (Figure 32).  
 
 
 
 
 
 
 
 
            Figure 32: Comparison between EHR-BR spectrum alone and the one derived from the 2:1 mixture with insulin MARE. 
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On the contrary, we did not observe any interaction with either the EHR-H3short fragment (227–263) 
or, interestingly, the entire BR (248–275) and the entire H3 (248–301). From these results, we can 
postulate that under physiological conditions and in the absence of speciﬁc DNA, MafA is in a 
dynamic equilibrium between folded and unfolded states. In particular, important β sheet and 
unordered contributions were found for 75mer DBD and its fragments in an hydrophilic environment, 
while an hydrophobic medium stabilized the α helix structure. This conformation is also dependent on 
two domains of the DBD: the LZ and EHR. This last region is characteristic and highly conserved 
within the Maf family. This region is rich in hydrophobic residues forming a hydrophobic cluster which 
is surrounded by hydrophilic amino acids.
7
  Our CD results demonstrated that, in the absence of DNA, 
these intramolecular hydrophobic interactions are effective in partially stabilizing the conformation of 
DBD. H1H2 (227–243) and H3short (248–263) fragments, in particular, could act as folding disrupters 
(Figure 29). The interaction with insulin MARE induces conformational changes by stabilizing the 
three-dimensional conformation of MafA domain in a similar manner as reported for other family 
members. Early CD studies on c-Maf and palindromic consensus MARE reported DNA sequence- 
dependent folding. In particular, the ﬂanking region of MARE was found to be dramatically important 
for the interaction with DBD, thus stabilizing the a helix structure, while the core seemed to have a 
scarcer relevance.
10
 The binding of MafA to insulin enhancer then represents a case in this paradigm, 
the MARE recognition sequence being not palindromic, and possessing degenerated core and ﬂanking 
regions.
9
 Our CD results, anyway, indicate that also in the case of a degenerated MARE, the interaction 
with DNA induces an increase of the helical content in MafA DBD (62% helical content found; Figure 
31). Further conclusions can be drawn starting from the interaction studies between MafA shorter 
fragments and insulin MARE. From the crystal structure of the MafG/MARE25 complex (PDB ID 
3A5T),
7
 it was evicted that conserved residues from BR are involved in DNA binding. In particular, 
Arg57 and Asn61 (corresponding to Arg259 and Asn263 in MafA) were shown to directly interact with 
DNA, while residues Arg62, Tyr64, Ala65, Arg69, and Lys71 (corresponding to Arg264, Tyr266, 
Ala267, Arg272, and Lys274) are fundamental for the correct spatial orientation of Arg57 and Asn61 
side chains.
7
 Our CD studies on BR, anyway, showed that both peptides H3short (248–263) and EHR-
H3short (227–263), containing the key residues Arg 259 and Asn 263, were found unable to interact 
with DNA, as well as the entire BR (248–275). Curiously, also the H3 peptide (248–301, 
corresponding to BR and LZ regions) was also unable to bind insulin MARE, whereas the EHR–BR 
(227–278) peptide interacted (20% helical content found; Figure 32). From these data, we can assume 
that the highly conserved EHR is not only important for DBD folding but also for binding to insulin 
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enhancer. Our hypothesis is that, since from the crystal data on MafG/MARE25 this part of the DBD 
seemed not to be directly involved in DNA interaction, its role probably lies in a correct folding 
inducer. In this context, the hydrophobic cluster within the EHR (in particular Leu 231 and Met 234) 
could then act as a local structural element that triggers the folding of the entire DBD in the presence of 
DNA. Considering that, from CD data, the LZ region seems not to be necessary for DNA binding, the 
dimerization of the DBD is an event that, probably, occurs after DNA recognition. Indeed, we can 
postulate that MafA undergoes a disorder-to-order transition through a coupled binding and folding 
mechanism similarly to that reported for other b-LZ domains.
11
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1.6. Creation of a c-Maf DBD homology model 
 
1.6.1. Theory 
1.6.1.1. Molecular dynamics 
Although the advantages of the availability of tridimensional structures of receptor-ligand complexes 
are evident for projecting new ligands, the crystallized structure represents a static image of a complex 
dynamic process. Molecular dynamics (MD) is a simulation computational method that constitutes an 
important instrument both for studying the temporal evolution of proteins and other biological 
macromolecules and for obtaining kinetics and thermodynamic information.
1,2
 Molecular dynamics is 
based on Newton’s second law:  
                                                    F= ma                                                                        (1.1) 
Where F is the net force acting on the object, m is the mass of the object and a is the acceleration of the 
object. Knowing the force exercised on every single atom of a complex system it is possible to 
determine the respective accelerations. For a complex system, the movement of every single atom is 
determined by the equation:  
       F1= miai,   mi=                           i= 1,2…., N                                                     (1.2) 
The total force Fi, exercised on each atom i can be expressed as a negative gradient of a potential 
energy:  
                                                                Fi= -                                                                     (1.3) 
 
That combined with the previous one gives: 
 
                                                                        - = mi                                                         (1.4) 
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Knowing the initial coordinates ( obtained from experimental data or theoretical studies taken from X 
rays crystallography, NMR of homology modeling), the initial speed attributed basing on the strating 
temperature and the forces applied on the system, it is possible to calculate the new coordinates and the 
atoms speed ata  determine time (trajectory). The aim of this simulation is thus solving the Newton 
motion equation for small intervals of time (time steps) using different algorithms (i.e. Verlet 
algorithm) and obtaining a trajectory that corresponds to the position and speed in time of each atom 
involved in the system. From a molecular dynamics trajectory it is possible to extrapolate macroscopic 
properties calculating the average of the values that these properties acquire during the simulation. The 
choice of the suitable energetic function describing the intermolecular and intramolecular interactions 
is critical for the molecular dynamics simulation success. The potential energy E, as a function of the 
position of all the atoms of a system, is expressed by the sum of two terms: 
                                                  E = Ebonded  + Enon-bonded                                                                     (1.5) 
Where Ebonded comprehends the  interactions between covalently linked atoms which depends from the 
bound length, angles and rotations of the molecules bounds; Enon-bonded is referred  to the interactions 
developed between non chemically bonded atoms or atoms separated by three or more covalent bounds. 
The use of the simple nuclear coordinates as a representation of the atoms ignoring the electrons is 
justified by Born-Oppenheimer approximation.
3
 The energetic function usually consists of a consisting 
number of parameterized terms. These parameters are extrapolated from empiric data obtained by 
model compounds with several experimental techniques (X rays, infrared spectroscopy, Raman 
spectroscopy, microwave spectroscopy) and/or quanto-mechanical studies on a small group of 
molecules or fragments assuming that these parameters could fit also a much larger group of molecules. 
The totality of the potential energetic functions  and of the parameters consists in the so-called force 
field. Almost all force fields are characterized by a similar mathematic expression, however they are 
distinguished by the different values of the parameters associated with different energetic terms that 
vary according to the molecular family considered. One of the most used force field is AMBER,
4
 which 
an analytic form is:  
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                              U                 = 
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+
   2 
                                       +                            (1.6) 
                                       +   
                                       +   
 
The force field terms are briefly illustrated as follows: 
1. Stretching energy 
                                     Ebond-stretch=  
In this expression, based on Hook law, the bond energy is written as a function of the divergence of the 
r bond length from the ideal r0. Kr  constant represents the bond force. Both r0 and Kr are specific for 
each couple of atoms bonded , thus they depend on the type of atoms involved in the bond.  
2. Bending energy 
                                  Ebond-bend=  
It is associated with the deviation of the bond angles from the ideal value θ0, based on the Hook law. 
Also in this case Kθ and θ0 depend on the atoms involved in the bond.  
3. Torsion energy 
                                   Erotate-along-bond=  
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It represents the potential energy deriving from the position of the torsion angle, it shows the same 
tendency of a period function, in which Kφ is the torsion energy (Kcal/mol), n is the torsion periodicity, 
φ and φ0 respectively are the torsion angle and the reference torsion angle (usually 0 or 180º). These 
elements represent the interactions involving covalently bonded atoms, however, commonly the force 
field takes in consideration also  the interactions between atoms not directly bonded, or rather Van der 
Waals forces and electrostatic forces. There are several force fields according to the family of 
molecules base on which they are parameterized. The most popular all-atom force fields usedn for 
biological macromolecules are AMBER, CHARMM, OPLS.
5
 A noteworthy variety of experimental 
conditions could be set up during the first molecular dynamics simulation. In the past, the first 
simulation were carried out considering the molecules as separated entities in the void, nowadays the 
inclusion of water is and obliged choice in order to make the simulation the more realistic possible. 
One of the most important solvent effect is the ability to act as a shield against electrostatic interactions. 
The solvent inclusion into molecular dynamics could occur in an explicit or implicit way. The first 
method, that is also the simplest one, consists in including a dielectric constant  in the electrostatic 
term of the potential energy, using, if necessary, an effective dielectric constant subjected to the 
distance from the solute. Common models of implicit solvent are: Poisson-Boltzmann (PB); 
Generalized Born (GB), Generalized Born Surface Area (GBSA). The principal advantage of these 
models is a reduction of the computational calculation time against the impossibility of identifying 
water molecules “functionally” relevant in receptor-ligand complexes. The explicit method consists in 
the explicit use of solvent molecules in the solvent energy calculation; those water molecules are 
treated with a specific force field, such as TIP3P, TIP4P, TIP5P. The explicit use of solvent molecules 
despise of implying the use of more power and calculating time, nowadays results to be the preferential 
approach. In the case of explicit solvent model, the so-called period boundary conditions are frequently 
chosen in order to prevent water molecule diffusion in areas too far from the solute and to guarantee 
that the simulation proceeds using the minimum number of solvent molecules. The solute is generally 
neutralized adding suitable ions and introduced in a box of solvent molecules of different shapes (cubic 
or poliedric). The molecular dynamics simulations in explicit solvent mode are usually carried out in 
“thermostatic” conditions, in which a system keeps the temperature stable. Besides isothermal 
conditions, a simulation can be also conducted at constant volume (NVT) or   isobaric conditions 
(NPT). The molecular dynamics are carried out on a time scale that goes from few nanoseconds to 
microseconds. The principal limitations regarding the molecular dynamics methods regard the 
approximations introduced to handle the massive amount of data and calculations necessary for 
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generating the trajectory of a system composed of several thousands of atoms. The first approximation 
is introduced by the exclusive use of classical mechanic: in a macroscopic system characterized by 
atoms belonging to the fist three groups and standard temperatures the margin of error is risible, 
however, classical mechanic is not able to describe events caused by the migration of electrons from 
one atom to another one (such as the breaking/formation of a covalent bond) for which a quanto-
mechanical component should be included. Moreover, the force fields are approximated since they 
don’t consider all the typology of atoms interactions but just the principal ones. For what concerns the 
Lennard-Jones interactions and the columbian interactions, the introduced approximation consists in 
not considering the interaction between one atom and all the rest of them but just the interactions 
between atoms that are at close distance (within the cut-off ray). Before proceeding with a molecular 
dynamic simulation, usually a preliminary phase with the aim of minimizing the energy and getting 
closer to a local energetic minimum is performed; this step is usually carried out by the same software 
used for the dynamics and it is based on two complementary algorithms: steepest descent and 
conjugate gradient, the first one leads rapidly in proximity to the closest minimum while the second 
one get more closer to it but it cannot work efficiently if the starting point is far from the minimum 
selected.  
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1.6.1.2. Molecular Mechanics Poison Boltzmann Surface Area (MM-PB/GBSA) 
The aim of conducting a molecular dynamics simulation is to obtain kinetic or thermodynamic data 
about the system used as a model of study. Many thermodynamic properties could be extrapolated by a 
sufficient number sampling pool of the system conformations, for instance the bond free energy of a 
protein-protein complex or a receptor-ligand complex. The bond free energy represents a measure of 
the complex stability, as a matter of fact only if it shows a negative value, the complex formation will 
be possible.
1
 Protein-protein interactions are critical for many biological processes, such as in the signal 
transduction pathways that regulates many aspects of cellular life and constitute an important potential 
therapeutic target. Several approaches presenting different characteristics in terms of accuracy and 
computational cost, are available which allow to estimate the bond free energy. Methods like the Free 
Energy Perturbation (FEP) or Thermodynamic Integration (TI) are computationally costly, however 
they are applied successfully to estimate the bond energy of several complexes.
6,7
 Many method were 
successively developed for estimating the free energy more rapidly, among which there are the Linear 
Interaction Energy (LIE),
8
 the Molecular Mechanics Poisson Boltzmann Surface Area (MM/PBSA)
9,10
 
method, the Chemical MonteCarlo Molecular Dynamics (CMC/MD)
11
 method and the λ-Dynamics 
method.
12
 MM-PBSA
13,14
 consists in a method for both evaluating the bond free energy and for 
calculating the absolute free energy of molecules in a solution, analyzed one the molecular dynamics 
simulation is completed.
4
 Generally, from the molecular dynamic trajectory some snapshots are 
extracted for calculating variation of the free energy between two states, typically, the receptor-ligand 
complex state or the protein-protein state and the state in which the two systems are isolated.  Only the 
initial and the final state of the system are evaluated for giving an estimation of the free energy 
change.
1
 The aim of this method is calculating the bond energy of a complex as shown in Figure 33. 
 
 
 
 
 
                                                                 Figure 33: Formation of the AB complex in solution 
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The bond free energy of the complex, ∆GBind is calculated basing on the following equation:  
                                                   Ḡ=ĒMM + ḠPBSA - TSMM                                                                         (1.7) 
Where G is the average free energy of the complex of interest, GPBSA in the solvation free energy, ĒMM 
is the average molecular mechanic energy and – TSMM is the solute entropy. The average molecular 
mechanic energy is typically defined by: 
                                      ĒMM = Ēbond + Ēangle + Ētors + Ēvdw + Ēellec                                                    (1.8) 
Where Ebond, Eangle, Etorsion, EvdW and Eellec  correspond to bonds, angles, torsions, Van der Waals 
interactions and electrostatic interactions of the force field. A Cut-off  that tends to the infinite is used 
for all the interactions. The salvation free energy could be fatherly parted into an electrostatic and a 
hydrophobic component: 
                                                          GPBSA= GPB + γA                                                        (1.9) 
GPBSA is the average solvation electrostatic component and it is calculated solving the Poisson-
Boltzmann (PB) equation, γ is the solvent superficial tension while A represents the solvent-accessible 
surface area. The average molecular mechanics energy (ĒMM) is calculated using SANDER, the 
program that constitutes the core of the suite software AMBER, according to the force field selected. 
The electrostatic component could be evaluated by an alternative approach that consists of using an 
approximation of the PB equation, that is the Generalized Born (GB). In other words, the two methods, 
MM/PBSA and the MM/GBSA are distinguished by the method used for calculating the salvation free 
energy electrostatic component while both of them determine the hydrophobic component evaluating 
the solvent accessibility to the solute. For a complete evaluation of the free energy of the complex it is 
possible also considering an entropic component that could be obtained, for instance, analyzing the 
normal modes. This component is much smaller compared to the average molecular mechanic energy 
(ĒMM) or to the salvation free energy (GPBSA) therefore frequently it is not considered in the free energy 
estimation. MM-PB(GB)SA method has the considerably advantage of being a retrospective method of 
analysis of the molecular dynamics trajectory and it results less expensive in term of calculation time-
consuming.  
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1.6.1.3. Computational alanine scanning 
Within  the molecular modeling techniques, frequently used in protein-protein interaction studies, there 
is a method called Computational Alanine Scanning (CAS), which evaluates, in a protein-protein 
complex, the impact of an alanine substitution in the interfacial residues in terms of free energy.
15
 The 
alanine is used because it presents a small and inert methyl group in its side chain. The methyl group, 
once substituted to one or more amino acidic residues,  permits to evaluate the functional contribute of 
the side chain of the substituted residue and, lastly, which residues provide strength and specificity of 
the bond. In the CAS method, as in the molecular mechanics/Poisson Boltzmann (Generalized Born)
16
 
surface area method, a retrospective approach based on snapshots extrapolated from a molecular 
dynamics trajectory, is used for calculating the free energy. The molecular dynamics can be carried out 
both in explicit
17
 and implicit solvent.
18
 The free energy variation between the wild type complex and 
the mutated one is defined as:  
                                  ∆Gbinding= ∆Gbinding_mutant - ∆Gbinding_wildtype                                                          (2) 
Keeping in mind that the bond free energy between two molecules id the difference between the free 
energy of the complex and the one of the singular monomers (receptor and ligand). The computational 
alternative to the alanine scanning mutagenesis has the consistent advantage of being much faster and 
less laborious, but, above all, it is able to reproduce experimental data of mutagenesis.
16
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1.7. Design of c-Maf LZ modulators 
 
1.7.1. Preparation of a c-Maf/T-MARE model 
Since nowadays structural X rays or NMR studies on c-Maf are not available in literature, the first part 
of this work focused on the analyses and description of the crystallographic complexes of Maf proteins 
with DNA, available on Protein Data Bank (PDB),
4
 that are 3A5T.pdb and 2WTY.pbd. The first one 
comprehends the MafG homodimer complexed with MARE25; the second one, the MafB homodimer 
creating a complex with a DNA sequence containing T-MARE site. Successively, using homology 
model strategies a template for c-Maf/T-MARE was obtained applying MafB as a template.  
 
1.7.2. Analysis of the crystallographic complexes 3A5T.pdb and 2WTY.pdb  
As previously described, recently the MafG crystal structure complexed with a double strand DNA 
sequence called MARE25 (15pb) was obtained (GTGCTGACTCATCAG).
19
 The MRE25 sequence 
includes the NF-E2 binding site, that binds the Maf homodimer.
20
 In MARE25 sequence was introduce 
a singular nucleotidic variation in comparison with the consensus sequence T-MARE 
(GCTGACTCAGCA) in order to evaluate the behavior of each monomer recognizing the DNA target. 
The crystallographic complex obtained by X ray diffraction, which includes the MafG homodimer 
bonded to MARE25, shows a resolution of 2.80Å and comprehends:  
1- Chain A: residues 19-111 (subunit A MafG); 
2- Chain B: residues 20-112 (subunit B MafG); 
3- Chain C: 5’-CTGATGAGTCAGCAC-3’; 
4- Chain D: 5’-GTGCTGACTCATCAG-3’; 
5- Crystallization water; 
6- Mg2+ ion. 
 
 
 
66 
 
1.7.3. Homology modeling and analyses of the complex c-Maf/T-MARE 
The homology model is a method that allows the construction of a computational model of a protein of 
interest with atomic resolution starting from its amino acidic sequence and available tridimentional 
structures obtained by X rays crystallographic techniques or NMR analyses (templates). The homology 
modeling could be a very useful tool for generating structural models, formulating hypothesis 
concerning the protein functions and carrying on preliminary studies of virtual screening to individuate 
molecules that could interfere with the protein functions. The model obtained will be as much accurate 
as higher is the sequence identity between the protein in exam and the template, thus the choice of the 
most suitable template results determinant. Lacking of a crystallographic data on c-Maf we choose to 
construct a homology model. We used, as a template, MafB, another large maf protein. The homology 
levels within the Maf family members are elevated (70-80%) especially in the LZ region. For the 
model preparation SWISS MODEL
21
 server was adoperated, which permits to generate homology 
models automatically, starting from the amino acidic sequence of human c-Maf. Once obtained the 
homodimer structure it was decided to introduce the T.MARE sequence derived from the 
crystallographic complex 2WTY.pdb. The homodimer complex of c-Maf/T-MARE is shown in Figure 
34. 
 
 
 
 
Figure 34: c-Maf homodimer complexed with T-MARE. The subunit A (purple) contacts the GC flanking region of the D chain, 
while the subunit B (in blue) binds the GC flanking region on chain C. 
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 -5 -4 -3 -2 -1 0 +1+2+3+4+5+6+7 
+5 +4 +3 +2 +1 0 -1 -2 -3-4-5-6-7 
H3 
H3 
H2 
H1 
H2 
H1 
H3 
H3 
H1 
H2 
H2 H1 
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The ancillary region is stabilized by the following hydrophobic interactions: Leu35, Leu28, Val25 of 
helix H3, Val20 from the connecting region between H2 and He helices, Leu17, Leu13 and Val10 od 
helix H2, Leu5 and Val6 of H1 helix (Figure 35). 
 
 
                                                              Figure 35: Hydrophobic cluster in the HER region of subunit A. 
 
As in the case of MafG, the charged residues are exposed on the surface (Figure 36): 
 
                            
                                                         Figure 36: Charged residues exposed on the surface of EHR region.  
 
In the EHR region we could identify: 
Hydrophobic amino acid residues: 11/35               31% 
H3 
H2 
H1 
Leu 35 
Leu 28 
Val 25 
Val 20 
Leu 17 
Leu 13 
Val 10 
Val 6 
Leu 5 
H3 
H1 
H2 
H3 
H1 
H2 
Arg 33 
Lys 29 
Lys 22 
Arg 32 
Arg 18 
Arg 15 
Arg 11 
Glu 3 
Asp 2 
Glu 12 
Glu 24 
Glu 23 
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Polar amino acidic residues: 10/35          29% 
Negatively charged amino acidic residues: 5/35            14% 
Positively charged amino acidic residues: 9/35              26% 
The contacts between monomers in the leucin zipper region of c-Maf are mediated both by 
hydrophobic residues (Leu55, Leu62, Leu63, Val66, Leu69, Ile73, Val77, Leu90) and electrostatic 
interactions (Gln51 with Arg52, Glu58 with Lys59, Glu79 witharg80) (Figure 37). 
 
   
 
 
 
 
 
 
 
 
 
                                    Figure 37: Interactions in the LZ region of c-Maf. Subunit A is in purple, subunit B in blue. 
 
The interaction between the c-Maf homodimer and the T-MARE can be reassumed as follows: 
Subunit A: Arg33 forms two hydrogen bonds with the carbonylic oxygen of chain D guanine in 
position +4. Thr34  creates a Van der Waals interaction with the sugar moiety of the thymine in 
position +2 on chain C and an hydrogen bridge with the phosphate group of the same base. Lys36 
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forms a Van der Waals interaction with the sugar moiety of thymine in position +5 of chain D. Asn37 
is connected to thymine +2 on chain D through a Van der Waals interaction and it forms an hydrogen 
bond in the NH moiety of  the cytosine +3 on chain D. Arg38 constructs an hydrogen bond with the 
phosphate group of thymine +2 on chain C. Tyr40 creates a van der Waals contact with the thymine in 
position + 5 and with the thymine in position +2  on chain D, an hydrogen bond with the phosphate 
group of the guanine in position +4 on chain D. Lys47 and the thymine residues in position +2 on chain 
D are connected through an hydrogen bond with the phosphate group on the base.   
Subunit B: Thr34 forms a vdW interaction with the sugar moiety of the thymine -2 on chain D and an 
hydrogen bridge with the phosphate group on the same base. Lys36 creates a vdW interaction with the 
thymine in position -5 and an hydrogen bond with NH2 of the cytosine in position -2 on chain C. Arg38 
is connected to the phosphate group on thymine -2 on chain D through an hydrogen bond. Tyr40 forms 
a vdW interaction with the sugar moiety of the thymine in position -5 and an hydrogen bond with the 
phosphate group of the guanine in position -4 on chain C. Arg45 creates an hydrogen bridge with the 
phosphate group of adenine in position 0 of chain D. Also in this case, Asn37 and Arg33 (equivalent to 
Asn61 and Arg57 in MafG and Asn248 and Arg244 in MafB) establish interactions principally with the 
flanking regions.  
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1.7.4. Molecular dynamic simulation 
1.7.4.1. Definition of a MD protocol 
A MD protocol is generally subdivided into four steps: 
1. Energetic minimization; 
2. System equilibration; 
3. Heating; 
4. Production run. 
In this case, the same MD protocol was carried out using two different force field (ff03.rl and ff99SB) 
both on the homodimer MafG in the absence and in the presence of MARE25 and on c-Maf 
homodimer in the absence and in the presence of T-MARE, with the aim of extrapolating information 
from the trajectory analyses about the behavior of small and large Mafs. The crystallographic structures 
derived from PDB data bank or obtained by homology modeling are not immediately suitable for a 
computational analyses. Frequently they don’t posses information about the position of hydrogen atoms 
and they lack of precise data regarding the sequence and nature of the atoms bonds, therefore it is 
necessary to set information about the protonation state of residues and their tautomery. The starting 
sequences of MafG and c-Maf were protonated using H++ server,
22
 calculating the electrostatic 
component through Poisson Boltzmann algorithm in ionic conditions of 0.15M pH 7.40 trying to 
reproduce the physiological conditions. The solvent molecules and Mg
2+
 ions were removed from 
MafG homodimer and both the C and the N- termini of each residue were protected using, respectively, 
ACE (acetamide) and NME (N-methyl). Once ultimate this preliminary steps, both the accurate atom 
type assignation and the correct protonation of the positively or negatively charged residues were 
visually evaluated. The following MD protocol was applied to both the models:  
8. Minimization of hydrogens, water and ions: 5000steps of which the first 1000 carried out with 
steepest descent algorithm and the subsequently 4000 steps with conjugate gradient algorithm; 
9. Volume constant  equilibration (NVT) and, successively, pressure constant (NPT); 90ps, from 0m 
to 300K, with an harmonic restraint of 5Kcal/mol on the backbone; 
10. Side chains, water and ions minimization: 5000steps of which the first 2500 carried out with 
steepest descent algorithm and the remaining 2500steps with conjugate gradient algorithm; 
11. Gradual heating from 0 to 300K in 6 consecutive steps of 5ps each with a ∆T of 50K; 
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12. Volume constant equilibration (NVT), 100ps at 300K with an harmonic restraint on the backbone 
of 5kcal/mol and successively at constant pressure (NPT) in 4 consecutive steps of 100ps at 300K 
where the harmonic restraint on the backbone is progressively reduced with a ∆of 1kcal/mol; 
13. Production run at constant pressure (NPT) without restraint at 300k: 8 steps of 1000ps each. 
The same protocol was performed using two different force fields: ff03.rl and ff99SB. The simulation 
time reached complexively 9620 ps for each MD. The minimization step is essential for relaxing the 
system and bringing the starting structure closely to the energetic minimum. The equilibration step that 
follows the gradual heating phase, allowed the convergence of the temperature, density, pressure and 
energy parameters, keeping them constant during time. The analyzed trajectory is obtained from the 
production run step. All the dynamics were conducted considering the covalent bonds comprehensive 
of the hydrogen atoms blocked using SHAKE
23
 algorithm (periodic conditions with a NPT model, 8Å 
cut-off ray, explicit solvent H2O TIP3P with a parallelepipeds-shape solvent box). All the charges were 
neutralized by Na
+
 and Cl
-
 ions. In order to keep stable the temperature at 300K the Berendsen
24
 
thermostat was used. The program utilized for the energetic minimizations was SANDER belonging to 
the Amber software.
4 
 
7.4.1.2. Analysis of the trajectories 
The trajectories post-processing step was performed with PTRAJ program, belonging to AMBER11 
and with VDM
25
 which has been used for the visual analyses of the trajectories and for realizing some 
pictures reported in this chapter. The visual analyses of MafG and c-Maf trajectories without the 
respective DNA target sequences, reveals that the leucine zipper region remain firmly coupled during 
all the production run time, while the DNA binding site, in both cases, shows a bending outside 
tendency that causes an increasing destructuring process of the α-helices regions EHR. This behavior is 
more evident using ff99SB force field (Figure 38 and 39). 
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Figure 38: MafG homodimer is the absence of its DNA target MARE25 after the product run step (8ns); respectively left side ff03.r1 
force field and right side ff99SB force field. 
 
                           
Figure 39: c-Maf homodimer is the absence of its DNA target T-MARE after the product run step (8ns); respectively left side ff03.r1 
force field and right side ff99SB force field 
 
The RMSD (Root-Mean-Square-Deviation) tendency during time compared with the initial structure, 
confirmed the results observed with the visual analyses obtained with ff99SB (Figure 40). 
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Figure 40: RMSD tendency of the backbone during time (left side c-Maf homodimer; right side MafG homodimer) conducted by 
ff99SB in the absence of the DNA target.  
 
The backbone fluctuations reach 19  in the case of c-Maf and 24Å in the case of MafG. At the 
contrary, the visual analyses of the trajectories of the MafG-MARE25 and c-Maf-T-MARE 
complexes revealed, using both force fields,  an opposite behaviour: the DNA binding site reagion 
mantains a stable α-helical structure remaining positioned at the DNA major groove locus (Figure 
41 and 42).  
                                    
Figure 41: MafG homodimer in the presence of MARE25 DNA  sequence at the end of the production run time. ( left side ff99Sb 
force field; right side ff03.r1) 
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Figure 42: c.Maf  homodimer in the presence of T-MARE DNA  sequence at the end of the production run time. ( left side ff99Sb 
force field; right side ff03.r1). 
 
 
The comparison between  the RMSD tendency of the complexes in time with the strarting structure 
(Figure 43) showed that the backbone fluctuations are much less significant than in the absence of the 
DNA target (around 7Å in both cases). 
 
               
Figure 43: RMSD tendency of backbones in both models studied as a function of the production run time (on the left side c-Maf 
homodimer; on the right side MafG; simulations carrie out with ff99SB). 
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As a confirmation of this theory, the distance measured from the C carbonilic of the ACE group to the 
N-terminal extremity of a c-Maf monomer, passes from 73.27Å in the absence of DNA to 40.13Å in 
the presence of the DNA target (in the case of MafG, from 87.23Å to 60.31Å). Circular discroism 
experiments coducted by Dlakić et all., showed that in the presence of the DNA target containing the 
flanking regions (MARE), the DNA binding domain undergoes a conformational change increasing its 
α-helical contents. On the contrary, an unfolding tendency could be observed in the absence of the 
DNA target.
26
  Therefore, the results obtained from the simulations showed that two different members 
of Maf family, a small maf, MafG, and a large Maf, c-Maf, have a similar folding behaviour in the 
absence/presence of the DNA target sequence. Moreover, these computational results are consistent 
with the circular dicroism experiments.  
 
1.7.5. Design of peptidic modulators using computational alanine scanning  
 
The free energy for the c-Maf homodimer formation was calculated using MMGBSA method (solvent 
type igb=5; salts concentration 100nM) on 50 snapshots derived from the homodimer trajectory in the 
absence of DNA target. The homodimer formation results thermodinamically favoured with a total free 
energy of -103.09 kcal/mol (st. dv. ±4.79) using ff03.r1 protocol and of -97.06 kcal/mol (st. dv. ± 4.78) 
with ff99SB force field. The protein-protein interface involves several residues: Leu55, Leu62, Val66, 
Leu69, Ile73, Val77, Leu90, Gln51 with Arg52, Glu58, Lys59, Glu79 and Arg80 (Figure 44). 
 
 
 
 
 
 
 
 
                               Figure 44: c-Maf homodimer interactions in the LZ region (subunit A in purple; subunit B in blue) 
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The CAS method allowed the retrospective free energy calculation using snapshots extracted from a 
molecular dynamics trajectory. The aim is to evaluate the impact in terms of the homodimer bond free 
energy change, of the mutation of each of the reported residues into alanine. In order to carry out a 
CAS analyses, each amino acidic residue involved into the binding was manually modified in the PDB 
file; 50 snapshots where then extracted from each trajectory of the mutated homodimer obtained with 
both ff03.r1 and ff99SB force field, in the absence of DNA target (salt concentration 100nM). A 
comparison was made between the wild type complex and the mutated ones. The interfacial amino 
acids were divided on the base of the variation of the free energy (∆∆G) provoked by their substitution 
with an alanine: hot spots (∆∆G > 4 kcal mol-1), warm spots (2kcal mol-1< ∆∆G< 4 kcal mol-1) or cold 
spots (∆∆G< 2kcal mol-1). Comparable results were obtained from both force fields. Hot and warm 
spots are equally distributed at the homodimer interface (Figure 45 and 46). 
                   
                                      Figure 45: Alanine scanning at the c-Maf  homodimer interface using ff99SB protocol 
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                                         Figure 46: Alanine scanning at the c-Maf  homodimer interface using ff03.r1 protocol.  
The rational besides the peptidic modulator design is that of using c-Maf wild type as a template and 
substituting the residues, identified as cold spot from CAS analyses, in order to increase the 
hydrophobic and or electrostatic interactions. On the other side, the hot spots residues will not be 
changes. Two classes of peptides were outlined: the first one that binds the N-terminal region of the LZ 
and the second one that shows affinity for the C-terminal region in order to inhibit the homodimer 
formation interfering with the dimerization process. The starting point was the study of the c-Maf 
homodimer interfacial interactions localized in the LZ region closest to the DNA binding site (Figure 
47). 
 
 
 
 
 
78 
 
 
                       Figure  47: Detailed representation of the c-Maf homodimer interfacial interactions in the LZ region closer to DBD. 
 
Taking c-Maf as a reference, it was decide to substitute Arg45 with a Glu, Arg48 with an acidic residue, 
such as Asp or Glu and Gln51 with an Asp or Glu in the aim of instauring additional electrostatic 
interactions compared with the wild type monomer. Even though Leu55 was identified as an hot spot 
during the CAS analyses, it was substituted with a basic residue and the adjacent Glu was modified into 
a hydrophobic leucine residues in order to keeping the hydrophobic interaction and creating an 
adjunctive salt bridge at the same time. Furthermore, Leu63 and Val66 were replaced with other  
hydrophobic residues. Peptide1, peptide 1_variant, peptide2 and peptide 2_variant were designed on 
the base of these considerations; in peptide 4 sequence instead residues Leu55 and Glu56 were 
maintained untouched (Table 4).  
 
 
 
 
R48 
R48 
Q51 
R 52 
L 55 E 56 
E58 
K59 
L63 
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V66 
R45 
R45 
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SEQUENCE LENGTH 
Peptide wild 
type 1 
RFKRVQQRHVLESEKNQLLQQV  22 aa 
Peptide 1 EFKEVQERHVRLSEKNQLIQQV 22 aa 
Peptide 
1_variant 
EFKDVQERHVKLSEKNQLIQQV  22 aa 
Peptide 2 EFKEVQERHVRLSEKNQLI  19 aa 
Peptide 
2_variant 
EFKDVQERHVRLSEKNQLLQQI  22 aa 
Peptide 4 EFKDVQERHVLESEKNQLL  19 aa 
 
Table 4: Sequences of the peptides designed with CAS: above the wild type monomer sequence is shown (in green are indicated the 
warm spots; in yellow the cold spots, in red the hot spots). The residues in purples are deviation from the wild type sequence.  
 
Figure 48 shows the far LZ region; only one peptide was designed interacting with this sequence, 
peptide 5 in which Ile73 and Leu90, both identified as warm spots, were replaced with leucine residues 
and Val77, a cold spot, substituted with a isoleucine residue in order to increase the hydrophobic 
interactions.  
 
 
 
 
 
 
 
 
                                    Figure 48: Detail representation of the c-Maf homodimer interaction in the far LZ region.  
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The peptide sequence is shown in Table 5: 
NOME SEQUENZA  LUNGHEZZA 
Peptide wild type 2 ISRLVRERDAYKEKYEKL 18 aa 
Peptide 5 LSRLLRERDAYKEKYEKI 18 aa 
 
Table 5: Sequences of the peptides designed with CAS: above the wild type monomer sequence is shown (in green are indicated the 
warm spots; in yellow the cold spots, in red the hot spots). The residues in purples are deviation from the wild type sequence.  
 
For each peptide, starting from the PDB file containing the c-Maf homodimer, the mutations were 
carried out only on one monomer using MOE software
27
 changing one residue per time. For all the 
designed peptides a molecular dynamics study (same protocol applied before) was performed using 
ff99SB force field. The visual analyses revealed that all the peptides remained bonded to the monomer 
for the entire simulation time (8ns). The association free energy was calculated by MMGBSA for each 
peptide (solvent model igb=5; salt concentration 100nM) basing on 50 snapshots taken from each 
trajectory. The energetic data, shown in Table 6 do not consider the entropic contribute. 
 
NAME 
BOND FREE ENERGY 
ESTIMATION 
ST. DV. 
Peptide wt1 -32,20 kcal/mol   
Peptide 1 -40,99 kcal/mol   
Peptide 1_variante -49,83 kcal/mol   
Peptide 2 -43,77 kcal/mol   
Peptide 2_variante -46,09 kcal/mol   
Peptide 4 -40,06 kcal/mol   
Peptide wt 2 -53,69 kcal/mol   
Peptide 5 -53,80 kcal/mol   
 
                 Table 6: Estimation of the bond free energy between c-Maf monomer and the designed peptides calculated by MMGBSA. 
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Successively, a CAS analyses was performed on the residues replaced in the designed peptides with the 
purpose of evaluating if the mutation into an alanine is more effective on the bond energy than the 
residues on the entire c-Maf wild type monomer (Figure 49). 
                                Peptide 1: EFKEVQERHVRLSEKNQLIQQV (22aa) 
                  
Glu45, Leu56, and Ile63 mutated into alanine have almost the same impact on the bond formation 
energy than Arg45, Glu56 and Leu63 of the wild type monomer; on the contrary the replacement of 
Glu48 and Glu51 residues provokes a much more significative change into the bond free energy than 
the equivalent Arg48 and Gln51 residues on the wild type monomer which means that this substitution 
is favorable.  
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Peptide 1_variant: EFKDVQERHVKLSEKNQLIQQV (22 aa) 
 
 
The only favorable substitution regards Arg48 residue with Asp, as a matter of fact once the 
replacement of Asp with alanine has a big influence on the complex formation energy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
Peptide 2: EFKEVQERHVRLSEKNQLI (19 aa) 
 
 
The substitution of Glu51, Glu48, and Arg55 residues with alanine weights much more on the complex 
formation energy than the corresponding mutations on the wild type monomer. Thus, the replacement 
results being useful.  
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                          Peptide 2_variant: EFKDVQERHVRLSEKNQLLQQI (22 aa) 
 
For what concerns peptide 2_variant all the substitutions result being more favorable than the 
corrispective residues on the wild type monomer.  
Peptide 4: EFKDVQERHVLESEKNQLL (19 
aa)  
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All the three substitutions result being favorable, moreover comparing the energetic data with 
peptide 2 from which peptide 4 differs only in mantaining the wild type residues Leu55 and 
Glu56, it could be assessed that the choice made is a potential succesful strategy.  
 
Peptide 5: LSRLLRERDAYKEKYEKI (18 aa) 
 
 
Peptide 5 is the only peptide designed for interfering in the C-terminal region of c-Maf 
homodimer.  The replacement of Ile73 with a leucine is not particularly favorite while both 
Val77 and Leu90 substitution with, respectively, leucine and isoleucine, result effective.  
In conclusion, using MMBGSA method it was possible to asses that both the two classes of 
peptides,  maintain the ability of binding the c-Maf monomer. Moreover, they results to be 
termodinamically favorite compared to the wild type sequence. The best results were 
obtained with peptide 5; as in the first class of peptides, the most promising peptides 
outlined were  peptide 1_variant; peptide2_variant and peptide2.  
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1.8. Synthesis of the c-Maf LZ modulators and circular dicroism studies 
1.8.1. Peptides synthesis 
The c-Maf LZ domain and the peptidic modulators outlined from in silico studies as described in 
chapter 1.7., were obtained by chemical synthesis using MW-SPPS strategies. In table 7 are 
recapitulated the amino acidic sequences and the synthetic strategy adopted for the designed peptides: 
  
PEPTIDE SEQUENCE 
ΔG 
estimation 
(kcal/mol) 
MW (Da) 
ADOPTED 
STRATEGY 
LZ C-terminal 
QQRHVLESEKNQLLQQVDHLKQ 
ISRLVRERDAYKEKYEKLV 
- 5076.08 MW-SPPS 
1 EFKEVQERHVRLSEKNQLIQQV -40.99 2737.1 MW-SPPS 
1_variante EFKDVQERHVKLSEKNQLIQQV -49,83 2695.05 MW-SPPS 
2 EFKEVQERHVRLSEKNQLI -43,77 2381.69 manual 
2_variante EFKDVQERHVRLSEKNQLLQQI -46,09 2737.09 manual 
4 EFKDVQERHVLESEKNQLL -40.06 2340.0 MW-SPPS 
Wt 2 ISRLVRERDAYKEKYEKL -53,69 2295.64 manual 
5 LSRLLRERDAYKEKYEKI -53,80 2309.67 manual 
                                                                  Table 7: Recapitulating table of the synthesized peptides  
 
1.8.2. Circular dicroism analyses 
1.8.2.1. c-Maf LZ domain characterization 
The CD studies were obtained in collaboration with the Pharmacy Department of Parma University. 
The role of the LZ domain is to allow homo or hetero-dimerization of b-ZIP factors through 
hydrophobic interactions due to the presence of several leucine residues. The spectrum of the entire c-
Maf LZ domain was carried out in phosphate buffer (20mM, pH 7.40); the presence of two negative 
bands, respectively around 208nm (amidic transition p-p*) and at 222nm (ascribed to the n-p* 
transition), typical of α-helices, can be observed (Figure 50). The absence of a maximum at 198nm, 
attributed to the excitation coupling of the p-p* transitions, suggests the presence of several secondary 
conformations. 
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                                           Figure 50: CD spectrum of c-Maf LZ domain in phosphate buffer pH 7.40 
 
 
The LZ domain appears to be well structured in the absence of the basic region (BR) and the extended 
homology region (EHR) that complete the DNA binding domain of Maf proteins. The analyses of the 
CD spectrum secondary structure was performed using CONTIN algorithm (Dichroweb server) as 
shown in Table 8.  
 
 
 HELIX STRAND TURNS UNORDER 
LZ c-terminal 43% 10% 15% 32% 
                      Table 8: Calculated percentage of different secondary structure motifs obtained by Dichroweb server. 
 
 
The high α-helical percentage even in the absence of the DNA target, could be ascribed to the 
hydrophobic interactions established by the leucine residues that allow the conformational disorder 
decrease through dimerization. In order to evaluate the oligomerization state in solution, essential 
information for optimizing the model of study for the dimerization inhibitors, the LZ domain CD 
spectrum was measured at different concentrations (Figure 51). In this study cuvettes presenting 
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different pathlength  were used with the aim of keeping the signal/rumor ratio constant compensating 
the lower signal with a longer pathlength.  
     
                                         Figure 51: CD spectra of c-Maf LZ domain at different concentrations 
 
The dilution provokes a diminishing in the α-helical content assuming a shift to the monomeric form of 
the LZ domain as a consequence of a loss of secondary structure. In Figure 52 are reported the c-Maf 
LZ domain ellipticity values at 208nm as a function of its concentration; a deceasing tendency could be 
observed corresponding to a minor α-helical contents. Thus it could be asserted that the 
monomeric/dimeric equilibrium state of the LZ domain is directly correlated to its concentration in 
solution. 
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                                         Figure 52: Ellipticity values at 208nm as a function of LZ concentration 
 
1.8.2.2. CD analyses of dimerization inhibitors 
Initially the spectra of the single peptides were measured at 20μM concentration (Figure 53).  
 
 
 
 
 
 
 
 
 
 
 
 
                                            Figure 53: CD spectra of the peptides alone (concentration 20μM) 
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In solution the peptides exhibit a unstructured form leading to the assumption that they would not be 
able to form homodimers. In a second time, the interaction studies with the LZ domain were also 
performed measuring the spectra of the binary mixtures at equimolar concentration (20μM) after 
overnight incubation (Figure 54).  
      
     
                               Figure 54: CD spectra of the LZ domain and its interactions with the inhibitors designed in silico. 
 
The spectra of the interactions showed an α-helical content higher than the spectrum of the LZ domain 
alone. In order to verify if the increase is caused by the contribute of the peptide or if an interaction is 
effective through a three dimensional structure stabilization, the spectra of the mixtures were compared 
with the ones obtained from the arithmetic sum of the LZ and the peptide ellipticity contributes taken 
singularly (From Figure 55 to Figure 61).  
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Figure 55: Comparison of the CD spectra of the LZ/peptide 1 interaction mixture and the arithmetic sum of the separated contributes of 
the two peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: Comparison of the CD spectra of the LZ/peptide 1V interaction mixture and the arithmetic sum of the separated contributes of 
the two peptides. 
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Figure 57: Comparison of the CD spectra of the LZ/peptide 2 interaction mixture and the arithmetic sum of the separated contributes of 
the two peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: Comparison of the CD spectra of the LZ/peptide 2V interaction mixture and the arithmetic sum of the separated contributes of 
the two peptides. 
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Figure 59: Comparison of the CD spectra of the LZ/peptide 4 interaction mixture and the arithmetic sum of the separated contributes of 
the two peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60: Comparison of the CD spectra of the LZ/peptide 4 interaction mixture and the arithmetic sum of the separated contributes of 
the two peptides. 
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Figure 61: Comparison of the CD spectra of the LZ/peptide 2wild interaction mixture and the arithmetic sum of the separated contributes 
of the two peptides. 
 
 
The spectra of the mixtures exhibit an α-helical content higher than the arithmetic sum of the 
contributes of the peptides taken singularly, as enlightened by the intensity of the peaks at 208nm and 
222nm, thus showing that a successful interaction occurs between the LZ domain and the inhibitors. An 
ulterior confirmation was obtained by a secondary structure analyses of the mixtures carried out using 
Dichroweb server (CONTIN server) (Table 9).  
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 HELIX STRAND TURN UNORDER 
LZ domain alone 43% 10% 15% 32% 
LZ + peptide 1 64% 1% 9% 31% 
LZ + peptide 1V 59% 1% 9% 31% 
LZ + peptide 2 69% 1% 10% 20% 
LZ + peptide 2V 74% 1% 9% 16% 
LZ + peptide 4 67% 1% 10% 22% 
LZ + peptide 5 64% 1% 10% 25% 
LZ + peptide 2wild 58% 2% 11% 29% 
 
                   Table 9: Secondary structure analyses of the LZ domain/inhibitors mixtures carried out by Dicroweb server. 
 
 
An increase of the α-helical percentage and a consequent decrease of the unordered fraction is 
noticeable for each mixture endorsing the hypothesis that a positive interaction occurs trough a LZ 
domain structure consolidation.  The most promising peptide results to be peptide 2V (74% α-helical 
contents). Peptide 2V inhibitory activity was investigated; in Figure 62 LZ ellipticity is displayed as a 
function increasing concentration of inhibitor. The results show a decreasing tendency in the LZ 
domain ellipticity supporting the hypothesis of an effective dimerization inhibition.   
 
 
 
 
 
 
 
 
 
98 
 
 
 
 
 
 
 
 
 
 
 
 
                                 Figure 62: LZ domain ellipticity values plotted as a function of  peptide 2V inhibitor concentration.  
 
With the aim of investigate the specificity of the dimerization inhibitors for c-Maf LZ domain, the CD 
spectra of the peptide with MafA LZ, which presents a high level of homology with c-Maf, were 
registered in the same experimental conditions (Figure 63).  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                           Figure 63: CD spectra of MafA LZ domain with the c-Maf LZ domain inhibitors. 
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It could be observed that MafA LZ domain itself is not structured however the presence of the 
inhibitory peptides not only doesn’t improve the secondary structure stability. An increase in the peak 
at 200nm is observed due to the sum of the ellipticity contributes of both the peptides as it is confirmed 
by the comparing the spectrum of the mixture with the one obtained from the arithmetic sum of the 
contributes of the two peptides (Figure 64).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64: Comparison of the CD spectra of the MafA LZ/peptide 2wild interaction mixture and the arithmetic sum of the separated 
contributes of the two peptides. 
 
 
From this study it can be evicted that the inhibitory activity of the peptides is specific for their target c-
Maf, the successful interaction occurs through a three dimensional stabilization that implies an increase 
in the α-helical contents of the complex.  
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1.9. Conclusions 
In this work our goal was to study the DNA binding of  Mafs proteins bLZ transcription factors whose 
sequence is well conserved within Maf family members. In particular, we focused on a large Maf, c-
Maf whose deregulation plays a fundamental role into a major pathology, currently untreatable, 
multiple myeloma. The overexpression of c-Maf is observed in the 50% of multiple myeloma cases 
associated with poor prognosis. Because of the lack of large Mafs crystallographic data available in 
literature, the creation of an c-Maf homology model was made decisive for the design of modulators.  
Moreover, thanks to the DBD similarity, and in order to have a better understanding of the target-
interaction mode of Mafs DBD, we decided to extend the study to another large Maf protein, MafA, 
which is involved into the regulation of insulin synthesis, secretion and metabolism.  
Starting from the crystallographic data available on PDB regarding the complex G-Maf, a small Maf, 
and its DNA target, MARE25, an homology model of the complex c-Maf/T-MARE was outlined. 
Successively, performing molecular dynamics studies, we observed the folding behavior of c-Maf in 
the presence and absence of its DNA target T-MARE. Comparing the results with the ones obtained 
from G-Maf/MARE25 complex we noticed a common behavior: in the absence of the DNA target, the 
EHR region, which represents, together with the basic region, the DNA binding domain, shows a 
progressive unfolding tendency diminishing its helical content.  On the other hand, in the presence of 
the DNA target, the DBD maintains a folded structure indicating that the interaction is effective 
through a three-dimensional conformation stabilization. Our observations are consistent with the CD 
experiments data previously reported in literature. We succeeded in obtaining the chemical synthesis of 
the entire 75mer  MafA DNA binding domain adopting MW-SPPS strategies. The folding properties of 
the entire MafA DBD and its fragmentations, and the interaction mode with its DNA target (the human 
insulin promoter) were also investigated using circular dicroism. These results gave us an ulterior 
confirmation of the previously enlightened tendency: a disorder-order transition is at the base of the 
recognition mechanism of Mafs DBD and DNA target sequence. In a second time, using computational 
alanine scanning method, we carried out the in silico design of c-Maf peptidic modulators that act as 
inhibitors of dimerization which is fundamental for DNA binding and transcription activation. The 
peptides were obtained by chemical synthesis and an activity screening was carried out by circular 
dicroism. These studies confirm the inhibitory activity and specificity of the peptides towards their 
target, c-Maf LZ domain. However, in this preliminary phase, the peptides pharmacokinetics and 
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pharmacodynamics aspects were not evaluated. The future developments of this project will be focused 
on the pharmacokinetics parameters improvement by creating peptidomimetics modulators.  
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1.10. Materials and methods 
 
1.10.1. Materials 
Fmoc protected amino acids, Rink amide PEG MBHA resin, HBTU and DIPEA were purchased from 
Iris Biotech Gmbh. HOBT, piperidine, acetic anhydride, triisopropylsilane (TIS), thioanisole (TAN), 
phenol, TFA, and HPLC-grade solvents were from Sigma Aldrich. 1-Methyl-2-pyrrolidinone (NMP) 
was obtained from BDH/VWR/PROLABO and 1,2-ethanedithiol (EDT) from Fluka. The DNA 
sequences were purchased at Primm Srl. All peptides were prepared by MW-SPPS using a Liberty 
Microwave Peptide Synthesizer (CEM Corporation) and puriﬁed by preparative RP-HPLC using Jasco 
BS-997-01 equipment and a DENALI C-18 column from GRACE VYDAC (10 lm, 250 9 22 mm). 
Two mobile phases were used: A = 95 % water, 5 % ACN, 0.1 % TFA; B = 95 % ACN, 5 % Water, 
0.1 % TFA. The peptides were analyzed by analytical HPLC using a Jasco BS-997-01 equipment and 
detector series Star 800 from VARIAN. The mass spectra were recorded on a LCQ Advantage 
spectrometer from Thermo Finnigan for ESI–MS analysis and on Autoﬂex 3 from Bruker Daltonics for 
MALDI-TOF analysis. The CD spectra were recorded at room temperature using a Jasco J-810 
spectropolarimeter and a 0.01 cm quartz cell (Hellma Suprasil). 
 
1.10.2. MW-SPPS 
Peptides were synthesized C-terminally amidated and N-terminally acetylated using Rink amide PEG 
MBHA resin with a loading of 0.35 mmolg
-1
 and on a 0.1 mM scale. Amino acid side-chain protection 
was as follows: tBu for Asp, Glu, Tyr, Thr, Ser; Pbf for Arg; Boc for Lys; Trt for Asn, Gln and His. 
Protocol A (for peptide up to 28 residues): single couplings were performed with Fmoc-amino acid (5 
equiv.) activated in situ with HBTU (5 equiv), HOBt (5 equiv.) dissolved in DMF, and DIPEA 1M in 
NMP (10 equiv.); each coupling was achieved using MW irradiation (5 min, 75 ºC, 20W; for His and 
Cys 50ºC, 2 min at 0W and 4 min at 25W). Fmoc cleavage was accomplished by treating the peptidyl-
resin with 20% piperidine in DMF (3 min, 75ºC, 40 W). Protocol B (for Arg and, starting from the 35th 
residue, for all amino acids): double couplings were performed with Fmoc-amino acid (5 equiv.) 
activated in situ with HBTU (5 equiv.), HOBt (5 equiv.) dissolved in DMF, and DIPEA 1M in NMP 
(10 equiv.). The ﬁrst coupling was performed at room temperature (1 h and without MW irradiation); 
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the second one was achieved using MW energy (5 min, 75ºC, 25W). Fmoc cleavage was accomplished 
by treating the peptidyl-resin with 20% piperidine in DMF (3 min, 75ºC, 40 W). 
1.10.3. N-terminal acetylation 
Synthesized peptides were manually acetylated at the N-terminus on resin using acetic anhydride (10 
equiv.) and DIPEA (10 equiv.) in DCM for 30 min at room temperature. 
1.10.4. Cleavage from the resin 
The peptides were manually cleaved from the resin with a mixture of TFA/water/TIS (90:5:5 v/v) for 6 
h at room temperature or, when Cys and Met were present with the mixture TFA/water/TIS/TAN/EDT 
(90:3:5:5:3 v/v). The crude peptides were precipitated from ice-cold diethyl ether and recovered by 
centrifugation at 4ºC for 5 min (4,500 rpm). Three diethyl ether washes/centrifugation cycles were 
carried out to efﬁciently remove the scavengers. If Cys was present, a mixture of t-butyl-methyl ether/ 
petroleum ether (1:1 v/v) was used to avoid oxidation. 
1.10.5. Peptide puriﬁcation and characterization 
HPLC and MS data of synthesized peptides   
The peptides were analyzed by analytical HPLC using two mobile phases: A = 95% Water, 5 % ACN, 
0.1 % TFA,  B = 95% ACN, 5% Water, 0.1% TFA and a gradient of: 95% A for 5 min., then 95-50% 
A over 50 minutes. UV detection was made at 220 nm. The mass spectra were recorded on a LCQ 
Advantage spectrometer from Thermo Finnigan for ESI-MS analysis and on Autoflex 3 from Bruker 
Daltonics for MALDI-TOF (sinapinic acid or 4-CHCA matrix) analysis (Table 10). 
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Human MafA DNA binding domain 
EERFSDDQLVSMSVRELNRQLRGFSKEEVIRLKQKRRTLKNRGYAQSCRFKRVQQRHILESEKCQLQSQ
VEQLKLEVGR 
Name Chain Length MWcalculate (Da) MWfound (Da) HPLC  
TR (min) 
Mg purified 
H3 short 248-263 2039.49 2038.18 14.08 4,0 
H1-H2 223-243 2592.85 2592.30 18.19 9,0 
LZP 277-301 3020.44 3019.65 16.91 16,0 
BR 248-275 3531.19 3532.30 15.27 18,3 
H2-H3short 236-263 3537.16 3536.12 16.54 35,7 
EHR-BR 227-278 6365.33 6360.5 23.84
 
14,6 
EHR-H3 227-263 4500,18 4494,6 18,80 9,3 
H3 248-301 6622.71 6621.30 16.39 23,0 
DBD 227-301 9001,48    
                                                         Table 10: Recapitulatory analyses of the synthesized peptides. 
 
 
 
 
 
 
 
         . 
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1.10.6. General procedure for DNA annealing 
The two complementary DNA oligomers were diluted in HPLC-quality water, heated at 95ºC and 
gradually cooled (10ºC every 10 min) to room temperature. The obtained duplex was stored at -20C 
before using. 
1.10.7. Circular dichroism on MafA 
Peptide stock solutions were prepared in HPLC-quality water (100 M, 1.5mL). Spectra were obtained 
from 195 to 250nm with a 0.1nm step and 1 s collection time per step, taking three averages. The 
spectrum of the solvent was subtracted to eliminate interference from cell, solvent, and optical 
equipment. The CD spectra were plotted as mean residue ellipticity h (degree 9 cm2 9 dmol-1) versus 
wave length k (nm). Noise-reduction was obtained using a Fourier-transform ﬁlter program from Jasco. 
1.10.8. Computational part 
Molecular dynamics protocols with AMBER11: 
The generation of prm top files (containing molecular topology description and force field parameters) 
and inpcrd files (describing the atomic coordinates) was performed with tleap. The solvation model 
used is TIP3P, the water box has a parallelepipeds shape.  
Hydrogens minimization phase: 
 Minimization conjugate gradient cycle number: 5000 (max cyc.); 
 Minimization steepest descent cycle number: 1000 (max cyc.); 
 Periodic condition (ntb=1); 
 Cut-off= 8; 
 Output frequency: 100. 
Water and ions minimization phase: 
 Minimization conjugate gradient cycle number: 5000 (maz cyc.); 
 Minimization steepest descent cycle number: 2000 (max cyc.); 
 Periodic condition (ntb=1); 
 Cut-off= 8; 
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 Output frequency: 100 (ntpr, ntwe, ntwx). 
NVT and NTP equilibration: 
 Freedom of movement just for water and ions; 
 Initial temperature 0K, final temperature 300K (temp0 and tempi); 
 Steps number: 3000/ Time step 0.0015ps (nstlim and dt); 
 Shake (ntc= 2); 
 Periodic condition (ntb= 1); 
 Cut-off= 8; 
 Output frequency: 500 (ntpr, ntwe, ntwx). 
Side chains, water and ions minimization phase: 
 Minimization conjugate gradient cycle number: 5000 (max cyc.); 
 Minimization steepest descent cycle number: 2500 (max cyc.); 
 Periodic condition (ntb=1); 
 Cut-off= 8; 
 Output frequency: 100 (ntpr, ntwe, ntwx). 
6 heating steps: 
 From 0K to 50K (5ps; backbone restraint: 10kcal/mol), from 50K to 100K (5ps; backbone 
restraint: 9 kcal/mol), from 100K to 150K 85ps; backbone restraint: 8 kcal/mol), from 150K to 
200K (5ps; backbone restraint: 6kcal/mol) and from 250K to 300K (backbone restraint: 
5kcal/mol). 
 Periodic conditions (ntb=1); 
 Output frequency: 500 (ntpr, ntwe, ntwx); 
 Temperature control (Berendsen thermostat, ntt=1); 
 For each phase: time step 0.0005ps; nstlim 10000; 
 Shake (ntc= 2); 
 Cut-off= 8. 
NVT dynamics for 100ps (backbone restrictions: 5kcal/mol):  
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 Periodic conditions (ntb= 1); 
 Output frequency: 500 (ntpr, ntwe, ntwx); 
 Shake (ntc= 2); 
 Time step 0.002ps; nstlim 50000; 
 Cut-off= 8; 
 Temperature control (Berendsen thermostat, ntt=1). 
4 dynamics phases NPT (for 100ps, backbone restraint: 5kcal/mol; 4kcal/mol, 3kcal/mol, 2kcal/mol; 
from 1000ps at 1kcal/mol without restraint):  
 Periodic conditions (ntb= 2); 
 Output frequency: 500 (ntpr, ntwe, ntwx); 
 Temperature control (Berendsen thermostat, ntt=1). 
 Shake (ntc= 2); 
 Cut-off= 8; 
 Time step 0.002ps; nstlim 50000. 
8 dynamics phases NPT for 1000ps without backbone restraint: 
 Periodic conditions (ntb= 2); 
 Output frequency: 500 (ntpr, ntwe, ntwx); 
 Temperature control (Berendsen thermostat, ntt=1). 
 Shake (ntc= 2); 
 Cut-off= 8; 
 Time step 0.002ps; nstlim 500000. 
MMGBSA calculation protocol 
 Endframe= 50 (time at which interrupting the snapshots extrapolation from each trajectory); 
 Verbose= 1 (variable describing the output file information amount); 
 Igb= 5 (Generalized Born method; solvent model 5); 
 Saltcon= 0.100 (salt concentration). 
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Alanine scanning calculation protocol  
 Startframe= 1 (starting time for extracting snapshots from the trajectory); 
 Endframe= 50 (time at which interrupting the snapshots extrapolation from each trajectory); 
 Verbose=1 (variable specifying the output file information amount); 
 Igb= 5 (Generalized Born method, solvent model 5); 
 Saltcon= 0.100 (Salt concentration). 
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Chapter 2: 
Construction of Ratiometric Fluorescent Sensors by 
Ribonucleopeptides 
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2.1. Introduction: fluorescent biosensors design strategies  
Molecular tools for shedding light on the complex interplay between macromolecules, signaling 
molecules, and biologically important ions inside the cells play a central role in molecular and cell 
biology. In the past two decades, a lot of attention has been devoted by chemists and biologists to 
develop a “biosensor” that allows the real-time tracking of a small molecule of interest in living cells. 
A biosensor consists of a receptor component to capture a target ligand and a signal transduction 
component to convert the ligand-binding event into measurable signals, such as fluorescence, 
chemiluminescence, colorimetric, electrochemical, and magnetic responses. Especially recent advances 
in the development of fluorescent biosensors have made an outstanding contribution to elucidating not 
only the roles of individual biomolecules, but also the dynamic intracellular relationships between these 
molecules.
1
 However, rational design strategies of fluorescent biosensors are not as mature as they look. 
Despite the fact that various sensors have been developed to date, a lengthy and laborious trial-and-
error procedure is usually required to obtain a sensor with optimized functions since the interplay 
between recognition and signal-transduction event is unique for each individual sensor. An insatiable 
request for the establishment of a more universal and versatile strategy continues to provide an 
attractive alternative, so-called modular strategy, which permits facile preparation of biosensors with 
tailored characteristics by a simple combination of a receptor and a signal transducer. Various kinds of 
fluorescent biosensors constructed by synthetic receptors
2-9
 and biological macromolecular receptors 
such as proteins
10
 and aptamers
11
 have been reported to date. The construction of fluorescent 
biosensors generally relies on the rational design strategy as follows. The first step requires an effort to 
find a macromolecular receptor with appropriate affinity and specificity to the target. The second step 
integrates the signal transduction function induced by the molecular recognition event into the receptor. 
Because the native biological receptor usually lacks an inherent property of the signal transduction 
function, foreign reporter moieties such as an auto-fluorescent protein (AFP) and a synthetic 
fluorophore must be introduced at the appropriate position of the receptor component. 
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2.1.1. Auto-fluorescent protein (AFP) based biosensors 
Auto-fluorescent proteins (AFPs) such as green fluorescent protein (GFP) from the jellyfish
12
 are well-
established and versatile reporter proteins for monitoring gene expression profiles
13
 and protein 
localizations
14
 in a variety of systems. It is noteworthy that AFPs exhibit spontaneous fluorescence 
emission in cells by the autocatalytic formation of the chromophore after  translation.
15,16
 Therefore, 
AFPs can be endogenously expressed in cells or tissues just by transfection of the plasmid DNA 
without interfering with their fluorescence properties and damaging the cells. In addition to the 
application of AFPs as a reporter tag, various kinds of AFP-based biosensors have recently been 
developed by fusion of receptor proteins or mutation of AFPs. There are practically two strategies for 
the construction of AFP-based biosensors; (a) analyte-sensitive sensors and, (b) conformation-sensitive 
sensors.
17
 The design of analyte-sensitive sensors is based on AFP variants, whose fluorescent 
properties are directly affected by the interaction between a target molecule and a chromophore moiety 
in AFP. Initially, pH and halide-sensitive AFP variants have been developed exploiting the intrinsic pH 
sensitivity of GFP mutants
18-20
 and the high pKas of YFP mutants.
21-23
 Mutations in close proximity to 
the GFP chromophore or the barrel structure of BFP lead to the specific biosensor for Hg
2+
 
24 
or Zn
2+
,
25
 
respectively. In this type of sensor, the receptor function is directly integrated into the chromophore 
itself by the alteration of the chemical nature around the chromophore. The conformation-sensitive 
sensors are designed so that the conformational change of the receptor associated with the ligand-
binding event transduces to a significant fluorescence response of AFPs. This design strategy is more 
versatile than that for the analyte-sensitive sensor, because this type of sensor could be applied to a 
variety of native receptor proteins. Actually, biosensors for Ca
2+
 
26-37 
as well as for small organic 
molecules such as ATP
38
, cAMP
39-42
, cGMP
43-45
, tryptophan
46
, glutamate
47,48
, and inositol 
phosphates
49,50
 have been reported based on this strategy. This type of sensors could be classified in 
three categories; (1) dual AFP-fused fluorescent resonance energy transfer (FRET)-based biosensors, 
(2) single circularly permuted (cp) AFP-based biosensors, and (3) split AFP-based biosensors. 
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2.1.1.1. Dual AFP-fused FRET-based biosensors 
FRET is a physicochemical phenomenon which only occurs when two fluorophores are in sufficient 
proximity (<10 nm) of each other, and the emission spectrum of the donor overlaps the excitation 
spectrum of the acceptor.
51
 In the AFP-based FRET strategy, CFP and YFP mutants have been 
favorably utilized as a FRET donor and an acceptor, respectively
52
 (Figure 1). Engineering with two 
AFPs in combination with the receptor protein affords a sensor protein that responds to dynamic 
fluctuation of intracellular ligand concentration by a ratiometric fluorescence change. The feasibility of 
this strategy strongly depends on the magnitude of the structural change of the receptor. In the case of 
the receptor with a large structural change upon binding the substrate, this strategy would be the most 
straightforward way to integrate the signal transduction function into the receptor of interest, although 
serious concerns have been pointed out that the obtained FRET signals do not simply reflect the change 
in the expected distance of FRET pairs.
52-53
 The trailblazing work for this sensor was reported by 
Miyawaki et al., in which a genetically encoded calcium indicator composed of two different colored 
AFP mutants and calmodulin, a Ca
2+
 receptor, has been constructed.
30
 The receptor complex that 
accompanies the dissociation or the association of multiple subunits upon ligand binding was also 
suitable for the design of FRET-based biosensors (Figure 1b). Zaccoro and coworkers constructed a 
ratiometric fluorescent biosensor for cyclic adenosine monophosphate (cAMP) on the basis of an 
intermolecular FRET system between regulatory (R) and catalytic (C) subunit of protein kinase A 
(PKA).
41-42 
This biosensor can detect the rise of intracellular cAMP concentration by the decrease in 
the FRET efficiency induced by the dissociation of C subunit from R subunit. 
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Figure 1: Schematic illustration shows a concept of ligand sensing by dual AFP-fused FRET-based biosensors. Currently, CFP and YFP 
mutants are preferentially selected as FRET donor and acceptor, respectively. (a) Intramolecular FRET-biosensors exploit the protein 
domains with a large structural change upon the ligand-binding event. (b) Intermolecular FRET-based biosensors accompany the 
dissociation or association of multiple subunits upon the ligand-binding event. The dissociation-type FRET-based biosensor is only 
depicted in this figure. 
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2.1.1.2. Single circularly permuted (cp) AFP-based biosensors  
As an alternative strategy, non-FRET biosensors based on a single circularly permuted (cp) AFP have 
been developed for targeting Ca
2+
,
32-34,37
 cGMP,
53
 H2O2,
54,55
 Zn
2+
,
56
 and an inositol phosphate 
derivative.
50
 cpAFPs were constructed by connecting original N and C termini by a short peptide linker 
and regenerating the novel N and C termini at a specific position. Although the dual AFP-fused FRET-
based biosensor is the most facile and robust strategy among AFP-based biosensors, the application of 
the strategy for FRET-based sensors is essentially difficult in the case of a receptor that undergoes just 
a slight structural change upon binding to the substrate. In such a case, a sophisticated manipulation of 
the interplay between the small perturbation of the receptor conformation and the alteration of 
photochemical property of the AFP chromophore in the ligand-binding event must be required. In the 
cpAFP-based biosensors, the receptor protein could be placed at the residues near the chromophore that 
would critically affect the photochemical property of the chromophore in AFP. Morii and coworkers 
developed a novel cpAFP-based sensor for  D-myo-inositol-1,3,4,5-tetrakisphosphate (Ins (1,3,4,5) P4), 
from a newly designed split pleckstrin homology (PH) domain of Bruton’s tyrosine kinase (Btk) and a 
single cpGFP
50 
(Figure 2). The resulting split PH domain-cpGFP conjugate, Btk-cpGFP, exhibited 
bimodal absorption spectra corresponding to the protonated and deprotonated states of the 
chromophore in GFP. Interestingly, the Btk-cpGFP realized a ratiometric fluorescence detection of Ins 
(1,3,4,5) P4 by the excitation of each distinct absorption band, and retained the ligand affinity and the 
selectivity of the original PH domain. 
 
 
 
 
 
Figure 2: Schematic illustration shows a fluorescent biosensor for inositol tetrakisphospgate based on the split Btk PH domain-cpGFP 
conjugate.50 The original N and C termini are linked with a short peptide linker (orange), and the novel terminal of cpGFP (purple) is 
fused to the split Btk PH domain (blue). The conformational change if the PH domain induced by the ligand-binding event was 
transduced to the structural perturbation at the chromophore of conjugated GFP, and then resulted in the ratiometric fluorescence change 
of cpGFP. 
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2.1.2. Chemically-modified protein based sensors 
Another strategy for constructing fluorescent biosensors is a structure-based design of a protein-based 
biosensor covalently modified with a synthetic fluorophore. Genetically encoded biosensors using 
AFPs can be expressed basically in all types of cells, allowing straightforward visualization of 
intracellular target molecules. In contrast, these protein-based biosensors require the invasive  
technique for translocating across the plasma membrane, such as electroporation,
57-59
  lipofection,
60.61
 
microinjection,
62
 and tagging arginine-rich sequences.
63,64
 However, this type of biosensors could be 
more advantageous in some respects. The relatively smaller size of the synthetic fluorophore is likely to 
contribute to the less perturbation of the property of the original receptor protein. Furthermore, since 
the amount of intracellular biosensors can be controlled easily compared to the genetic expression 
system, the interference to the molecular geography of the analyte in cells could be suppressed 
minimally. In the synthetic fluorophore-attached biosensors, the principle of the signal transduction 
mechanism is generally based on the alteration of microenvironment of the fluorophore during the 
ligand-binding event. Especially, polarity-sensitive fluorescent probes are the most widely utilized due 
to the abrupt change in hydrophobicity in the vicinity of the protein surface.
10
 The central issue for the 
construction of these biosensors is the way to introduce the fluorophore into the receptor protein  site-
selectively. Current methodologies for the site-selective incorporation of synthetic fluorophores into 
protein are divided into three groups; (1) incorporation of a thiol reactive fluorophore by engineering of 
a mutant receptor with a unique cysteine residue, (2) a site-specific unnatural amino acid mutagenesis 
with an expanded genetic code, and (3) a post-photoaffinity labeling modification. 
In the first method all the original cysteine residues must be initially substituted with other amino acids 
followed by the introduction of a unique cysteine residue at the specific position to avoid the non-
specific labeling. The incorporation site of a fluorophore could be determined by the  three-dimensional 
structure of the receptor protein obtained from crystallographic analysis. Morii and coworkers 
constructed novel biosensors for inositol 1,4,5-trisphosphate (Ins (1,4,5) P3) and 1,3,4,5-
tetrakisphosphate (Ins (1,3,4,5) P4) by utilizing the pleckstrin homology (PH) domain of phospholipase 
C (PLC) δ1
65
 and the general receptor for phosphoinositides 1 (GRP1) (Figure 3), respectively. In these 
biosensors, a synthetic fluorophore was attached at the proximity of the  ligand-binding site so that the 
changes in orientation of the fluorophore induced by the substrate binding leads to a sufficient 
fluorescence response. This structure-based design of synthetic fluorophore-modified biosensors is a 
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powerful method to produce biosensors with high selectivity and appropriate affinity to target inositol 
derivatives in living cells.
66,59,64 
 
 
 
 
 
Figure 3: Schematic illustration shows a fluorescent biosensor for Ins (1.3.4,5) P4 based on the GRP1 PH domain covalently modified 
with a fluorescein (green) as a reporter probe. The original cysteine residues(cyan) were replaced with other amino acids. The fluorophore 
was designed to be oriented near the binding pocket. The position labeled by the fluorescein at Glu82 is indicated in magenta. The local 
environmental change of the fluorophore induced by the ligand-binding event was transduced to the fluorescence change. 
 
Unlike the post-labeling of unique cysteine residues, a mutagenesis technique for direct incorporation 
of synthetic fluorophores as unnatural amino acids into desired positions in proteins has been 
developed. Such a site-specific 0mutagenesis with an expanded genetic code that employed an amber 
suppression method
67,68
 or a four-base codon method
69
 in cell-free translation systems has provided a 
variety of fluorescently modified proteins.
70-72
 Hohsaka and coworkers synthesized unnatural amino 
acids modified with BODIPY derivatives and incorporated two of them into different positions of 
calmodulin as a donor and acceptor pair for FRET using two four-base codons.
72
 The doubly modified 
calmodulin exhibited a substantial FRET signal in response to the conformational change of 
calmodulins induced by the addition of the calmodulin binding peptide. 
When a three dimensional structure of a receptor protein is not available, it is difficult to convert such a 
receptor into a fluorescent biosensor by applying the above mentioned methods. An approach enabling 
a site-specific incorporation of a signal transducer proximal to the binding pocket of intact protein, for 
which little or no structural information is available, is also highly desirable. 
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2.1.3. Signaling aptamers 
Combinatorial chemistry with in vitro evolution, known as SELEX (systematic evolution of ligands by 
exponential enrichment), offers an effective strategy for generating DNA or RNA receptors (aptamers) 
with appropriate affinity and specificity for various targets ranging from small molecules to proteins.
73-
77
 Because most of the structurally characterized aptamers undergo induced-fit type conformational 
changes upon binding of their cognate ligands,
78
 the introduction of signal transduction function can be 
accomplished by taking advantages of the ligand dependent change in the local environment around the 
attached fluorophores. Even if does not exist a report of a specific or an appropriate protein receptor for 
the substrate of interest, aptamers for the substrate can potentially be generated through in vitro 
selection. In this respect, the design of aptamer-based fluorescent sensors represents an attractive and 
promising alternative to the protein-based sensors. Additionally, development of the various types of 
fluorescence-signaling aptamers has been accelerated by the facile preparation of aptamers modified 
with synthetic fluorophores in a site-selective manner.  
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2.2. Structural aspects of RNP aptamers 
In vitro selection provides one of the most powerful strategies for obtaining functional RNA 
molecules.
1-5
 The selection and evolution technique has produced RNA aptamers that specifically bind 
small molecules
1-8
 or ribozymes that catalyze a variety of chemical reactions
1-5,9,10
 from randomized 
pools of oligo-ribonucleotides. Recent advances in the in vitro selection method have provided 
signaling nucleic acid aptamers
11-16
 applicable for biosensors and allosteric ribozymes regulated by 
both ligands and proteins.
17-21
 The key feature of RNA to perform such a variety of function has been 
attributed to the fact that a random pool of RNA provides a large number of different shapes that 
facilitate the chance to select RNA molecules with desired functions.
22
 RNA performs a wide range of 
functions in conjugation with proteins in all cells. One of such examples is found in the three-
dimensional structures of RNA-protein complexes, particularly in that of the ribosome.
23,24
 The 
ribosome is the ribonucleoprotein that performs the remarkable task of selecting the amino acids to be 
added to the growing polypeptide chain by reading successive messenger RNA codons. It has been 
considered that RNA, not protein, is responsible for catalysis of the peptide transferase activity and that 
the ribosomal proteins stabilize and orient the RNA into a specific, active structure.
22,25
 Such protein 
cofactors are required by many RNA enzymes, including RNase P and most group I and group II 
introns, for catalysis under physiological conditions.
26
 The remarkable diversity of RNA-protein 
complexes suggests that its miniature analogue, a ribonucleopeptide, serves as an alternative 
framework for the design of tailor-made receptors and enzymes. Morii et al. developed a strategy that 
allows assembly of a ribonucleopeptide receptor by means of the structure-based design
27,28
 and the in 
vitro selection method. On the basis of the Rev response element (RRE) RNA and HIV-1 Rev peptide 
complex,
29
 an RNA subunit, referred to as RRENn, was designed consisting of two functionally 
separated regions, a possible ligand-binding region with 20 randomized nucleotides, successively 
extended to 40 nucleotides, and an adjacent stem region that serves as a binding site for the Rev peptide 
(Figure 4). 
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Figure 4: Schematic illustration of the structure of Rev-RRE complex (left) and Rev-RRENn ribonucleotide complex (right). The amino 
acid sequence of the Rev peptide (34-50, Ac-Rev) is shown at the bottom.  
 
Gel mobility shift assay of the RRENn and the Rev peptide (Ac- Rev) confirmed an RNA-peptide 
complex formation, indicating that the introduction of the additional ligand binding region did not 
interfere with the specific complex formation between RRENn and the Rev peptide. Ribonucleopeptide 
receptors for ATP were isolated from a pool of RNA sequences (4
20
) by the in vitro selection method 
(Figure 5). 
               Figure 5: Schematic representation of the in vitro selection method applied to the preparation of RRENn RNA pool. 
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2.2.1. Rev peptide-RRE RNA recognition mode 
 
RNA-protein interactions are central features of many fundamental biological processes, including 
translation, mRNA processing, and transcription. The HIV-1 Rev protein is an RNA-binding protein 
that regulates viral gene expression by affecting the relative amounts of spliced and un-spliced mRNAs 
that are exported to the cytoplasm. Rev mediates its function by binding to the RRE RNA located 
within the env gene of HIV.
30
 Biochemical analyses have identified a high-affinity Rev-binding site in 
stem-loop IIB of the RRE (Figure 6A).
31
 A short α-helical peptide, corresponding to the arginine-rich 
RNA-binding domain of Rev (Figure 6B), bind specifically to this small RNA element,
32
 providing an 
effective scaffold for the construction of RNP receptors.  
 
 
 
 
 
 
Figure  6: Minimal RRE-Rev complex. A) Sequence of RNA derived from stem-loop IIB of wild-type RRE. Boxed nucleotides were 
invariant in RNA selection studies of the Rev-RRE interaction in vitro, and the bold letters indicate a G-G base pair that was found to 
covary to an A-A base pair. Filled circles represent phosphates that interfere with Rev protein  binding when ethylated. The numbering in 
the internal loop region is the same as for wild-type RRE, and non-wild-type nucleosides, in lowercase, are not numbered sequentially. B) 
Sequence of the Rev peptide, which contains amino acids 34 through 50 of the RNA-binding domain. Bold letters indicate amino acids 
that results in a > 10-fold decrease in binding specificity upon mutation to alanine. C) Hydrogen-bonding arrangement of two purine-
purine base pairs in the internal loop of the RRE determined from previous NMR analyses. 
 
The Rev peptide binds the major groove of the RNA in an α helical conformation, as indicated by 
circular dichroism studies.
32,33 
 DNA-binding proteins often use α helices to recognize specific bases in 
the major groove. However, the major groove of an A-form RNA helix is deep and too narrow to 
accommodate an α helix, thus requiring non-Watson-Crick interactions to widen the groove. In the 
Rev-RRE complex, two purine-purine base pairs locally open the major groove, a process which 
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appears to be facilitated by a pronounced distortion of the RNA backbone that results primarily from 
formation of the G48-G71 base pair in a locally parallel-stranded orientation.
34
 This distortion results in 
an S-shaped architecture to the backbone from nucleotides G70 to A73, an undertwisting of the base 
pairs in the internal loop, and an opening of the major groove by ~5 Aº (Figure 7).  
 
 
 
 
 
 
 
 
 
The GG base pair is important for Rev binding, yet it is not in direct contact with the peptide through 
hydrogen bonds, suggesting that it provides a critical structural feature for specific binding. The Rev α 
helix penetrates much more deeply into the major groove than is typical of DNA-binding proteins. In 
contrast to the shallow major groove of a B-form DNA helix, the RRE internal loop retains the 
characteristic deep groove of A-form RNA, and the Rev peptide must bind deep within the groove to 
allow side chains to reach the bases. In addition to binding deep within the groove, the Rev peptide has 
an extensive interface with the RNA, interacting over three to four turns of the α helix. Four amino 
acids make important base- specific contacts in the major groove (Figure 8). The residues Arg35 and 
Arg39 interact with nucleotides U66, G67, and G70 on one side of the groove, and Asn40 and Arg44 
interact with nucleotides U45, G46, G47, and A73 on the opposite side of the groove. Almost all of 
these nucleotides were invariant in vitro selection experiments or showed chemical modification 
Figure 7: RNA major groove width and depth. Views down the α helix axis of Rev (blue) and GCN4 (green) with the major 
grooves of the RNA (or DNA) aligned with a standard A-form RNA duplex (red). 
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interference of Rev binding.
35
 These important nucleotides all have functional groups within reasonable 
hydrogen-bonding distance of these four amino acids; however, the precision of the side chain 
positions is insufficient to determine exact hydrogen bond arrangements for these contacts. 
Nevertheless, Asn40 is clearly coplanar with the purine-purine G47-A73 base pair and makes hydrogen 
bonds to groups in the major groove. All four of the amino acids that make potential base-specific 
contacts are critical for peptide-binding specificity,
32
 and mutation of any of these three arginines to 
lysine results in a significant loss of binding activity in vivo, suggesting the existence of hydrogen 
bonds rather than simple electrostatic contacts.
33
 In addition to the bases specific interactions, Thr34 
and several arginines contact the phosphate backbone. In the average structure, the y-OH of Thr34 is a 
potential hydrogen bond donor to a phosphodiester oxygen ofG47 (Figure 8A). Mutation ofThr34 
results in a >10-fold decrease in binding specificity, and chemical modification of the G47 phosphate 
reduces binding specificity.
32,35
 Interestingly, Thr34 is also forming an "N-cap" structure at its NH2- 
terminus that presumably stabilizes the α helix.36 In addition to Thr, there are six arginines (Arg38, 
Arg4l, Arg42, Arg43, Arg46, and Arg48) that are positioned to make either hydrogen-bonding or 
simple electrostatic interactions with the phosphate backbone (Figure 8B).  
  
 
 
 
 
 
 
 
Figure 8: RNA-peptide contacts. A) View of the core binding site (nucleotides 44 to 53, 65 to 76, and amino acids 33 to 50). Amino 
acids that give > 10-fold or >3-fold decrease in binding specificity are shown in yellow and orange, respectively. The RNA is shown in 
blue, with the invariant nucleotides from in vitro selection studies colored green and phosphates that interfere with binding when 
ethylated as blue spheres. B) Schematic of specific RNA-peptide interactions. Black arrows, open arrows and hatched arcs indicate base-
specific, phosphate backbone and van der Waals contacts, respectively. Thick boxes and black circles indicate important nucleotides and 
phosphates, respectively. 
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Arginine-38 is positioned near the phosphates of U66 and G67, which both give chemical modification 
interference,
35
 and it is likely that Arg
38
 makes bridging hydrogen bonds between the two ŋ-nitrogens 
and the phosphodiester oxygens of U66 and G67, because it cannot be functionally substituted by 
lysine.
33
 Arginine-38 and Thr
34
 make phosphate contacts flanking the region of the base-specific 
contacts and probably stabilize this region of the peptide. An especially arginine-rich face of the α helix 
makes phosphate contacts on the 3' side of the hairpin containing two single-nucleotide bulges, which 
brings many phosphates in close proximity. In particular, Arg
46
 probably stabilizes the unfavorable 
electrostatic interactions near the U72 bulge, where the phosphorus atoms of G70 and U72 are -4 Å 
apart. Mutation of Arg
46
 to alanine, but not to lysine, results in a sevenfold decrease in binding 
specificity, consistent with a specific electrostatic contact.
33
 In addition, Arg
46
, Arg
48
, and Arg
50
 at the 
COOH-terminus of the peptide, which mutational data suggest are moderately important for specific 
binding,
32
 are making phosphate and Van der Waals contacts that may help orient the isolated α helix 
in the groove. The arginine-rich motif (ARM) is defined solely by a short region containing a high 
density of arginines. There are now two structural examples of short ARM peptides bound to RNA, 
bovine immunodeficiency virus Tat-TAR (trans-acting region) and HIV-1 Rev-RRE, and each peptide 
adopts a different secondary structure (β hairpin and α helix, respectively). Therefore, the ARM does 
not represent a unique structural motif.
37
 Despite the differences, both peptides bind deeply in the 
major groove, and the high density of arginines characteristic of the ARM may be important for charge 
neutralization as the peptide penetrates the deep groove and forms a large interface. This feature 
probably also allows these 10- to 20-amino acid ARM peptides to bind as structurally independent 
elements, which is another characteristic feature of the ARM. The distinctive RNA structures formed 
by the binding sites undoubtedly also contribute to the folding and binding of these small ARM 
peptides. 
38 
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2.2.2. SELEX, Systematic Evolution of Ligands by Exponential Enrichment 
The probability that a given sequence polynucleotide or peptide chain will fold to form a stable three-
dimensional structure with a given ligand binding is unknown, but is generally thought to be very low. 
A related problem, which has been equally difficult to address theoretically, is to estimate the number 
of fundamentally different classes of structures capable of carrying out a given binding or catalytic 
function. These questions are important for theories of the origin and early evolution of life, as the first 
biological catalysts presumably arose from random sequence polymers.
39-41
 Szostak et al. addressed 
these questions by developing methods for the synthesis of large numbers of random sequence RNA 
molecules, and for the isolation of molecules with specific ligand binding properties from such 
populations.
42 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX), also referred to as in vitro 
selection or in vitro evolution, is a powerful process to select and isolate receptors for target recognition 
from a combinatorial library. An in vitro selection experiment comprises a number of sequential steps, 
the first of which is the generation of a nucleic acid library of random sequences. This starting pool of 
mainly nonfunctional RNA or DNA sequences is generated using a standard DNA-oligonucleotide 
synthesizer.
43
 The design of such libraries involves the synthesis of a short defined sequence, followed 
by a random region of variable length and another defined sequence at the 5’-end. The length of the 
random region is normally between 20 to 40 basepair, which creates a library with a large number of 
random sequences (10
15
 to 10
16
). This pool of synthetic single-stranded DNA is amplified in the 
polymerase chain reaction (PCR). Generating several copies of each DNA in its double-stranded form. 
By in vitro transcription, a corresponding library of RNA molecules can be generated which can then 
be used for the in vitro selection. If the transcription reaction contains nucleoside triphosphate 
derivatives that are chemically modified but still are substrates for RNA polymerases, libraries of 
modified RNAs can be generated in which sequences are equipped with a broad variety of additional 
chemical functionalities, normally not present in natural nucleic acids.
44-46
 Aptamers selected from 
chemically modified libraries can, in some cases, be completely resistant toward degradation by 
nucleases. The additional functional groups can lead to ligands with novel physical and chemical 
properties or can provide additional handles to be utilized for functional improvement. Alternatively, 
mixtures of ssDNA or chemically modified ssDNAs can be generated by omitting the transcription step 
in the SELEX procedure. The selection of DNA aptamers adds the challenge to separate both strands in 
order to obtain libraries of ssDNA.
47
 DNA aptamers are slightly more stable toward nuclease digestion 
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but seem to be less competent to fold into ligand-binding scaffolds. Moreover, RNA aptamers have the 
advantage of being actively transcribed in vivo from suitable templates, whereas DNA aptamers have to 
be introduced externally. By using combinatorial nucleic acid synthesis, remarkably complex libraries 
comprising up to 10
16 
different RNA, ssDNA, modified RNA, or modified ssDNA sequences can be 
produced at once. This number exceeds the diversity of antibodies raised by the immune system by 
several orders of magnitude. From this huge diversity, the challenge is to select active molecules from 
oligonucleotide libraries of such complexity. The high pool complexity ensures the presence of 
oligonucleotide-structures that are complementary to virtually any shape. Thus, if the pool is incubated 
with the immobilized ligand, binding sequences will tightly attach to it, so that nonbinding ones can 
easily be removed. The bound material can be subsequently collected, amplified and used to perform 
the next selection cycle. Depending on the nature of the ligand, this procedure has to be repeated until 
the desired ligand-specific aptamers have been enriched (Figure 9).  
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Figure 9: Schematic representation of RNA receptor selection using in vitro selection strategy. RNA sequences that have specific 
recognition to target cells are evolved to enrich the selection pools. The enriched pools are cloned and the positive clones are sequenced to 
determine those RNA receptors.  
 
Particular aptamers can then be obtained from the enriched library by cloning and their sequence can be 
elucidated by standard sequencing protocols. Besides the possibility to perform the selection itself with 
modified nucleic acid sequences, which depends on whether the replicating enzymes accept the 
modified templates and monomer substrates, individual aptamers can also be equipped in a modular 
manner with additional functions
48-50
 and therefore can be specifically tailored for many potential 
applications in biotechnology, molecular medicine and molecular biology.     
 
2.2.3. Preliminary data 
2.2.3.1. Aptamers selection and functional evaluation 
Application of the selection and evolution technique is not limited to obtain functional macromolecules 
solely composed of RNA or DNA. It can also be used on ribonucleopeptides (RNP), such as complexes 
of the Rev peptide and RRE (Rev Responsive Element) RNA (Figure 10), which have a known three-
dimensional structure and the interaction mode is described in the previous paragraph. Comparison of 
the characteristics of the RNA aptamers and RNPs targeting the same ligand provides an opportunity to 
understand the structural features that influence the fundamental molecular recognition mechanisms. 
To establish a proof of principle for the RNP-based selection strategy, Morii et al. initially chose ATP 
as a target for selection from the RNP library
51,52
 and compared the characteristics of this ATP-binding 
RNP with those of the reported ATP-binding RNA aptamer
53
 and other RNA aptamers targeting the 
ATP analogues cAMP,
54
 FAD,
55
 NAD
+
 and S-adenosyl methionine (SAM).
56
 These aptamers share 
quite similar consensus sequences for recognizing the adenosine moiety. The isolated ATP-binding 
RNPs,
57
 in contrast, reveal consensus sequence that is different from the ones already reported for the 
ATP-binding aptamers. Given the fact that the above mentioned RNA aptamers are all selected against 
the ATP analogues by using the target ligand tethered through the C-8 position of the adenine ring, 
ATP-binding RNPs obtained by the selection against ATP immobilized through the 2
’
 or 3
’
-OH group 
of ribose may reveal a different consensus sequence because in vitro selection would afford diverse 
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binding structures that vary significantly in accordance with the nature of ligands.
5,58,59
 In fact, Burke e 
Gold have suggested that an entirely different RNA aptamer would be expected for the ATP-analogues 
if the adenosine has been linked to the resin trough a position other than the C-8.
56
 It has been 
postulated that RNA aptamers obtained by in vitro selection from random sequence pools tend to be the 
simplest, most abundant structures for a given ligand.
60
 RNA aptamers can specifically bind to the 
adenine ring of ATP by A:U Watson-Crick and Hoogsteen base pairing, or the triplex type U:A:U 
formation by both Watson-Crick and Hoogsteen base paring. However, structural analyses of the 
Sassanfar aptamer-AMP complex
61,62
 revealed that the aptamer did not realize the base selectivity by 
simple Watson-Crick or Hoogsteen base pairing. In this chapter,  we described the isolation of ATP-
binding RNP, in which the RNA consensus sequence is different from those reported for RNA 
aptamers targeting the ATP analogues and have evaluated their affinity and selectivity for the ATP 
analogues.  
 
 
 
 
 
 
 
 
 
Figure 10: In vitro selection method for RNP receptors for ATP. Rev peptide and RRE RNA complex of which the three-dimensional 
structure and the interaction mode of each subunit have been established was utilized as the stable scaffold of RNP receptors.RNP library 
was constructed by introducing the randomized sequence adjacent to RRE sequence and complex with the Rev peptide. ATP-binding 
RNP were isolated by using the ATP-immobilized agarose resin and amplify by PCR after conversion to RNA-DNA duplex by reverse 
transcription to construct the DNA library for the next round. Selection and amplification was repeated until the saturation of the binding 
ratio to the substrate ATP on the resin. Then the sequence and affinity of RNP receptors were evaluated. 
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2.2.3.2. In vitro selection of ATP-binding RNP receptors from Nn library  
ATP-binding RNP receptors have been isolated from the RREN30 RNP library,
56
 in which RNA has a 
randomized region with a fixed length of 30 nucleotides (Table 1). Because only a limited number of 
nucleotides would participate in ATP-binding, these RNPs contain nucleotides that are not directly 
involved in formation of the binding pocket. Therefore, an RRENn RNP library
51
 that possesses 7 to 40 
nucleotides in the randomized region was used to select ATP-binding RNP receptors with less than 30 
nucleotides in the ATP-binding region. From this library it is thus possible to obtain ATP-binding RNP 
with the minimum of nucleotides for ATP binding. ATP attached through the ribose 2’- or 3’-hydroxyl 
groups via a 22 atom spacer to agarose beads was used for the selection. After the selection from the 
RRENn RNP library, RNAs with the randomized region of various lengths from 17 to 34 nucleotides 
were found (Table 2). Comparison of the nucleotide sequence of each RNP revealed a consensus 
sequence 5’-GUAGUGG---UGUGUGUG-3’ that was the same as the one found in ATP-binding RNP 
selected from the RREN30 RNP library
56
 (Table 1 and Table 2). Thus, RNPs selected from the 
RRENn RNP library are likely to share a similar ATP biding mode with the RNPs obtained from the 
RREN30 RNP library. This consensus sequence differs from those  reported for the ATP aptamer,
52
 
cAMP aptamer,
53
 adenine aptamer,
63
 adenine riboswitch,
64
 and S-adenosyl methionine responsive 
riboswitch.
65
 The nucleotides in the non-consensus region between the 5’-half and the 3’-half of the 
consensus sequence are different for each RNP. Furthermore, there is a variable region connecting the 
RRE and the consensus region, which often contains complementary nucleotides expected to form base 
pairs. The affinity of RNP selected from the RRENn RNP library for the substrate ATP was analyzed 
by converting the RNP receptor to the fluorescent RNP sensor by utilizing 7-methoxycoumarine-
labeled Rev (7mC-Rev) for the RNP complex formation.
51,56
 Titration of the fluorescent RNP with 
increasing concentration of ATP gave the titration curve for the complex formation of RNP and ATP, 
from which the equilibrium dissociation constants (KD) for the complex of ATP and RNP could be 
deduced. The KD values for the ATP binding ranged from 0.2 to 15µM and are listed in Table 2. For 
the further structural study, we focused on An16RNP from the RRENn RNP library because its RNA 
subunit An16 had a relatively small ATP-binding site of 19 nucleotides with the 5’-GUAGUGG---
UGUGUGUG-3’ consensus sequence and it showed a relatively high affinity to ATP (KD=1.1µM). 
Formation of the RNP complex by An16RNA and the Rev peptide was verified by titration of 
An16RNA with the Rev peptide. A gel mobility shift assay showed that An16RNA (1µM) formed a 1:1 
RNP complex (87%) in the presence of 1.2 equivalent of Rev (Figure 11). 
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Table 1: Nucleotide sequences of ATP-binding RNP receptors isolated from RREN30 RNP library. The consensus sequence is indicated 
in bold character. The irregular nucleotides in the variable region are shaded in gray. The equilibrium dissociation constant (KD) of each 
RNP was obtained from the fluorescence titration of RNP complexed with 7-methoxy coumarin-labeled Rev (7mC-Rev) by ATP at 20ºC. 
 
 
 
 
 
 
 
 
Table 2: Nucleotide sequences of ATP-binding RNP receptors isolated from the RRENn RNP library. The consensus region is indicated 
in bold with the irregular nucleotides marked in pink. The non-consensus region is boxed in red. Nucleotides expected to form base pairs 
in the variable region are shaded in grey. The equilibrium dissociation constant (KD) for the ATP complex of each RNP was obtained 
from the fluorescence spectral changes of each RNP complexed with 7-methoxy coumarin-labeled Rev (7mC-Rev) by titration with ATP 
at 4ºC. 
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Figure 11: The autoradiogram of the gel shift assay shows that An16RNA forms a 1:1 complex with the Rev peptide in a buffer 
containing 10mM Tris-HCl (PH 7.6), 100mM NaCl, 10mM MgCl2, 0.005% Tween 20, and 6% sucrose at 4ºC. Peptide concentrations 
added to An16RNA (1µM) are shown under each lane (0, 1.0, 1.2, 1.4, 1.6, 1.8 and 2.0µM). The table shows the percentage of band 
intensity for free RNA, the 1:1 RNP complex (RNP) and RNP complexes with more than one equivalent of Rev (Non-specific). 
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2.2.3.3. Functional evaluation of An16 ATP-binding RNP receptor 
Information on the affinity and selectivity of An16RNP for its target can be obtained from the 
comparison of the KD values of An16RNP with various ligands and correlating the change in affinity 
with the structural differences of ligands. An16RNP revealed low affinities for UTP, CTP, or GTP, but 
high affinities for AMP, ADP, dATP, adenosine (Ado) and adenine that were similar as for ATP 
(Figure 12 an 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Saturation curves for the relative fluorescence intensity changes of An16RNP complexed with 7mC-Rev by titration with (a) 
ATP, ADP, AMP, Ado and Ade, with (b) dATP, 1-Me-Ado, 2-Cl-Ado, 3-Me-Ade, 7-deaza-Ado, Ino, and 8-Br-ATP, and with (c) GTP, 
UTP, and CTP at 4ºC indicate that an16RNP responds sensitively to the adenine base but moderately to the phosphate group and the 
ribose moiety of the ATP analogues. 
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This indicates that the adenine ring dominantly contributes in the complex formation. Because the 
affinities for Ado and adenine were slightly lower than for ATP, An16RNP could interact with the α-
phosphate group to a certain extent. As An16RNP barely showed affinity to the adenosine analogues 1-
methyl-adenosine (1-Me-Ado), inosine (Ino) and 7-deaza-adenosine (7-deaza-Ado), N-1 and N-7 atoms 
and the 6-amino group are essential for An16RNP to bind the adenine ring (Figure 13).  
 
 
 
 
 
 
 
Figure 13: A schematic illustration summarizes the affinity and the selectivity of the ATP-binding An16RNP for ATP analogues. 
Equilibrium dissociation constants of An16RNP for ATP, ADP, AMP, Ado, adenine, 1-Me-Ado, 2-Cl-Ado, 3-Me-Ade, 7-deaza-Ado, Ino, 
8-Br-ATP, dATP, GTP, CTP and UTP obtained by the fluorescence titration of An16RNP complexed with 7mC-Rev with the indicated 
ligand are shown in between brackets (µM). 
 
The affinity for 3-methyl-adenine (3-Me-Ade), on the other hand, is almost similar as for adenine, 
indicating that An16RNP does not contact the adenine N-3 position. The lower affinity for 2-chloro-
adenosine (2-Cl-Ado) is possibly caused by a steric hindrance or an electrostatic repulsion. The ATP 
aptamer selected by Sassanfar et al.,
52
 mainly recognizes the N-1, N-3 and the 6-amino group by the 
direct interaction of a guanine base of the aptamer with the adenine base of the substrate ATP.
60-62
 The 
cyclic-AMP aptamer selected by Koizumi et al.,
53
 interacts with N-1, N-7 and the 6-amino group of the 
adenine ring, which are also the determinants for the ATP complex formation of An16RNP. 
Additionally, the cAMP aptamer is sensitive to the nucleotide conformation  and prefers to bind cAMP 
in the anti conformation of the adenine ring. The affinity of An16RNP for the 8-bromo-ATP (8-Br-
ATP) was found to be lower than for ATP. Because 8-Br-ATP preferentially takes the syn 
conformation when free in solution,
66
 the observed lower affinity is possibly caused by the unfavorable 
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energetic cost to change the conformation of the substrate from syn to anti. Alternatively, An16RNP 
might bind 8-Br-ATP in its syn conformation with reduced complex stability due to the steric hindrance 
at the ribose moiety. These results indicated that An16RNP recognizes mainly the adenine base moiety 
and interacts less with the phosphate group and the ribose moiety (Figure 13). An16RNP had exquisite 
properties as ATP-binding receptor and revealed nearly quantitative formation of the RNP complex 
with the Rev peptide. An16RNP showed higher affinity for ATP than An16RNA alone
50
 (Figure 14). 
These characteristics made An16RNP as an ideal model to study the structure of the ATP-binding RNP 
receptor.  
 
 
  
 
 
 
 
 
 
Figure 14 Titration curves show the ATP-binding of 5’-32P-labeled An16RNA in the absence (open circles) or presence (closed circles) 
of the Rev peptide in a buffer containing 10mM Tris-HCl (pH 7.60), 100mM NaCl, 10mM MgCl2, and 0.005% Tween 20 at 4ºC. 
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141 
 
 
Figure 15: Schematic illustration of the stepwise construction of RNP receptors and fluorescent RNP sensors. Randomized RNA 
sequences are introduced as loop into the stable RNP complex to afford the RRENn RNP library.1 By applying the in vitro selection 
method on this library, RNP receptors that bind specifically to various target ligands are obtained. RNP receptors are subsequently 
converted to RNP sensors by introducing a fluorophore at the N-terminus of the Rev peptide.1,2 
 
2.3.1. Modular strategies for tailoring RNP fluorescent biosensors 
A modular strategy that permits a facile preparation of biosensors with tailored characteristics by a 
simple combination of a receptor and a signal transducer has recently emerged as a new paradigm for a 
versatile design of fluorescent biosensors. Stojanovic and coworkers have reported a modular design of 
signaling aptamers based on the allosteric regulation of binding events.
3
 These chimeric aptamers 
composed of two modular aptamers, one for the target recognition and another for holding a reporter 
dye, displayed robust fluorescence responses to three different targets. At paragraph 2.2. we introduced 
the innovative concept of simultaneous preparation of fluorescent biosensors with diverse functions 
based on a framework of ribonucleopeptide (RNP)
4
 using the stable complex between Rev peptide and 
RRE RNA as scaffold.
5-8
 The RNP receptors obtained by in vitro selection have an assortment of RNA 
structures and reveal different affinity to the target molecule, and therefore are considered as an RNP 
receptor library (Figure 16).   
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Figure 16: Schematic illustration for a screening strategy of a tailor-made RNP fluorescent sensor. Combination of the RNA subunit 
library of the RNP receptor and several fluorophore-labeled Rev peptide subunits generates combinatorial fluorescent RNP receptor 
libraries, from which RNP sensors with desired optical and/or binding properties are screened. 
 
 
 
From the structural analyses of ATP-binding RNP receptors, the binding mode for substrate and the 
interaction mode of each nucleotide were evaluated.
6
 The ATP-binding RNP receptors show structural 
changes upon substrate binding, as a result a change in the fluorescence spectrum is also observed 
(Figure 17). 
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Figure 17: The concept of aptamer-conjugated fluorescent sensor by using fluorophore modified ribonucleopeptides. The aptamers that 
induced structural changes upon substrate binding can be converted into a fluorescent sensor by introducing the RNP motif modified with 
a fluorophore. 
 
In conclusion, it can be postulated that the structural changes upon substrate binding and the stability 
acquirement of the triple complex of Rev, RNA, and the substrate occur in a comprehensive manner. 
Therefore, every aptamer, constructed independently,  that shows structural changes upon the substrate 
binding event, has a potential for an easily conversion into fluorescent sensor (Figure 17). The 
transmission of the structural change can be achieved fusing the aptamer to the Rev-RRE complex and 
subsequently, converting it into a fluorescent sensor. This methodology can be applied for the 
convenient construction of aptamer-based sensors with desired fluorescent properties taking advantages 
from the possibility of freely choosing the fluorophore that matches to the target detection. In order to 
verify the successful application of this strategy, I studied the development of seminaphthorhodafluor 
(SNARF)-tethering RNP fluorescent biosensors. This work is material of a paper published in 2012 
(Org. Biomol. Chem. 2012, 10, 8767-8769). 
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2.3.2. Design of seminaphthorhodafluor (SNARF)-tethering RNP fluorescent biosensors  
As for fluorescence detection, ratiometric sensing presents several advantages, such as enhanced 
dynamic range, precise correction without being affected by environmental variables, and convenient 
visual monitoring that make it suitable for bio analytical measurements.
9
 For the purpose of expanding 
the suitability of this technique, we developed an innovative strategy for obtaining universally 
applicable ratiometric fluorescent sensors with modular RNP structure by using targets specific RNA 
aptamers as a receptor module and ratiometrically detectable fluorophore-attached Rev as a reporter 
module. Seminaphthorhodafluor (SNARF)
9
 (Figure 18 C) is a representative red-emitting fluorophore 
that shows pH dependent dual-emission properties. RNPs that tether SNARF through the Rev peptide 
were designed in order to sensitively detect micro-environmental changes associated with substrate 
binding.
10-19 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: A) Schematic illustration of fluorescent ratiometric biosensor based on RNP. B) Peptide sequences of SNARF-Rev derivatives 
used in this study. C) Structure of SNARF (6-isomer). 
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Two types of SNARF-attached Rev peptide ((Figure 18 B), which incorporate linkers of different 
length, were designed. The first one (SNARF-Rev) was obtained by directly modifying the N-terminus 
of Rev peptide with 6-carboxy-SNARF isomer (Figure 18 C). The second one (SNARF-abu-Rev) 
contemplated the insertion of a spatial linker (γ-aminobutyric acid) between the N-terminus of Rev 
peptide and SNARF (Figure 18 B). These Rev-peptides were characterized by UV-visible, HPLC, 
fluorescent spectroscopy and mass spectrometry (See Materials and Methods).
19
  
 
2.3.3. Tetracycline selective sensors 
As first trial, tetracycline selective ratiometric fluorescent sensors were designed. Tetracycline is an 
antibiotic, which inhibits prokaryotic translation by interfering with binding of the aminoacyl-tRNA to 
the ribosomal A-site. It is a widely used therapeutic agent of low toxicity, active against most common 
pathogens, which has also been used at sub-therapeutic levels in animal feed to stimulate weight gain, 
as well as for prophylactic disease control.
20-22
 To construct tetracycline-binding RNA receptor module 
of RNP, tetracycline binding aptamer cb28, isolated by Berens et al., via in vitro selection,
23
 was fused 
to RRE RNA (tet-RRE) (Figure 19).
24,19
  
 
  
 
 
 
 
 
Figure 19: Nucleotide sequences of the tetracycline aptamer, RRE RNA, and modular tetracycline-binding RNP (tet-RRE RNA). The 
tetracycline aptamer fused to the RRE sequence (tet-RRE) was complexed with 6-carboxy-SNARF-modified Rev (SNARF-Rev and 
SNARF-abu-Rev).  
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SNARF modified Rev-peptides were then complexed with the tet-RRE providing fluorescent RNPs 
(tet-RRE/SNARF-Rev). The sensing capability and selectivity of tet-RRE/SNARF-Rev RNP were 
initially evaluated by fluorescent titration experiments with tetracycline.  
  
Figure 20: A) Comparison of the fluorescence spectrum of tet-RRE/ SNARF-Rev with (plane line) or without (dash line) tetracycline (30 
µM). (inset) Fluorescent images of tet-RRE/SNARF-Rev with or without tetracycline (30 µM) filtered at 580 ± 25 nm (red) and 640 ± 20 
nm (blue).  B) Fluorescence titration plots of the emission intensity ratio (645 nm / 600 nm) of tet-RRE/ SNARF-Rev vs. antibiotics 
concentration. Tetracycline (black filled circle), streptomycin (black filled triangle), chloramphenicol (black opened square).  
 
Figure 20A shows the fluorescence spectra of tet-RRE/SNARF-Rev with or without tetracycline in 
aqueous buffered conditions (pH 7.60). A typical ratiometric fluorescence change, that consists of a 
decrease in the emission at 600nm, which is due to the acidic phenol form of SNARF, and a 
simultaneous increment of the emission at 645nm, which is due to its basic phenolate form (excitation 
wavelength 534nm), is apparently observed (Figure 20 A and Figure 21).
9,19 
 
 
 
 
 
 
147 
 
 
 
 
 
 
 
 
Figure 21: Fluorescent spectral change of tet-RRE/SNARF-Rev upon the addition of tetracycline (0-30µM). The arrows show the 
direction of change of the spectrum at that position as tetracycline concentration is increased. 
 
A change in the fluorescent colour of tet-RRE/SNARF-Rev was clearly detected in the presence of 
tetracycline (inset of Figure 20 A). The emission intensity ratio R (I645nm/I600nm) plot showed good 
saturation behaviour (differential R=0.7) and afforded a dissociation constant much lower than 1µM. 
On the other hand, no significant spectral change was observed when tet-RRE/SNARF-Rev was titrated 
with streptomycin or chloramphenicol (Figure 20 B). These results indicate that ratiometric fluorescent 
change could successfully read-out the binding of tet-RRE/SNARF-with tetracycline.  
In order to clarify the mechanism of the ratiometric fluorescent change, subsequently, a fluorescent pH 
titration of the SNARF unit on tet-RRE/SNARF-Rev in the absence or presence of tetracycline was 
accomplished (Figure 22). The pH-dependent fluorescence emission spectrum of tet-RRE/SNARF-Rev 
alone is moderately shifted compared to the one achieved in the presence of tetracycline (Figure 23),  
indicating that the SNARF fluorophore displays more acidic pKa upon the substrate binding.
19
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Figure 22: A) Fluorescence spectral change of tet-RRE/ SNARF-Rev at different pH values (6.00 to 8.00). B) Fluorescence spectral 
change of tet-RRE/ SNARF-abu-Rev at different pH conditions (pH 6.00 to 8.00). 
 
 
                                             
 
 
 
 
 
 
 
 
Figure 23: A pH titration (pH 6.00 to 8.00) of SNARF alone (light blue snow contraction line), SNARF-Rev peptide (filled red circle), 
tet-RRE/SNARF-Rev RNP (filled purple triangle) and tet-RRE/SNARF-Rev upon 3 µM tetracycline addition (dark snow construction 
line).  
 
This pKa shift towards acidic pH region suggests that the basic phenolate form of SNARF unit is 
stabilized. These results strongly suggest that the ratiometric fluorescent emission change of tet-
RRE/SNARF-Rev upon the tetracycline binding is ascribed to the pKa shift of the SNARF unit as a 
result of micro-environmental change of SNARF, which is induced by the conformational change of 
RNA upon tetracycline binding.
7 
Another interesting consideration comes from the observation of a 
more remarkable response of tet-RRE/SNARF-Rev RNP  (Figure 24) compared to the attached-linker 
one (Tet-RRE/SNARF-abu-Rev) (differential R=0.5). The result indicates that the proximity to the 
binding pocket is an important factor affecting the efficiency of these sensors.
19
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Figure 24: A) Fluorescence spectral change of tet-RRE/ SNARF-abu-Rev upon the addition of tetracycline (0-30 µM). B) Fluorescence 
titration plot of the emission intensity ratio (645 nm / 600 nm) of tet-RRE/ SNARF-abu-Rev vs. the antibiotic compounds concentration. 
Tetracycline (black filled circle), streptomycin (black filled triangle), chloramphenicol (black opened square). 
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2.3.4. Dopamine selective sensors 
The applicability of the design strategy of modular fluorescent RNP was further tested by fluorescence 
titration using dopamine aptamers DH05 and DHc65 previously isolated by our group.
25 
Because 
dopamine is a valuable heuristic bridge in defective brain chemistry study over the past medical 
history,
26
 it is of particular interest to prepare a suitable analytical detecting tool that would accelerate 
clear understanding of the relationship between the function and the structure of each biologically 
active catecholamine.
25
 Both DH05-RRE/SNARF-Rev and DHc65-RRE/SNARF-Rev complexes 
showed changes in the fluorescence intensity ratio R (I645 nm/I600 nm) upon addition of dopamine (Figure 
25A and 26A).
19
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: A) Fluorescence spectral change of DHc65-RRE/SNARF-Rev upon the addition of dopamine (0-300 µM). B) Fluorescence 
spectral change of DHc65-RRE/SNARF-abu- Rev upon the addition of dopamine (0-300 µM). C) Fluorescence titration plot of the 
emission intensity ratio (645 nm / 600 nm) of DHc65-RRE/SNARF-abu-Rev with dopamine (filled black circle), norepinephrine (open 
red triangle), L-tyrosine (filled red square). 
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Figure 26: A) Fluorescence spectral change of DH05-RRE/SNARF-Rev upon dopamine addition (0-300 µM). B) Fluorescence spectral 
change of DH05-RRE/SNARF-abu-Rev upon dopamine addition DH05-RRE/SNARF-abu-Rev with dopamine (filled black circle), 
norepinephrine (open red triangle), L-tyrosine (filled red square). C) Fluorescence titration plot of the emission intensity ratio (645 nm/ 
600 nm) of DH05-RRE/SNARF-Rev with dopamine (filled black circle), norepinephrine (open red triangle), L-tyrosine (filled red square). 
D) Fluorescence titration plot of the emission intensity ratio (645 nm/ 600 nm) of DH05-RRE/SNARF-abu-Rev with dopamine (filled 
black circle), norepinephrine (open red triangle), L-tyrosine (filled red square). 
 
The increase in the emission intensity of basic phenolate form (645 nm) occurred in concomitance with 
a decrease in the emission intensity of the acidic phenol form at 600 nm (differential R=0.1). These 
results indicate that the modular RNP constructed from the induced fit-type aptamer
9
 and the 
fluorescent RRE/Rev module successfully transduces the dopamine-binding event into measurable 
fluorescence signals. Each catecholamine has a distinct structure of a benzene ring with two hydroxyl 
groups and a terminal aminoethyl group. The selectivity of DHc65-RRE/SNARF-Rev and DH05-
RRE/SNARF-Rev for dopamine against other catecholamine derivatives was also evaluated to state 
whether the subtle difference in their structure could be selectively recognized by SNARF-RNP 
sensors. The dissociation constants for the complexes of DHc65-RRE/SNARF-Rev and DH05-
152 
 
RRE/SNARF-Rev with dopamine and the catecholamine derivative norepinephrine were obtained from 
the fluorescence titration curves (Figures 25C and 26C; Table 3).  
 
Ligand KD [µM] 
DHc65 DH05 
 SNARF-Rev SNARF-abu-
Rev 
SNARF-Rev SNARF-abu-
Rev 
Dopamine 1.1 1.2 1.1 1.5 
Norepinephrine 1.9 1.3 2.0 1.5 
Tyrosine >100 >100 >100 >100 
 
Table 3: Equilibrium dissociation constants KD (µM) of dopamine-binding RNPs. 
 
 
The affinity of both RNPs to tyrosine was much lower than that to dopamine. However, both DHc65-
RRE/SNARF-Rev and DH05-RRE/SNARF-Rev showed scarce efficiency in discriminating dopamine 
from norepinephrine while SNARF-abu-Rev containing RNPs failed in showing selectivity (Figure 26 
C).  
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2.3.5. Streptomycin selective sensors 
 
 
 
 
 
 
 
 
 
 
Figure 27: Nucleotide sequences of the streptomycin aptamer, RRE RNA, and modular streptomycin-binding RNP (str-RRE RNA). The 
streptomycin aptamer fused to the RRE sequence (str-RRE) was complexed with 6-carboxy-SNARF-modified Rev (SNARF-Rev and 
SNARF-abu-Rev). 
 
 
Our modular RNP structure was also applied to the detection of streptomycin obtaining positive results. 
SNARF-Rev peptides were complexed with streptomycin aptamer
27
-modified RRE (Figure 27).  
As observed for the case of tetracycline detection by tet-RRE/SNARF-Rev, the titration curve of str-
RRE/SNARF-Rev addition shows a similar spectral change upon streptomycin that consists in a 
decrease of the phenol form at 600 nm and a simultaneous increase of the phenolate form at 645 nm 
with an isosbestic point at 625 nm (Figure 28).
19
  
 
 
 
 
 
 
 
 
Figure 28: A) Fluorescence spectral change of str-RRE/SNARF- Rev upon the addition of streptomycin (0-300 µM). B) Fluorescence 
spectral change of str-RRE/SNARF-abu- Rev upon the addition of streptomycin (0-300 µM). 
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2.3.6. Discussion  
 We have developed a versatile ratiometric fluorescence sensing system by using an RNA subunit 
that fuses a target specific aptamer to RRE RNA and a SNARF-modified Rev peptide.  The 
mechanism of the dual emission sensing is ascribable to the pKa shift of the SNARF chromophore 
of the reporter module that is induced by a ligand-binding event at the binding pocket of the 
receptor module.  
 This statement is strongly suggested by the observation that the efficiency and selectivity of 
detection decrease when a spatial linker is inserted at the fluorophore-labeling position as in the 
case of SNARF-abu-Rev peptide.   
 It is likely that a micro-environmental pH change near the fluorophore, which is caused by 
structural changes in the receptor module upon substrate binding, is a prerequisite for effective 
communication between the binding event at the receptor module and the fluorescence changes at 
the reporter module.  
 
 Prospective applications enclose not only quantitative detection of a tagged analyte in vitro, but 
also for in vivo evaluation. 
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2.4. Development of covalently linked RNP sensors: a successful example of cross-
linking 
 
                                            Figure 29: Schematic representation of the RNP sensors construction strategy. 
 
2.4.1. Introduction  
 
Almost all biologically important events inside living organism are regulated in well-coordinated 
manner by various molecules such as small organic molecules, ions, and proteins. Therefore, it is 
necessary to develop a strategy for the construction of stable fluorescent biosensors that can detect two 
or more cell signaling molecules at the same time in the cell. Generally, usable biosensors require 
optical and chemical properties, such as tunable wavelengths and concentration ranges for the ligand 
detection and, in some cases, stability in the cell media. In addition, the biosensor has to be easily 
tailored for a target and applicable to different target molecules at the same time. As a promising 
candidate, we have developed a strategy for constructing fluorescent sensors by utilizing a 
ribonucleopeptide (RNP) framework. However, the non-covalent configuration becomes a 
disadvantage for the practical measurements, especially when the sensor concentration is reduced. 
Previously reported bimolecular sensors, such as the signaling aptamer and the aptamer sensor non-
covalently embedded with a fluorophore, would face the same issues. An effective method to overcome 
such disadvantages of the non-covalent character was developed for antibody engineering. 
Immunoglobuline Fv fragments, formed by the non-covalent complex of heterodimers of the heavy-
chain variable domain (VH) and the light-chain variable domain (VL) are the smallest functional 
modules of antibodies required for antigen high-affinity binding. Because of their intrinsic non-
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covalent nature, unmodified FV fragments showed a limited stability at low protein concentration and 
under physiological conditions. Therefore, in order to improve the stability, the FV fragments chains 
were covalently linked with disulfide bond or connected with a flexible peptidic linker to form a single-
chain FV molecule. The concept of stabilizing the complex formation by covalently linking can also be 
applied to a fluorescent RNP sensor; moreover it is not only expected to enhance the stability of the 
complex formation, but also to avoid exchange reactions between the subunits when multiple RNP 
sensors coexist. We report here the synthesis of stable fluorescent RNP sensors by the covalently 
linking of RNA and fluorophore-modified Rev peptide subunit and demonstrate the usefulness of the 
covalent RNP sensor by target sensing.  
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2.4.2. Covalently linked RNP assembling strategy  
 
Non-covalent fluorescent RNP sensors for nucleotide triphosphates have been constructed as 
previously reported. To construct the stable fluorescent RNP sensor, the RNA subunit and peptide 
subunit were covalently tethered by a chemical modification (Figure 30).  
 
 
 
 
 
 
 
 
 
 
                                      Figure 30: Schematic illustration of the covalently linking strategy for RNP sensors.  
 
The RNA subunit of the fluorescent RNP sensor was treated with sodium periodate to form a 3’-
dialdehyde group. On the other hand, a hydrazide-derivatized linker peptide, that has flexible amino 
acid sequences (GGSGGSGGSG), was introduced to the C-terminus of Rev peptide to be used for the 
covalent bond formation with RNA subunit. The length of the peptide linker was determined from the 
three-dimensional structure of the complex of the Rev peptide and RRE RNA. These two modified 
subunits were expected to form a covalent RNP complex between the 3’-terminal of RNA subunit and 
C-terminus of peptide subunit by a hydrazone bond. To confirm the effectiveness of the strategy, we 
chose the fluorescent RNP sensor for ATP and GTP as a model. At the first step, ATP-binding RNP 
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receptors and GTP-binding RNP receptors were selected from an RNP library as described previously. 
A26RNA and G23 RNA that show relatively high fluorescence intensity to each substrate were utilized. 
A26  RNA and G23 RNA were constructed by in vitro transcription and purified by denaturing 
polyacrylamide gel electrophoresis. Purified RNA was treated with freshly prepared sodium periodate 
to modify the 3’-terminal ribose to 3’-dialdehyde by periodate oxidation. After the reaction, the excess 
of sodium periodate was quenched by glycerol and the resultant RNA was purified with ethanol 
precipitation. The peptide subunit for the covalent linkage was obtained by introducing a fluorophore to 
the N-terminus and a hydrazide linker peptide at the C-terminus of Rev peptide. The Rev peptide with 
the linker sequence was synthesized by 4-HMBA (hydroxymethylbenzoic acid)-PEG resin according to 
the Fmoc chemistry protocols. 5-Carboxyfluorescein and 1-pyrenesulfonyl chloride were conjugated 
with N-terminal of the Rev peptide upon the cleavage from the resin. After the deprotection of the 
function groups on the chains, both peptides were purified by HPLC and characterized by MALDI-
TOF MASS spectrometry. [5-Carboxyfluorescein hydrazine modified Rev peptide (5FAM-Rev-HZ): 
m/z 3469.1 (calcd. for [M+H]+ 3469.7); 1-Pyrenesulfonyl acid modified Rev peptide (Pyr-Rev-HZ): 
m/z 3379.2 (calcd. for [M+H]+3376.7)]. Subsequently, these two modified subunits were covalently 
linked. Coupling reaction of the 3’-modified A26 RNA with 5-carboxyfluorescein modified Rev 
peptide hydrazide (5FAM-Rev-HZ) and G23 RNA with 1-pyrenesulfonyl acid modified Rev hydrazide 
(Pyr-Rev-HZ) was performed in sodium acetate buffer (pH 5.2). The covalent RNP complex was 
purified by phenol-chloroform extraction and ethanol precipitation. Furthermore, collected RNP was 
purified with a denature PAGE to remove unreacted RNA and peptide. The recovery yields of RNP 
were calculated to be 36% (c-A26/5FAM-Rev) and 32% (c-G23/Pyr-Rev) by confirmed by MALDI-
TOF mass spectroscopy, c-G23/Pyr-Rev was found; m/z 21745.3 (calcd for [M+H]+ 21588.3). These 
results indicate that the covalent fluorescence RNP complex was successfully formed according to our 
design. 
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2.4.3. Fluorescent response of the covalent RNP complex 
Fluorescence responses of the covalently linked c-A26/5FAM-Rev, c-G23/Pyr-Rev and each non-
covalent RNPs (A26/5FAM-Rev, g23/Pyr-Rev complexes) were evaluated in the presence of 
increasing concentration of ATP or GTP (Figure 31). In the case of ATP-binding RNP sensors, relative 
fluorescence intensity (I/I0) of ATP sensors was calculated by dividing fluorescence intensity in the 
presence (I) by fluorescence intensity in the absence (I0) of Ado (Figure 31 a). Relative fluorescence 
intensity was plotted against the Ado concentration to calculate the dissociation constant (KD) of 
fluorescence RNP sensor and Ado saturation values of the changes in relative fluorescence intensity 
was found to be 1.8 for 0.1µM c-An16/5FAM-Rev, similar to the value of 1.8 for An16/5FAM-Rev. 
KD values for the Ado complex of nc-A26/5FAM-Rev and c-A26/5FAM-Rev were 12.8 and 51.5µM, 
respectively (Figure 31 b). The binding affinity of A26/5FAM-Rev was increased by forming the 
covalent complex. Non-covalent complex exhibited almost no fluorescent response when the RNP 
concentration was decreased to 100nM, indicating that the non-covalent RNP complex was mostly 
dissociated into each subunit (Figure 31 a). As expected, the covalently linked sensor c-A26/5FAM-
Rev still provided distinct fluorescent signals even at 100nM. The non-covalent RNP sensor was 
converted to a covalently linked assembly stabilized by an intramolecular interaction of the peptide and 
RNA subunits without diminishing the sensing function. On the other hand, GTP sensor cG23/Pyr-Rev 
shows slightly lower affinity to GTP than that of non-covalent sensor. However, the relative 
fluorescence intensity is significantly higher. The stability of interaction between RNA and peptide 
subunit clearly effect to the affinity and the fluorescence intensity change.   
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Figure 31: (a) Saturation curves for the relative fluorescence intensity changes of nc-A26/5FAM-Rev and c-A26/5FAM-Rev by titration 
with Ado in a buffer containing 10 mM  Tris-HCl (pH 7.6), 100 mM NaCl, 10 mM MgCl2 and 0.005% Tween 20 at 4 °C. Titration of  
ATP-binding fluorescent RNP complex c-An16/5FAM-Rev (0.1 µM; red circle) and nc-An16/5FAM-Rev (0.1 µM; purple reverse 
triangle, 0.5 µM; green triangle, 1.0 µM; blue square) with Ado (0.1, 1, 10, 100, 1000 µM) were shown. (b) Saturation curves for the 
relative fluorescence intensity changes of nc-G23/Pyr-Rev and c-G23/Pyr-Rev by titration with GTP in a buffer containing 10 mM Tris-
HCl (pH 7.6), 100 mM NaCl, 10 mM MgCl2 and 0.005% Tween 20 at 4 °C. Titration of GTP-binding fluorescent RNP complex c-
G23/Pyr-Rev (0.1 µM; showing in red circle) and nc-G23/Pyr-Rev (0.1 µM; purple reverse triangle, 0.5 µM; green triangle, 1.0 µM; blue 
square) with GTP (0.1, 1, 10, 100, 300 µM) were shown. Dissociation constants and the maximum relative fluorescence intensity for the 
ATP and GTP complex of each RNP are shown in the figure, respectively.  
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2.5. Conclusions 
The fluorescent RNP sensors represent a successful example of RNA aptamer-based artificial receptors 
for small target molecules. The non-covalent RNA complex embedding an aptamer function and a 
fluorophore-labeled peptide affords a fluorescent ribonucleopeptide (RNP) framework for constructing 
fluorescent sensors. Taking advantage of the non-covalent properties of the RNP complex, the ligand-
binding and fluorescence characteristics of the fluorescent RNP can be independently tuned according 
to the nature of the RNA and peptide subunits, respectively. Fluorescent sensors tailored for given 
measurement conditions, such as a detection wavelength and a detection concentration range for a 
ligand of interest can be easily identified by screening of fluorescent RNP libraries. We reported in this 
work, an effective strategy for obtaining ratiometric fluorescent RNP sensors tethering 6-SNARF 
(Seminapthorhorhodafluor) fluorophore However, the non-covalent nature of RNPs could represent a 
disadvantage when very low concentrations are required or when multiple sensors are coexisting in the 
same environment. In order to overcome this drawback, we developed a strategy to convert a non-
covalent fluorescent RNP sensor into a covalently linked stable fluorescent RNP sensor. The covalently 
linked sensors enabled ligand detection at a low sensor concentration, even in cell extracts. 
Furthermore, application of different target specific sensors allowed simultaneous detection of different 
targets monitoring each wavelength corresponding to the respective sensor. Further application of this 
technique will be shown in chapter 3. 
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2.6. Materials  and methods 
2.6.1. Materials 
Tetracycline, dopamine, norepinephrine and tyrosine were purchased from Sigma Aldrich. 
Chloramphenicol, gel electrophoresis grade acrylamide and bisacrylamide was provided by Wako 
Chemicals GmbH. Streptomycin was obtained from Nacalai Tesque. N-Fmoc-protected amino acids, 
Fmoc-NH-SAL-PEG resin (0.23mmol/g), HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate), HOBt (1-hydroxybenzotriazole), DIEA (N,N-
diisopropylethylamine), TFA (trifluoroacetic acid) and distilled DMF (N,N-dimethylformamide) were 
purchased from Watanabe Chemical Industry. Gel electrophoresis grade acrylamide and bisacrylamide 
were obtained from Wako Chemicals. All other chemicals were reagent grade and used without further 
purification.  
 
2.6.2. Nucleic acids synthesis 
The original double-stranded DNA pools were constructed by Klenow polymerase (New England 
Biolabs) reaction from a synthesized oligonucleotide containing 40 random nucleotides [5’-
GGAATAGGTCTGGGCGCA-N40-P(OH)-3’] and a synthesized oligonucleotide containing 7 random 
nucleotides (5’-GGAATAGGCCTGTACCGTCA-N7-OH-3’) followed by PCR amplification to add 
the promoter for T7 RNA polymerase using Pyrobest DNA polymerase (TaKaRa) with 3’-DNA (5’-
GGAATAGGCCTGTACCGTC-3’) and 5’-DNA primer (5’-
TCTAATACGACTCACTATAGGAATAGGTCTGGGCGCGCA-3’: T7 RNA promoter underlined). 
RNA transcription was performed using an AmpliScribeT7 kit (Epicenter) for 3h at 37ºC, according to 
the supplier’s recommended protocols. The resulting RNA was phenol/chloroform extracted, 
precipitated with ethanol, and pelleted by centrifugation. The RNA was purified by denaturing 
polyacrylamide gel electrophoresis and eluted. RNAs concentration was determined by UV 
spectroscopy. 
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2.6.3.  Preparation of ribonucleopeptide receptors 
 
RNPs that bound ATP were selected as follows: RNA was heated at 80ºC for 3 minutes and cooled to 
room temperature for 2h for proper secondary structure. A binding buffer (100µL, 10nM Tris-HCl pH 
7.60, 100mM NaCl, 10nM MgCl2) containing 1.0µM RNA, 1.5µM Rev, and a 50µL volume of ligand-
conjugated agarose was incubated to allow a formation of a specific ribonucleopeptide complex for 30 
minutes on ice. RNA-peptide-resin complexes were washed three time with 300µL (6-volume of resin) 
of binding buffer to remove unbound RNA-peptide complexes and eluted three times with 150 µL (3-
volume of resin) of binding buffer containing 4mM ATP. Recovered ribonucleopeptide complexes 
were precipitated with ethanol and resuspended in TE buffer. After reverse transcription with AMV 
reverse transcriptase (Promega) of the selected RNA using the 3’-DNA primer used in PCR 
amplification and successive PCR amplification (RT-PCR) using 5’- and 3’- DNA primer, DNA 
templates were transcribed, and the resulting RNAs were subjected to the next round of selection. 
Selected RNA pools were converted to DNA and PCR-amplified to introduce BamHI, EcoRI 
restriction sites by using primers 5’-GCGGGATCCTTTCGGCCTGTACCGTCA-3’ and 5’-
CGGAATTCTAATACGACTCACTATAGG-3’. After enzymatic digestion (New England Biolabs), 
DNAs were cloned into the pUC19 vector using Ligation Kit Version 2 (TaKaRa) and sequenced using 
a BigDyeTerminator Cycle Sequencing Kit (Applied Biosystems) with a model 377DNA sequencer 
and 3130/3130x1 genetic analyzer (Applied Biosystems). 
 
2.6.4. SNARF-Rev and SNARF-Abu-Rev preparation 
 
The procedure for the synthesis of fluorophore-labeled Rev peptides were previously reported.
3 
Briefly, 
the two Rev peptides were synthesized on a Shimadzu PSSM-8 peptide synthesizer according to the 
Fmoc chemistry protocols. In SNARF-Abu-Rev two residues of γ-aminobutyric acid were manually 
attached to the N-terminus of the peptide applying Fmoc-SPPS strategies (HOBt, HBTU as activators, 
DIEA as base). SNARF, which was synthesized according to previous report
7
, was directly coupled, 
after activating the carboxyl function, to the N-terminal deprotected residue of Rev peptide on the 
resin. SNARF-Rev and SNARF-Abu-Rev peptides were then deprotected, cleaved from the resin and 
purified by using RP-HPLC. Characterization was achieved by MALDI-TOF MS spectrometry 
(AXIMA-LNR, Shimadzu Biotech) [6-carboxy-SNARF-Rev+H]
+ 
calc. m/z 3314.12 obs.m/z 3313.35; 
[6-carboxy-SNARF-abu-Rev+H]
+
 calc. m/z 3729.38 obs. m/z 3728.23. 
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6-carboxy-SNARF-Rev 
SNARF-TRQARRNRRRRWRERQRAAAAR-NH2 
The SNARF-Rev peptide purification was achieved using HPLC methodology. The gradient 
optimization was settled in analytical conditions using Hypersil GOLD 250x4.6 column:  
 Flow rate: 1.000 ml/min; 
 Sample preparation: 50% distilled H2O+ 50% ACN; 
 Wavelength detected: 548nm; 
 Gradient selected (0.5%): 
Time (min.) %A %B 
3 75 25 
53 50 50 
58 0 100 
60 75 25 
65 75 25 
                                                 Table 4: A= distilled H2O + 1‰TFA; B= 50%ACN + 1‰TFA 
Purification was accomplished using COSMOSIL ARII column (4.6x250mm) and the presence of the 
desired compound was confirmed by MALDI-TOF mass spectrum (m/z 3313.35; calcd for [M+H]+):  
 
 
 
 
 
 
 
 
 
 
 
 
                                                         Figure 32: Hplc chromatograph of purified 6-SNARF-Rev peptide 
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                                                             Figure 33: MALDI-TOF mass spectrum of 6-SNARF-Rev peptide 
 
In order to verify SNARF pka change upon Rev peptide coupling, a fluorimetric assay was 
accomplished screening several pH conditions: 
 Sample concentration: 5 M; 
 pH titration: 5.13, 6.07, 6.53, 7.11, 7.54, 8.03, 9.02; 
 Emission range: 570-700nm (excitation wavelength 534, 514, 488nm) 
 Absorption range: 280-800nm 
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6-carboxy-SNARF-Abu2- Rev 
                      
                                    
Purification was achieved by HPLC  COSMOSIL AR II column, applying  a 0.5% gradient: 
Time (min.) %A %B 
3 75 25 
53 50 50 
55 0 100 
57 75 25 
67 75 25 
  Table 5: Phase A: distilled H2O +1 ‰ TFA; phase B: 50%ACN + 1‰ TFA. Flow: 1.000ml/min; 100 l injected; wavelength     checked: 
548nm. 
 
                                              Figure 34: Hplc chromatograph of purified 6-SNARF-Abu2 -Rev peptide. 
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                                         Figure 35: MALDI-TOF mass spectrum of 6-SNARF- Abu2- Rev peptide. 
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The fluorescence emission spectrum of the obtained compound was determined at different pH 
conditions, using Infinite M200PRO instrument: 
 Excitation wavelength: 534, 514, 488nm; 
 Emission scan range: 570-700nm; 
 Wide pH range buffer: Acetate + Mes + Tris 
 pH titration: 4.02, 5.13, 6.07, 6.53, 7.11, 7.54, 8.03, 9.02; 
 Samples final concentration: 5µM; 
 Absorbance range: 280-800nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.6.5. Fluorescent measurements on the microplate 
 
The 96-well fluorescence measurements were performed on an Infinite M200PRO instrument (TECAN 
co. ltd.). For tetracycline titration, a binding solution (100µl) containing 1µM of fluorescent RNP in 
10mM Tris HCl (pH 7.00), 250mM NaCl, 5mM MgCl2, 0.0005% Tween 20 was prepared. For 
dopamine and other catecholamine derivatives, a binding solution (100 µl) containing 1µM fluorescent 
RNP in 10mM Tris HCl (pH 7.60), 300mM NaCl, 5mm MgCl2, 0.005% Tween 20 was prepared. For 
streptomycin, a binding solution (100µl) of 1µM concentration of fluorescent RNP was prepared in 
50mM Tris HCl (pH .60), 250mM NaCl, 10mM MgCl2, 0.005% Tween 20 buffer conditions. Well-
mixed samples with different concentrations of substrates were incubated at 25ºC for 30 minutes 
followed by the measurement of emission spectra (measures emission spectrum range: 570-700nm; 
excitation wavelength utilized: 534nm). 
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2.6.6. Determination of dissociation constants 
 
The dissociation constant was achieved applying the following equation: 
 
Fobs = A(([RNP]T + [substrate]T + KD)-(([RNP]T + [substrate]T + KD)
2
 –(4[RNP]T 
[substrate]T)
1/2
)/2[RNP]T) 
 
where A is the increase in fluorescence at saturating substrate concentrations (Rsat-R0), KD is the 
equilibrium dissociation constant,  [RNP]T and [substrate]T are the total concentrations of RNP and the 
substrate, respectively.  
 
 
2.6.7.  Cross linking reaction for constructing covalently linked RNP sensors 
 
RNA subunits of RNP receptors were purified by denaturing 8% polyacrylamide gel electrophoresis. 
The purified RNA subunit was treated with freshly prepared sodium periodate to convert cis-diol of the 
3’-terminal ribose to 3’-dialdehyde by periodate oxidation. Freshly prepared 50eq. of 0.01M sodium 
periodate (10µL; 100nmol) was added to about 100µM RNA (20µL; 2nmol) in 32µL of 0.02M sodium 
acetate (pH 5.20) and the reaction mixture was incubated for 30minutes 37ºC in the dark. After the 
reaction, the excess of sodium periodate was reduced by adding 1M glycerol and the resultant oxidized 
RNA was purified with ethanol precipitation. In order to assess the oxidation reaction success, 5 µl 
sample was mixed with 100µl of a BODIPY-NHNH2 solution (1mg/ml in TE buffer pH 7.60) and let 
reacting for 1hour at room temperature in dark conditions. Sample was then purified by EtOH 
precipitation and checked by gel image (Pharos imager) (Figure 36). 
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                             Figure 36: Oxidation step check on A26 by BODIPY-NHNH2 (Pharos Imager, Exc. Wv. 488nm) 
 
 
The peptide subunit was synthesized by introducing a fluorophore to the N-terminus and the peptide 
linker (GGSGGSGGSG) with a hydrazide group synthesized as follows, 4-hydroxymethylbenzoic acid 
PEG resin (HMBA-PEG resin, 0.22mmol/g) was placed in a dry flask and was added sufficient amount 
of DMF to soak the resin and allowed to swell for 30 minutes. N-α-Fmoc-glycine (10eq. relative to 
resin loading) was dissolved in DMF, and then mixed DIC (5eq. relative to resin loading). After 
incubating for 20minutes, the solution is mixed to the resin prepared above and a catalytic amount of 
DMAP is added. The resin/amino acid mixture was incubated at room temperature for 1 hour with 
occasional swirling. The first coupling was repeated 2 times. The resin with the first amino acid was 
loaded onto an automated peptide synthesizer PSSM-8 (Shimadzu) and the subsequent synthesis was 
performed according to the Fmoc chemistry protocols by using protected Fmoc-amino acids, and 
HBTU. A fluorophore with an activated group (5-carboxyfluorescein N-succinimidyl ester or Cy-5 
mono NHS ester) was directly coupled to the Fmoc-deprotected synthetic peptide on the resin. The 
fluorophore-labeled peptide was cleaved from the resin with 0.1M hydrazine hydrate in DMF for 1 
hour at room temperature, washed with DMF and then deprotected by a solution containing phenol 
(0.75g), distilled water (0.5mL), thioanisol (0.5mL), 1,2-ethandiol (0.25mL), and TFA (10mL) for 3 
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hours. The modified peptide was purified by reverse phase HPLC (Figure 37), and characterized by 
MALDI-TOF mass spectrometry (AXIMA-LNR, Shimadzu Biotech); 5-carboxyfluorescein modified 
Rev peptide hydrazine (5FAM-Rev-NHNH2), m/z 3485.87 (calcd for [M+H]
+
 Na
+
3484.7) (Figure 38). 
 
 
                                    Figure 37: Hplc chromatogram of 5-FAM-Rev-GGSGGSGGSG-NHNH2 peptide 
 
 
 
 
 
 
 
 
                          Figure 38: MALDI-TOF mass spectrum of 5-FAM-Rev-GGSGGSGGSG-NHNH2 peptide 
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The coupling reaction between the 3’oxidized RNA and fluorophore labeled Rev-NHNH2 (1.5eq.) was 
carried out in 0.02M sodium acetate  buffer pH 5.20 containing 0.01M NaCl (total 50µL) at 37ºC in the 
dark. After 8 hours, the reaction mixture was extracted by phenol-chloroform and then purified by 
ethanol precipitation. The precipitate was dissolved in TE buffer. The sample solution was purified by 
6M urea 15% denature PAGE, and was subsequently quantified by the absorption at 260nm (A26 ɛ= 
738400 M
-1
cm
-1
, A17 ɛ= 695700 M-1 cm-1, An15 ɛ= 612200 M-1 cm-1, An16 ɛ=635500 M-1 cm-1); 80% 
yield was recovered (Figure 39 and 40). 
 
 
 
Figure 39: 15% urea acrylamide gel image of An16 and A26 cRNPs before purification. On the left side EtBr staining; on the right side 
fluorescence image (exc. Wv. 488nm) and EtBr staining overlaid image.  
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Figure 40: Mobility shift variation after coupling reaction; 15% urea acrylamide gel image of covalently liked RNPs, respectively from 
left to right, An15tag02, an16tag04, A17tag03 and A26tag01.  
 
The purity was confirmed by gel image (Pharos Imager, Exc. Wv. 488nm/EtBr staining) as shown in 
Figure 41 (Yield after purification: .A26 82%; An16 75%; An15 67%; A17 66%). A mass spectrum 
was also obtained using MALDI-TOF sprectometer (Figure 42 and 43). 
 
 
Figure 44: An16 and An15 covalently linked RNP purity check. Left side, fluorescence image (Exc. Wv. 488nm); right side, EtBr 
staining image. 
 
 
A26 cRNP  calcd. mass m/z  28039.5 
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               Figure 41: Covalently linked RNPs purity check. From left to right: An15tag02, An16tag04, A17tag03, A26tag04.  
 
                                Figure 42: MALDI-TOF mass spectrum of A26tag01 cRNP (Mass founded:  m/z 27846.3). 
 
An16 cRNP  calcd. mass m/z  24538.6 
 
 
 
 
 
 
 
                               Figure 43: MALDI-TOF mass spectrum of A26tag01 cRNP (Mass founded:  m/z 24216. 
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2.6.8. Fluorescence spectral measurements of  RNPs 
Fluorescence spectra were recorded on a Hitachi F-4500 fluorescence spectrofluorophotometer with 
excitation and emission bandwidth of 5nm. The measurements were performed in a buffer (100µL) 
containing 10nM Tris-HCl (pH 7.60), 100mM NaCl, 10mM MgCl2, 0.005% Tween 20, non-covalent 
or covalent RNP and an indicated amount of substrate. Excitation wavelength was 485nm for 5FAM-
Rev and 350nm for Pyr-Rev. The emission wavelength was 535nm for 5FAM-Rev and 390nm for Pyr-
Rev were used for the determination of affinity and relative fluorescence intensity. 
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Chapter 3: 
Construction of a molecular switchboard by assembling 
ribonucleopeptide biosensors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
179 
 
3.1. Introduction 
 
3.1.1. Nanomaterial based on DNA  
DNA is one of the most important components of all living organisms. Genomic DNA is the archive of 
genetic information, which comprehend fundamental information for many species including humans, 
even though the sequence has always been continuously changing. This instability in terms of over 
millions of years has been changing the organisms, and some of those changes have allowed them to 
adapt to new environments and some others have resulted in their disappearance. For example, humans, 
other primates and guinea pigs have lost the ability to produce ascorbic acid, or vitamin C,
1
 even 
though they require the vitamin for healthy living. Genetic mutations sometimes cause diseases, even 
when only one base is deleted, or replaced by a different base if the change is critical to the expression 
of a functional protein at a normal level.
2-5
 Most of mutations in genomic DNA are corrected by 
enzymatic systems to keep the information unchanged.
6,7
 The double stranded structure of DNA makes 
this correction process precise, because the strand without mutations is used as a template for the 
correction. From the structural point of view , there are many advantages in using DNA as a building 
block of nano-sized material with precisely designed architecture.
8-13
 In particular, the specificity of the 
hydrogen interactions between adenine-thymine and guanine-cytosine allows us to design the whole 
structure of DNA-based materials. In addition, two strands of double-stranded DNA can be covalently 
bound to each other using DNA ligase when the 5’-end of one strand is complimentary to the 3’-end of 
another strand. Oligomers or polymers of DNA can be chemically synthesized by automated machines 
in a large amount, so that DNA with a proper length and sequence can be obtained with high purity in 
amounts required for clinical application. Under conditions where there are no enzymes degrading 
DNA, DNA is very stable compared with proteins, another component candidate for nano-sized 
materials with designed architecture. Moreover, restriction enzymes, ligases and other enzymes are 
available to design and modify the properties of DNA-based materials. DNA materials science related 
to structural DNA nanotechnology has grown rapidly as a research area in the past two decades. The 
technology allows the construction of various self-assembled scaffolds, which can be used for the 
placement and arrangement of functional molecules and nanomaterials and for the production of 
complex molecular devices. The field of DNA nontechnology can be traced back to the words written 
by Nadrian Seeman in 1982: “ It is possible to generate sequences of oligomeric nucleic acids which 
will preferentially associate to form migrationally immobile junctions, rather than linear duplexes, as 
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they usually do.”14 Seeman had wanted to organize proteins in three-dimensional (3D) crystals so that 
he could study their structure with X-ray crystallography. Three decades later the field has outgrown its 
roots in protein crystallography and delivered numerous advances in the control of matter on the 
nanoscale. 
15 
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3.2. DNA origami technology development 
3.2.1. 2D DNA origami 
DNA origami, developed by Rothemund in 2006, has enabled the construction of a wide variety of 2D 
structures of around 100nm in size, including rectangles, triangles, and even a smiley face and five-
pointed star (Figure 1).
1 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: DNA origami structure. A) The method employed to prepare DNA origami structure from the template single-stranded DNA 
and staple strands. B) Design and AFM images of self-assembled DNA origami structures.  
 
In this method, a long single-stranded DNA (M13mp18; 7249 nucleotides) and the sequences-designed 
complementary strands (called “staple strands”; most are 32-mer) are mixed and then annealed from 
95ºC to room temperature over 2h, resulting in the formation of target structures by self-assembly 
(Figure 1). The structure can be imagined using atomic force microscopy (AFM), and the assembled 
structure can be formed according to a design. To create 2D DNA origami structures, adjacent double-
stranded DNAs (dsDNAs) should be connected to each other via a cross-over. In this design, the 
geometry of the double helices involved has three helical rotations fro 32 base pairs (Figure 2). For 
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example, two neighboring crossovers of the central dsDNA in an arrangement of three adjacent 
dsDNAs should be located at the opposite sites (180º rotated, 0.5turns). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Design of a self-assembled DNA origami structure and geometry of the incorporated dsDNAs. Colored strands and a 
gray/black strand represent staple strands and template single-stranded DNA, respectively. Staple strands connect the adjacent duplexes 
with crossover. Inset: structure of harpin DNA for a topological marker. 
 
Therefore, the crossovers should be separated by 16 base pairs (1.5 turns). To maintain a stable planar 
structure, this rule should be followed when placing multiple staple strands. DNA origami structures 
are formed using many different staple strands, so that hairpin DNA markers can be placed at any 
position on the surface of the DNA structure. Hairpin DNA used as a topological marker is observed as 
a dot under AFM imaging. In this case, hairpins are placed perpendicular to the surface of DNA 
origami, therefore each hairpin should be placed at a position eight base pairs from the crossover (270° 
rotation). The distance between the centers of the adjacent staples is about 6 nm, so the adjacent 
hairpins can be observed as distinct spots according to the spatial resolution of the AFM. Using the 
hairpin markers, patterns, such as the map of a hemisphere (Figure 3) can be drawn precisely on the 
DNA origami surface.  
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Figure 3: Drawing of a hemisphere on the DNA origami with hairpin DNAs (with dots) and an AFM image of the assembled DNA 
origami. 
 
In addition, when functional molecules and nanoparticles are conjugated to specific staples, they can be 
placed on the origami surface at selected sites. A remarkable property of DNA origami is that all the 
positions of the structure have DNA sequence information (an address). Before the emergence of DNA 
origami technology, it was difficult to create ∼100 nm-sized structures through the self-assembly of 
small DNA components. DNA origami technology solved this problem and provided the breakthrough 
that enabled expansion of the shape design and the creation of addressable structures. Since the DNA 
origami system uses a long single-stranded template DNA, the size of the 2D structure is determined by 
the length of the template strand. Various single-stranded DNAs were isolated and used as a template 
in the preparation of DNA origami.
2,3
 A strategy of using DNA tiles (17 × 16 nm) instead of staples has 
also been developed, which allows size expansion by the introduction of 25 to 56 DNA tiles.
4 
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3.2.2. Programmed arrangement of multiple DNA origami components  
The programmed arrangement of DNA origami is an important technique for preparing the desired 
large structures, particularly in terms of integrating complicated functions. Sugiyama et al. explored 
techniques for arranging multiple DNA origami components, and developed methods to arrange 
rectangular DNA origami tiles horizontally in a programmed fashion.
5
 In addition, as the ends of the 
helical axes align at both edges of the DNA origami rectangles, a rectangular DNA origami tiles can be 
assembled via π-interaction at the edges. Specific concave and convex connectors were introduced into 
the origami rectangles to align these rectangles precisely with neighboring origami tiles. DNA 
rectangles should correctly assemble by shape and sequence complementarity, where complementary 
strands are introduced into the concavity and the convex connectors. After self-assembly, it was 
observed that the DNA tiles were aligned and oriented in the same direction. Furthermore, to align 
origami tiles accurately, the positions of the connectors and the concavity were changed to connect two 
specific tiles. Five tiles were designed to align horizontally. In this system, a two-step self-assembly 
was adopted: first, individual origami tiles were prepared, and then the multiple tiles were assembled in 
the second stage by slower annealing from 50 °C. The DNA origami is stable enough to heat at 50 °C 
in secondary annealing. To allow the identification of the DNA tiles, hairpin markers were introduced 
onto the individual tiles. After self-assembly, judging by the order of the markers, the five tiles were 
aligned correctly. In addition, hairpin markers were used to display letters of the alphabet on the 
origami surface. The letters D, N, A, N, and O were each introduced onto one of the five tiles. After 
self- assembly using the first three tiles and last four tiles, the words “DNA” and “NANO” were 
displayed, respectively. Using five tiles with the letters K, Y, O, T, and O, the five-letter word 
“KYOTO” was formed (Figure 4).  
 
 
 
 
 
Figure 4: Programmed self-assembly of DNA origami. Structure of DNA origami having a concavity and a convex connector; the 
structure is called a “DNA jigsaw piece” for 2D assembly. A 3x3 assembly of nine tiles and the AFM image of the assembly.  
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The method described above was applied to prepare the 2D assembly system.
6
 The shape and sequence 
selectivity were introduced to both lateral edges for extension in the vertical direction. Nine DNA tiles 
were designed and prepared. Three tiles were then programmed to be connected vertically or 
horizontally, and three sets of vertical or horizontal trimers were finally assembled into a 3 × 3 
assembly with ∼30% yield; this assembly was confirmed by hairpin markers introduced onto the 
individual origami tiles.  
 
3.2.3. 3D DNA origami structures 
Given the geometry of the periodic double-helical DNA structure, 3D structures can be designed by 
extending the 2D DNA origami system. Two strategies for preparing 3D DNA origami structures have 
been developed: one is the bundling of dsDNAs, where the relative positioning of adjacent dsDNAs is 
controlled by crossovers, and the other is the folding of 2D origami domains into 3D structures using 
interconnection strands. In the former method, developed by Shih and co-workers, relative positioning 
of adjacent dsDNAs is geometrically controlled by the crossovers. By arranging the positions of the 
crossovers, tubular and multilayered structures can be constructed (Figure 5).
7 
                   
Figure 5: Design and construction of 3D DNA origami structures. Scheme for folding the 2D pleated structure into a 3D multilayered 
structure using staple strands connecting adjacent layers. Sectional views of the positions of the cross-overs in the multilayered structure 
sliced at seven-base-pair intervals. 
 
By increasing or decreasing the number of base pairs between crossovers (in this case, two helical 
rotations for 21 base pairs), the relative positional relationship between adjacent dsDNAs is controlled. 
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Using the rotational angle of 240° for seven base pairs, three adjacent dsDNAs can be placed at a 
relative angle of ±120° with cross-overs every 7 or 14 base pairs. By alternating this relative 
positioning between adjacent dsDNAs, the duplexes form a pleated structure. When adjacent dsDNAs 
are placed to rotate in one direction, the contiguous duplexes finally form a six-helix bundled tubular 
structure. Thus, when some parts of the pleated structures are turned backward by the introduction of 
one-directional rotation of adjacent dsDNAs, the structures fold to become a stacked layer structure. In 
this case, to stabilize the 3D structures, adjacent layers of dsDNAs should be further connected by 
crossovers. Due to the complexity and high density of the introduced crossovers, an accurate folding 
into the target 3D structure requires a week-long folding time. When the pleated structures were 
integrated as multilayered structures, the repeating units of the six-helix bundled tubular structures 
formed a honeycomb lattice, viewed from the axial direction of the double helices. It was also possible 
to create more complex structures by perpendicularly joining these 3D structures. In addition, a 
wireframe icosahedron structure was assembled from three double-triangle monomers made of a six-
helix bundled tubular structure with connections. caDNAno software, which is publicly available, has 
been developed to support the design of these 3D structures.
8
 Furthermore, using the layered structures 
described above, new 3D structures were built by changing the helical twist from the average helical 
pitch of 10.5 base pairs per turn to 10 or 11 base pairs per turn.
9
 When dsDNAs having diﬀerent helical 
pitches were bundled together, torque and repulsion between base pairs caused overall structural 
changes including twisting or 30–180° bending (Figure 6).  
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Figure 6: Global twisted structures of six-helix DNA bundles obtained by the selective deletion or insertion of nucleotides to change the 
helical turns from the normal 10.5 base pairs to 10 or 11 base pairs. TEM images of the polymerized ribbons containing 10.5-base-pair, 
10-base-pair and 11-base-pair helical pitches. 
 
Using these structures as building blocks, left-handed or right-handed helical ribbon structures were 
prepared. In addition, when angle-controlled duplex bundles were connected to each other, a six-tooth 
gear and a spherical wireframe capsule were created (Figure 7).  
 
 
 
 
 
 
 
Figure 7: Global bending of six-helix DNA bundles by the deletion and insertion of nucleotides in the adjacent duplexes. Assembly of 
four components of a quarter circle with three teeth (50nm radius) and TEM images of the 12-tooth gear. 
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3.2.4. Construction of 3D structures from sequentially connected subunits 
Using a diﬀerent strategy, a DNA box structure was created by folding multiple 2D origami domains 
with interconnecting strands.
10
 Six independent rectangles were sequentially linked, and were designed 
to be folded using interconnection strands in a programmed fashion (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Design and construction of 3D structure from sequentially connected multiple rectangular plates. A) DNA box structure by 
folding of six DNA origami rectangles using interconnection strands introduced at the edges of rectangles. B) The DNA box model 
reconstructed from cryo-EM images. C) Controlled opening of the box lid using selective DNA strands (key). Lid opening event was 
monitored by FRET.  
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Analyses of the assembled structure by AFM, cryo-electron microscopy (cryo-EM), dynamic light 
scattering, and small-angle X-ray scattering indicated that the size was close to the original design. The 
lid of the box could be opened using a specific DNA strand to release the closing duplex by strand 
displacement, and the opening event was monitored by fluorescence resonance energy transfer (FRET) 
(Figure 8 C).  
3.2.5. Applications of DNA origami structures 
A wide variety of designs of 2D and 3D structures of around 100nm in size have been realized by 
constructing DNA origami. Compared with the use of small DNA assemblies, the DNA origami 
method reduces experimental labor and the need for strict stoichiometry and eliminates uncertainties. 
The DNA origami method was first reported in 2006. In the relatively short time multidimensional 
structures, functionalization, single-molecule imaging,  and the construction of molecular of molecular 
machines have been realized. Functionalized DNA origami has already been combined with top-down 
nanotechnology, including semiconductor processing techniques. As the size of DNA origami is 
compatible with cellular uptake, it is expected that cell-targeting applications will benefit from the 
design of various shapes and effective functionalizations. Here I reported examples of state-of-art 
effective applications of this technique. 
3.2.5.1. Single molecule chemical reactions 
Selective bond cleavage and bond formation reactions were performed on a DNA origami surface. 
Target organic molecules with specific reactivity were introduced into specific positions on the DNA 
origami. Reductive cleavage of disulfide bonds and oxidative cleavage of olefin by singlet oxygen were 
carried out on the DNA origami surface, and the reactions proceeded quantitatively at the single-
molecule level.
11
 In addition, amide bond formation and click reactions on alkine were performed with 
80–90% yield, sequencing reactions were also performed (Figure 9). These chemical reactions were 
monitored by the cleavage of biotin-attached chemical linkers and bond formation with biotin-tethered 
functional groups, which can be labeled with streptavidin for visualization by AFM. 
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Figure 9: Single chemical reaction on DNA origami. A) Reactive groups (azido, amino, and alkyne groups) were incorporated into the 
DNA origami by conjugation with staple DNA strands. The coupling reactions were then performed using the biotin-attached functional 
groups. The completion of the reactions was visualized by the binding of streptavidin. B) AFM images of the three individual reactions 
and three successive reactions by the treatment of three biotin-attached functional groups. Yields are presented below. 
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3.2.5.2. Single biomolecule imaging 
Direct observation of enzymes interacting with DNA is expected to be one of the most significant 
technologies for investigating the mechanical behavior of enzymes. Because DNA origami is used as a 
scaﬀold for AFM observation, the movement of biomolecules, including proteins and enzymes, and the 
DNA structural change itself can be visualized and analyzed if the substrate dsDNAs and the target 
DNA structures are attached onto the origami scaﬀold. DNA modification using enzymes often 
requires bending specific DNA strands to facilitate the reaction. The DNA methylation enzyme EcoRI 
methyltransferase (M.EcoRI) bends dsDNA by 55–59° during the methyl-transfer reaction.12  
 
To control the methyl-transfer reaction of M.EcoRI and examine the structural eﬀect on methylation, 
2D DNA scaﬀold was designed and prepared, named a “DNA frame”, which accommodates two 
diﬀerent lengths of dsDNA fragments: a tense 64-mer dsDNA and a relaxed 74-mer dsDNA (Figure 
10).
13
 
 
 
 
 
 
 
 
 
Figure 10: Control of the enzyme reactions in the DNA origami scaffold. A), B) DNA frame structure for incorporation of two different 
dsDNAs; tense 64-mer dsDNA and relaxed 74-mer dsDNA having the specific sequence for M, EcoRI at the centre. AFM images of 
DNA frame C) two-dsDNA attached DNA frame D), and M. EcoRI bound to the 64-mer dsDNA E) and the 74-mer F) dsDNA. 
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High-speed AFM revealed the diﬀerent dynamic movements of the dsDNAs and complexes of 
M.EcoRI with 64-mer and 74-mer dsDNAs. After treatment of the dsDNA in the DNA frame with 
M.EcoRI and subsequent digestion by the restriction enzyme EcoRI, AFM analysis revealed that, 
compared with the 64-mer dsDNA, the 74-mer dsDNA was less eﬀectively cleaved, indicating that the 
methylation preferentially occurred in the relaxed 74-mer dsDNA, rather than in the tense 64-mer 
dsDNA. Biochemical analysis of the methylation and specific digestion using real-time PCR supported 
the above results. These results indicate the importance of structural flexibility in the bending of 
dsDNA during the methyl-transfer reaction with M.EcoRI. Therefore, DNA methylation can be 
regulated using the tension-controlled dsDNAs incorporated in the DNA frame nanostructure. We next 
developed a novel method for the analysis of DNA repair by employing a DNA frame containing 
various dsDNAs and using high-speed AFM.
14
 Sugiyama et al. employed DNA base excision repair 
enzymes, 8-oxoguanine glycosylase
15
 and T4 pyrimidine dimer glycosylase,
16
 for the analysis of a 
reaction on the defined DNA nanostructure. These enzymes have glycosylase/ AP lyase activity for 
removing damaged nucleobases and cleaving the DNA strand.
17
 Various dsDNAs with a damaged base 
were placed onto a DNA nanochip as a dsDNA cassette and analyzed the repair reaction at the single-
molecule level. We placed two diﬀerent lengths of substrate dsDNAs, tense 64-mer and relaxed 74-mer 
dsDNAs, onto a DNA frame to examine the structural eﬀect on the glycosylase/AP lyase activity, 
including cleavage of the DNA strand and trapping of reaction intermediates. The relaxed 74-mer 
dsDNA trapped the enzymes with NaBH4 reduction and was cleaved more eﬀectively compared with 
the 64-mer dsDNA. In addition, dynamic movement of the enzymes and the single DNA repair reaction 
were directly observed in the DNA frame using a high-speed AFM. The DNA frame system serves to 
elucidate the detailed properties of the repair enzymes by direct observation of the events involved in 
DNA repair. This method can be used for other DNA-modifying and repair enzymes that bend the 
double helix during the enzymatic reaction. The method can be extended to the direct observation of 
various enzymatic phenomena in the designed nanoscale space. 
 
3.2.5.3. DNA nanostructures for cellular application  
The various applications of DNA origami nanostructures described above have great biological 
potential and have already been extended to cellular studies. A few examples of DNA nanostructures 
being resistant to various types of endo- and exonucleases have been reported.
18
 DNA origami 
constructs were able to maintain their integrity without degradation or damage in cell lysate of a series 
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of cell lines.
19
 The high stability of DNA nanostructures in a biological system and their favorable 
compatibility with functional biomolecules, such as proteins and aptamers, demonstrate that the 
nanostructures are promising biomaterials for living-cell analysis and as platforms for safe drug 
delivery. 
Besides intracellular signal triggering, Douglas and co-workers created a hexagonal barrel called a 
DNA nanorobot (Figure 11 A) for transporting molecular payloads to target cells and subsequent 
multiple interactions with the cellular system.
20
 By employing an aptamer-based locking mechanism, 
the reconfiguration of the nanorobot structure for payload delivery was triggered using sensing of 
molecules on the cell surface as signal inputs. Aptamer-complement duplexes were introduced on the 
left and right sides of the front of the barrel. This hexagonal barrel nanodevice can be unlocked in 
response to the protein keys between an aptamer-complement duplex and aptamer–target complex 
(Figure 11 B). The hollow inside can be loaded with diﬀerent types of payloads, such as proteins and 
nanoparticles (Figure 11 C, D), in a highly organized fashion for the delivery of various payloads, and 
the innate conformational regulation of the robot can be controlled selectively. To obtain a high yield 
of the nanorobot in a closed state, two “guide” staples were incorporated close to the locking site 
(Figure 11 E). 
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Figure 11: Design of aptamer-gated DNA nanorobot. A) Schematic drawings of the closed nanorobot in hexagonal barrel shape loaded 
with protein payloads inside in front orthographic view. The nanodevice was fastened by two DNA aptamer based locks on the left 
(dashed box) and right side. B) The nanodevice is unlocked when a DNA aptamer (orange) and the complementary strand (orange) 
dissociate in the presence of antigen key (red). C) Schematic view of the open state of nanorobot by protein key displacement of aptamer 
locks.   D) Gold nanoparticles (gold) and Fab’ antibody fragments are employed as payloads inside of the nanorobot after modifications. 
E) Guide staples with toe-holds are incorporated to obtain the high yield of nanorobot in the closed state. F) AND-gated nanorobot is 
activated (aptamer-encoded unlock) by molecular inputs expressed by target cells.  
 
The aptamer locking mechanism was designed to play the role of a logic gate by binding to the target 
cells. When the same aptamer sequences are used at two locking sites, the robot can be activated in 
response to only one type of key, whereas two types of inputs (cell surface antigens) as keys are 
required at the same time if two diﬀerent aptamer sequences are employed in order to activate the 
robot’s function and expose the payload for further interactions with target cells (Figure 11 F). 
Furthermore, this robot can be used to interface with cells and stimulate their signaling in an inhibition 
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or activation manner by selective regulation of the nanorobot function. Therefore, DNA origami aﬀords 
a new strategy for applications in cellular studies.
21 
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3.3. Networks of functional modules on DNA origami 
 
 
 
 
 
 
 
 
 
Biological systems use complex macromolecular nanostructure networks to mediate a range of cellular 
functions, such as biomolecular synthesis, signal transduction, and gene expression and regulation, all 
with high efficiency and specificity. Many of these macromolecular systems have evolved through the 
spontaneous self-assembly of components into highly organized spatial structures, where the position 
and orientation of molecules are precisely controlled to facilitate functionality. For example, the 
multienzyme cascades
1
 found in biochemical synthesis pathways and the light harvesting system in 
photosynthetic reaction centers
2
 both rely on very specific arrangements of components. Over the past 
few decades, molecular self-assembly processes have been exploited to construct various 
nanostructures including vescicles, nanofibers, and nanotubes from self-assembling  lipids, peptides, 
nucleic acids, and polysaccharides.
3
 However, it remains a challenge to accurately arrange multiple 
heterogeneous components into geometric patterns with nanometer precision, as in natural systems. 
Additional challenges include the development of novel assembly algorithms to increase structural 
complexity and improve the fidelity and yield of the assembly process. DNA is among the most 
promising biomolecules for the construction of complex biomolecular networks.
4
 One of the most 
attractive properties of DNA origami structures is the addressability of the surface, the result of the 
unique sequence at each oligonucleotide staple position. Thus, various patterns can be displayed by 
selectively modifying staple strands at desired locations with single-stranded probe extensions. The 
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DNA origami method has several advantages over “tile-based” assembly approaches: 1) scaffolded 
DNA can be folded into nearly any symmetric or asymmetric structure; 2) well-formed nanostructures 
are generated with high yield using unpurified oligonucleotides, because the scaffold imposes the 
correct stoichiometry between strands; 3) spatially addressable assembly is achieved with a resolution 
of ~6nm. Moreover, DNA origami nanostructures are reliable directors in the organization of 
heterogeneous nanoscale entities such as peptides,
5
 proteins
6
 and nanoparticles.
7
 Supermolecular 
networks of molecules that are scaffolded by DNA nanostructures exhibit well-controlled 
intercomponent distance and relative numbers. This characteristic presents exciting opportunities for 
fundamental studies of distance-dependent molecular interactions and for practical applications 
including biosensing, molecular biophysics, biocatalysis, drug delivery, and responsive nanodevices. 
 
 
3.3.1. Light-harvesting networks 
In natural photosynthesis, light is harvested by antenna systems that consist of networks of spatially 
organized chromophores to facilitate unidirectional energy transfer to a red-ox center.
8
 In artificial 
systems, DNA nanostructures can be used to arrange multiple pairs of fluorescence donors and 
acceptors into precise geometric patterns to achieve efficient energy transfer. In Figure 12 A, a DNA 
origami tile was used to organize several distinct fluorophores into closely packed linear arrangements 
to achieve multicolor energy transfer, observable at the single-molecule level.
9
 Energy transfer was 
directed along a path from a blue to red dye or from a blue to IR dye by placing a “jumper dye” 
between the primary donor and the final acceptor. As shown in Figure 12 B, an artificial light-
harvesting antenna was constructed by assembling multiple donor–acceptor pairs on a seven-helix 
DNA bundle.
10
 Steady-state and time-resolved fluorescence spectroscopy was used to measure the 
efficiency of energy transfer for networks with various ratios of donor to acceptor dyes. 
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     Figure 12: Energy-transfer within DNA nanostructures. (A) Four-color FRET and (B) artificial light-harvesting network. 
 
 
3.3.2. Organization of multienzyme reaction pathways 
The metabolism of living systems involves complex synthetic pathways with numerous multistep 
reactions that possess extraordinary yields and specificities. Many enzyme systems carrying out these 
reaction pathways are highly organized complexes with precisely controlled enzyme positions and 
orientations, facilitating efficient diffusion of substrates between the enzymes.
1
 Artificial synthesis of 
these multienzyme systems is generally achieved by genetic fusion,
11
 chemical cross-linking and 
coimmobilization;
12
 however, precise control over spatial organization of components is lacking for 
these methods. With DNA nanostructures as assembly scaffolds, it has become feasible to organize 
multiple enzymes with controlled spacing in linear as well as 2D or 3D geometric patterns, which 
enables the study of cascade activity.
13
 One of the first demonstration was the assembly of a 
bioenzymatic NAD(P)H:FMN oxidoriductase and luciferase cascade on a double-stranded DNA 
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scaffold with an observed ~3fold increase in activity compared with the corresponding unassembled 
enzyme pair (Figure 13 A).
14
 
 
 
 
 
 
 
 
 
 
Figure 13: DNA/RNA nanostructures for engineering multienzyme systems. A linear double-stranded DNA scaffold for (A) assembling 
an enzyme cascade, NAD(P)H:FMN (NFOR) oxidoreductase and luciferase (Luc), and (B) evaluating the distance-dependent activity of 
cytochrome P450 BM3 by varying the spacing between the BMR reductase domain and the BMP porphyrin domain. (C) Two-
dimensional DNA strip for organizing GOx/HRP cascades. (D) In vivo assembly of RNA nanostructures to organize the [FeFe]-
hydrogenase and ferredoxin enzyme pathway for improved hydrogen production. (E) Organization of a GOx/HRP cascade on DNA 
origami tiles with controlled spatial positions (top), and a protein bridge for facilitating surface-limited intermediate diffusion between 
enzymes (bottom).  
 
This strategy was later applied to probing the distance-dependent activity of multi-domain complexes 
of cytochrome P450 BM3 by varying the length of spacing scaffolds between the BMR reductase 
domain and the BMP porphyrin domain (Figure 13 B).
15
 Two-dimensional DNA nanostructures 
provide an even greater opportunity to organize multienzyme systems into more complicated geometric 
patterns. There was a report of the self-assembly of a glucose oxidase (GOx) and horseradish 
peroxidase (HRP) enzyme cascade on 2D hexagonal DNA strips, with the distance between the two 
enzymes controlled by the underlying nanostructure (Figure 13 C).
16
 A greater than 10-fold activity 
enhancement was observed compared with the corresponding unstructured enzymes. In addition to in 
vitro assembly, multienzyme pathways can also be organized by introducing nucleic acid 
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nanostructures as assembly scaffolds in vivo, an approach facilitated by recent advances in RNA 
nanotechnology.
17
 This idea was demonstrated by the assembly of an intracellular reaction pathway 
([FeFe]-hydrogenase and ferrexodin) for enhancing bacterial hydrogen production.
18
 In Figure 13 D, 
discrete, 1D and 2D RNA scaffolds were assembled in vivo through the incorporation of aptamers for 
capturing the target enzyme cascade. Remarkably, a 48-fold enhancement of hydrogen production was 
observed for the RNA-templated [FeFe]-hydrogenase and ferroxidin network. This work suggests that 
a metabolic engineering approach can be used to introduce structural nucleic acid nanostructures inside 
cells for the organization of multienzyme reaction pathways. Recently, a GOx/HRP cascade was 
organized on DNA origami tiles with precisely controlled spatial positions, which was applied to 
investigating the distance-dependent interenzyme substrate diffusion (Figure 13 E).
19
 The study 
revealed that substrate transfer between enzymes might occur at the connected hydration shells for 
closely paced enzymes and demonstrated this idea by constructing a protein bridge to facilitate the 
intermediate transfer across protein surfaces. 
 
3.3.3. Orthogonal adaptors for site-specific protein positioning on DNA origami 
Methods to attach proteins at specific locations on DNA scaffolds have been reported and include those 
based on antibody–antigen interactions,20-23 aptameric binding,24,25 Ni-NTA–hexahistidine 
interactions,
26-28
 and biotin–avidin interactions.29-35 Orthogonal targeting of specific locations can also 
be achieved by hybridization with DNA-tethered proteins,
36-39
 sequence-specific DNA binding of 
pyrrole-imidazole polyamides,
40-42
 and self-ligating protein tags.
43,44
 Many of these methods require 
modification of the protein. Therefore, a method that is fully based on protein components would 
accelerate the specific assembly of proteins on the DNA nanoarchitecture. Morii et al. reported that 
different locations within DNA-origami structures could be site-specifically and orthogonally targeted 
by using sequence-specific DNA-binding proteins as an adaptor, and demonstrated that adaptor-fused 
functional proteins are assembled at specific locations within DNA-origami structures. Zinc-finger 
proteins (ZFPs) are one of the best characterized classes of DNA-binding proteins;
45,46
 designed, 
artificial ZFPs bind to a wide variety of DNA sequences.
47-52
 Each zinc-finger domain is capable of 
recognizing a tract of four base pairs in the major groove of a DNA duplex. A three-fingered protein 
recognizes a tract of ten base pairs with nanomolar affinity. Two well-characterized ZFPs, zif268
53
 and 
AZP4,
54
 each with an affinity for a unique sequence of ten base pairs in the low nanomolar range, were 
chosen as the orthogonal adaptors for specific locations in the DNA-origami structures. Each ZFP was 
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engineered to possess an N-terminal cysteine residue (C-zif268 and C-AZP4) as a selective chemical 
modification site (Figure 14).  
 
 
 
 
 
 
 
Figure 14 a) Illustrations showing the structure of the zinc-finger adaptors and adaptor-fused proteins. b) A structural image of the DNA- 
origami structures. The addressable cavities are indicated by the numbers I, II, III, IV, and V. The positions of the addresses (binding 
sites) of zinc-finger adaptors are indicated by asterisks. Bp=base pairs. c) Nucleotide sequences for the specific binding site of the zinc- 
finger adaptors. 
 
ZFPs turned out to be convenient and site-selective adaptors for targeting specific locations within 
DNA-origami structures. The diversity of target DNA sequences and the semi-programmable design of 
ZFPs offers orthogonal adaptors, thereby enabling the placement of multiple engineered proteins at 
different locations onto DNA-origami structures. Nature uses multiple proteins and/or enzymes in close 
proximity to efficiently carry out chemical reactions and signal transductions. Such assemblies of 
multiple proteins may be realized in vitro by using DNA-origami structures that have defined binding 
sites and various kinds of ZFP adaptor-fused proteins.
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3.4. Objectives and challenges  
 
 
 
 
 
 
 
                                 Figure 15: Schematic illustration of covalently linked RNPs arranged on DNA origami 
 
Receptor clusters are important sources of information related to biological processes and complex 
metabolic functions of the cell. The presence of biologically relevant functional modules in these 
networks has been theorized but up-to-date the availability of in vitro reproducible models to study this 
phenomenon is limited. In this project we approached the issue of constructing reproducible clusters of 
ATP-binding RNP receptors with varied distances and combinations outside the cell, using DNA 
origami technology. As previously mentioned, DNA origami technology
1
 presents the unique feature of 
fully addressable nanoarchitectures that are easily designed and constructed. By taking advantage of 
their addressable nature, DNA nanostructures have been used as one of the ideal scaffolds for the site-
directed assembly of multiple proteins at specific locations on a DNA origami scaffold, termed as 
molecular switchboard.
2,3
 The molecular switchboard strategy is also applicable to construct nano-
assembled clusters of fluorescent sensors on DNA origami. ATP selective biosensors based on 
ribonuceopeptide (RNP) that consist of a noncovalent complex of ATP-binding RNA and a 
fluorophore-labeled peptide
4
 were described in chapter 2.
 
Covalently linked fluorescent RNP sensors 
enabled ligand detection at a low sensor concentration.
4
 We have constructed molecular switchboards 
with programmable placement of multiple ATP-binding biosensors at defined locations on DNA 
origami.  
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3.5. Strategy for assembling covalently linked RNP receptors on DNA origami 
 
3.5.1. Tag design 
The versatility of biomolecular recognition supports the high-affinity, high-specificity recognition of an 
enormous range of molecular targets. Despite these positive attributes, biological recognition exhibits a 
potentially significant limitation: the physics of single-site binding produces a hyperbolic dose-
response curve for which the useful dynamic range spans a fixed change in target concentration. 
Specifically, the transition from 10% to 90% site occupancy requires a fixed 81-fold span of target 
concentration (Figure 16).  
                    
 
 
 
 
 
 
 
 
 Figure 16: Using nature’s tricks to extend or narrow the fixed dynamic ranges of single-site receptors. Top: The dynamic range of 
sensors with a single-site receptor spans an 81-fold range of target concentration over which the sensor response transits from 10% to 
90% of its signal output. Bottom: This useful dynamic range can be extended by combining multiple receptors differing in their affinity 
for the same target. 
This fixed dynamic range complicates the use of biosensors in many applications, for instance they are 
poorly suited for applications requiring the very precise measurement of target concentration or the 
therapeutic indices of many drug, that are often less than an order of magnitude.
6,7
 Faced with the 
above limitations, evolution has invented a number of simple mechanisms by which the normally fixed 
dynamic range of single-site binding can be extended, narrowed or otherwise “edited” to better ensure 
the survival of an organism. For example, in order to create extended or even more complex three-state 
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dose-response sensing systems, evolution often employs pairs of closely related receptors.
8,9
 This 
project has the aim to expand the potential applicability of a system of affine receptors arranging a 
detection field on DNA origami surface.  
Four ATP specific RNA receptors, previously isolated by in vitro selection by Morii et al., presenting a 
wide range spectrum of affinity towards the target, were selected. Respectively An16, A26, An15 and 
A17 (KD values reported in the box) which nucleobase sequences are reported in Figure 17. 
 
 
                                       Figure 17: ATP specific RNP receptors nucleic base sequences. KD values are reported in the box.
 
 
In order to locate the RNP receptors with precise positioning on DNA origami, the RNA modules were 
modified by a DNA-complementary tag at the 5’ terminal. With the aim of avoiding interferences with 
the target binding region and to guarantee the proper folding of the RNA structure, the orthogonal 4 
types of tag sequences were designed as follows. 
A26 
Aptamer sequence: 
GGUCUGGGCGCAUUCCGGUAGUGGUUGUGUGUGUGCGGUUUUUGACGGUACAGGCC 
Complementary sequence:  
GGC CUG UAC CGU CAA AAA CCG CAC ACA CAC AAC CAC UAC CGG AAU GCG CCC AGA CC 
Complementary  Reverse sequences:  
CCA GAC CCG CGU AAG GCC AUC ACC AAC ACA CAC ACG CCA AAA ACU GCC AUG UCC GG 01 
CC AGA CCC GCG UAA GGC CAU CAC CAA CAC ACA C AC GCC A AA A AC UGC CAU GUC CGG 02 
C CAG ACC CGC GUA AGG CCA UCA CCA ACA CAC ACA CGC CAA AA A CUG CCA UGU CCG G 03 
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Start sequence    GGA or GGU 
Aversive Sequence CAN, ACN, CGN, GAC, CCR, 
GCS, AAM 
Potential Aversive Sequence   
UAN, UGN, GCN, GUN, AUN, GAU, UCR, CUR, UUR, 
GGN, AAN, AGN, GAN 
W: A,T (U)R:A,G  M: A, C  K: T(U), G  Y: T(U), C  S: G, 
C  
H: A, C, T (U)  B: G, C, T(U)  V: A, G, C  D: A, G, T(U) 
N: A, G, C, T (U) 
Blue: aversive sequence 
Frequency-indicated Aversive Sequence ⇒ Frequency-indicated Potential Aversive Sequence 
 5 CAC     YRY 
 4 CCA, ACA    YYR, RYR 
 3 AAA, GCC    RRR, RYY 
 2 ACC, CAU, CAA, CCG, CGC  YRU, YRR, YYG, YGY 
 
Sequence Component  GGA UUN UAB GGD CUH 
Add Frequency Aversion GGA UUN UAR GGY CUH (green: deliberate permission) 
Example1 GGA UUC GGC UAA CUAGGCUUG4A 6U :4C 7G (10:11):total 21  
          GGA UAAUUC GGCGGCCUAUG4A 5U :4C 7G (9:11):total 20 
 
A nucleobase sequence analysis was carried out evaluating the composition and the frequency with 
which the base combinations (considered as codons pairings) appear in the aptamer sequence. The less 
frequent combinations were selected as potential candidates for the tag framework design. As second 
selection criterion, the melting temperature, the process by which the interactions between the strands 
of the double helix are broken, separating the two nucleic acid strands, was taken in consideration. 
T and A rich sequences are more easily melted than C and G rich regions stabilized by the formation of 
three hydrogen bonds. These mechanical features are reflected by the use of sequences such 
Total
A U C G
A
AAA (3)
AAC (2)
AUC
AUG
ACC (2)
ACA (4)
ACG
ACU
AGG
AGA
U UAA
UUG
UUA
UCA
UCG
UCC
UGU
UGC
C
CAG
CAU (2)
CAC
CAA (2)
CUG
CUA
CCA (4)
CCG (2)
CCC
CGC (2)
CGG
CGU
G
GAC (5)
GAU
GUA
GUC
GCG
GCC (3)
GGC
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as TATAA at the start of many genes to assist RNA polymerase in melting the DNA for transcription. 
It was set to keep the melting temperature above 55ºC in order to obtain a RNA sequence sufficiently 
stable (See material and methods). Successively, in order to verifying that the tag moiety has no 
interference with the correct folding of the RNA module,  a software simulation was performed 
(Figure 18). 
Tag: GGAUAAUUCGGCGGCCUAUG 
GGUCUGGGCGCAUUCCGGUAGUGGUUGUGUGUGUGCGGUUUUUGACGGUACAGGCC 
 
 
 
 
 
 
 
 
Furthermore, the necessity of handling nanomolar order concentrations required the creation of 
covalently linked RNPs sensors (cRNPs).
5
 As previously reported in chapter 2, an hydrazine 
functionalized poly glycine chain was inserted at the C-terminus of the 5-carboxyfluorescein (5FAM) 
modified-Rev peptide and the coupling reaction occurred through a six member ring formation on the 
3’-terminal ribose on the RRE RNA subunit.  
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3.5.2. DNA origami scaffold design  
A rectangular DNA-origami structure (100nm x 96nm) that has five addressable cavities, has been 
proven to be a useful scaffold for locating RNP biosensors at specific addresses and modifying sensors 
population distribution: the circles represent the distance distribution from the center, varying he tag 
disposition is possible to increase or diminish the receptors density around the central cavity (Figure 
19). On the left side above an hairpin motif was introduced as topological marker.  
 
 
 
 
 
 
 
 
                                         Figure 19: 5well-frame rectangular DNA origami scaffold design 
With the aim of analyzing the clustering effect of ATP receptors on their affinity towards the target, 
different DNA origami switchboards were designed varying the number of binding sites located around 
the central cavity. Respectively, 4, 6, 12 and 18 binding sites (Figure 20).  
 
 
 
 
                                 Figure 20: Density variation of cRNP sensors population around the central cavity on DNA origami 
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3.5.3. Atomic force microscope (AFM) analysis 
3.5.3.1. Theory 
Atomic force microscopy (AFM) was invented by Binnig et al. in 1986.
10
 AFM is being used 
increasingly for the study of biomacromolecules at the single-molecule level.
10-12
 It is a force-based 
technique that works by scanning the surface of the sample using the sharp tip of a cantilever. For 
imaging, the sample must be immobilized on a ﬂat surface such as mica, glass, highly oriented 
polygraphite, or gold-coated surfaces. Topographical images are produced by monitoring the deﬂection 
of the cantilever caused by the tip-sample interactions during raster scanning of the tip over the surface. 
AFM is operated usually in three diﬀerent modes: contact, tapping, and noncontact. Originally, samples 
were imaged in contact mode.
10
 However, the contact mode is unsuitable for analysis of less robust 
biological samples, such as proteins, because the continuous contact between the tip and the sample 
leads to damage of the sample, which also often detaches from the surface on which it is adsorbed. In 
1993, the tapping mode was invented,
13
 in which the cantilever oscillates at a constant frequency and 
the tip-sample interaction is considerably reduced. Studies using tapping mode have demonstrated that 
it is highly eﬀective for nondestructive imaging of biological samples. A schematic diagram of the 
instrumentation of a typical tapping-mode AFM is given in Figure 21. At the early stage of AFM, 
analysis was performed only in air. Observation in liquid was ﬁrst reported in 1987, when researchers 
imaged the surface of a sodium chloride crystal in a paraﬃn oil environment.14 Later developments 
produced a method suitable for single-molecule analysis of biomolecules in physiologically relevant 
solutions. 
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                         Figure 21: Graphical representation of the components and a typical instrumental setup of AFM.  
 
Despite the success of AFM in imaging protein structure, detailed investigations of the structural 
dynamics of proteins have been hampered by the intrinsically slow scanning speed of conventional 
AFM. The scanning rates of commercially available AFM instruments usually range from several 
seconds to several minutes per frame, whereas biological reactions occur on the sub-second time scale 
or even faster. Several improvements have been implemented to achieve an AFM instrument that is 
much faster and compatible with the study of biological samples.
15-20
 The early stage of AFM 
development was carried out by Hansma et al.,
16,21
 who published the first report on application of 
AFM with improved scanning speed to study biomolecular activity in real-time.
17
 Developments of 
Quate et al. led to imaging of a large area in a single scan.
22,23
 Developments of the components for 
high-speed (HS) AFM were also reported by Fantner et al.
19
 and Kindt et al. However, these 
improvements alone were insufficient to enable a HS-AFM that would revolutionize biomolecular 
analysis. One of the key breakthroughs for enabling HS-AFM was the use of small cantilevers.
24
 Also, 
the design of stiff and compact piezo scanners in combination with methods from control theory have 
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improved the imaging speed.
25
 Work by Ando et al. improved the performance of several components, 
including the cantilever, scanning stage, amplitude-to-dc converter, and dynamic PID controller. These 
developments culminated in realization of a first-generation HS-AFM instrument with an image 
acquisition speed of 12.5 frames/s.
26,27
 Further developments enhanced the image acquisition speed and 
led to construction of a second-generation HS-AFM instrument with a scan speed of 20 
frames/s.
28
 Developments continued, and current laboratory-built HS-AFM instruments can record a 
movie with an imaging speed of 33 frames/s and temporal and spatial resolutions compatible with the 
dynamic analysis of biological samples.
29,30 
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3.5.3.2. cRNP sensors binding ability confirmation on DNA origami 
The general approach for DNA origami annealing procedure requires preparing a solution of M13 
(10nM), the staple strands mixture (5eq.) in DNA origami buffer (40mM Tris-HCl, 20mM acetic acid, 
12.5mM MgCl2) at pH 8.30. The solution so obtained is heat-shocked at 95ºC for 1minute and 
successively cooled down at 53ºC, the temperature is maintained stable for 30 minutes-1 hour in order 
to permit the annealing process and then reduced at 4ºC. Samples are purified by size-exclusion 
chromatography to get rid of excess amount of staple strands and analyzed by AFM image (Figure 22).  
 
                           Figure 22: High speed AFM image of rectangular 5-well-frame DNA origami after purification 
In order to hybridize cRNPs sensors on DNA origami, two protocols were adopted. The first one 
consists into two separated steps: first DNA origami was annealed (at pH 7.60) and purified by gel 
size-exclusion chromatography; in a second time the hybridization process was carried out incubating 
DNA origami with 3 equivalent of RNP sensors starting from 40⁰C and decreasing the temperature 
with a ramp rate of 0.1⁰C/3 secs. DNA origami hybridized was purified a second time by gel size-
exclusion chromatography in order to remove the excess amount of non-hybridized cRNPs. An 
optimized protocol consists in a one-pot reaction in which DNA origami annealing and cRNPs 
hybridization are carried out in a time-product saving manner (Figure 23).  
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                                                    Figure 23: PCR machine set up optimized for the one-pot reaction 
 
The cRNPs sensors (3eq.) are directly added to the DNA origami mixture after the heat-shock process; 
the annealing and hybridizations events occurs consecutively without need of intermediate purification 
steps. 
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The cRNPs sensors binding ability on DNA origami was confirmed both by gel image and AFM 
measurement as shown in Figure 24 and Figure 25. 
 
 
 
 
 
 
 
 
                      Figure 24: AFM image of rectangular 5-well-frame DNA origami hybridized with cRNPs (12 binding sites) 
 
 
 
 
 
 
 
 
 
 
         Figure 25: AFM image of rectangular 5-well-frame DNA origami hybridized with cRNPs (4 binding sites at the central cavity) 
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The AFM measurements, performed at pH 7.60,  show the presence of clusters of cRNP sensors around 
the central cavity on DNA origami as expected; an increase of height around 1nm is also observed. 
Even though it was possible to discriminate between 12, 18 and four binding sites analyzing AFM 
images (Figure 26), the image resolution doesn’t permit to evaluate the exact number of cRNPs bound. 
For this reason the binding yield was calculated by volume analyses on gel image (Figure 27). This 
technique also allowed us to evaluate the specificity of the binding event and its covalently nature not 
provable from AFM analyses. It was observed that the one pot reaction method produced DNA origami 
well formed and a binding yield ability around 85%. The non specific biding percentage, around 4%, 
can be considered negligible.    
 
Figure 26: On the left side, schematic illustration of the binding sites distribution on DNA origami. In the centre, AFM image of 
hybridized cRNPs on DNA origami and measured height. 
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cRNP F.I. on 
fluorescence 
Concentration F.I. on EtBr Origami 
concentration 
Yield 
Total F. I. on 
fluorescence 
 
U1+U2 
3eq.to DNA 
origami 
(900nM) 
   
F. I. on DNA 
origami 
(without 
purif.) 
 
U1 
Proportional 
to 3eq. 
(174uM) 
 
U4 
    
        10nM 
       96.8% 
  
(174.4/180)  
 
F. I. on DNA 
origami 
(with purif.) 
 
U3 
Proportional 
to U1 
 
U5 
Proportional 
to origami 
concentration 
       
87% 
 
 
Figure 27: Yield evaluation on gel image: The Fluorescence image (Exc. Wv. 488nm) revealed the presence of 5-FAM tethering-cRNPs, 
the  ethidium bromide (EtBr) image corresponds to the  DNA origami staining. The overlaid image shows that the sample contains both 
222 
 
DNA origami and cRNPs giving confirmation of the effective hybridization event (yellow color). Moreover, calculating the fluorescence 
intensity of each band before and after purification, it is possible to evaluate the binding yield on DNA origami.  
 
3.5.4. Orthogonal binding ability confirmation 
With the aim of varying not only the sensors density but also combining different sensors on the same 
DNA origami platform, four different tags were designed. To confirm the orthogonal binding ability of 
our designed tag a gel image study was carried out. In the following example, An16 tag04 cRNP was 
incubated with both, tag01-modified DNA origami and tag04-modified DNA origami. Only in the 
presence of the complementary tag04 a successful hybridization event was observed (Figure 28).  
Figure 28: Orthogonal binding ability check on gel image. On the left side, the fluorescence image (Exc. Wv. 488nm) shows the presence 
of An16tag04 cRNP receptors. On the right side, a fluorescence/EtBr staining overlaid image confirms the presence of both DNA origami 
and cRNPs (yellow color) only in the presence of the complementary tag04 on DNA origami. In the case of tag01-modified DNA origami, 
only a red band, corresponding to the DNA alone, is observed indicating that no binding event occurred.  
 
From this study it was evicted that the four designed tag are able to bind specifically their DNA-
complementary target in an orthogonal manner. 
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3.5.5. Dissociation constant evaluation on DNA origami 
In order to explore the behavior of cRNP receptors on DNA origami, a dissociation constant study was 
performed. The KD was evaluated from ATP titration experiments on a microplate reader. DNA 
origami hybridized with cRNPs was prepared as previously reported; after gel size-exclusion 
chromatography purification, the samples were incubated 30minutes at 4ºC in the presence of 
increasing amount of ATP. Successively, they were analyzed on a plate reader (Exc. Wv. 470nm) and 
the fluorescence intensity change plotted against ATP concentration (Figure 29-32).  cRNP 
concentration was assessed by volume analysis on gel image. 
 
 
Figure 29: KD evaluation on A26tag01 cRNP. Respectively, in bulk conditions (red circle); 4 binding sites (blue triangle); 12 binding 
sites (green ribbon); 18 binding sites (purple square). 
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Figure 30: KD evaluation on An15tag02 cRNP. Respectively, in bulk conditions (red circle); 4 binding sites (blue triangle); 12 binding 
sites (green ribbon); 18 binding sites (purple square). 
 
 
Figure 31: KD evaluation on A17tag03 cRNP. Respectively, in bulk conditions (red circle); 4 binding sites (blue triangle); 12 binding 
sites (green ribbon); 18 binding sites (purple square). 
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Figure 32: KD evaluation on An16tag04 cRNP. Respectively, in bulk conditions (red circle); 4 binding sites (blue triangle); 12 binding 
sites (green ribbon); 18 binding sites (purple square). 
 
cRNP/KD (µM)  Bulk conditions  
On DNA origami 
4 binding sites  
On DNA origami 
12 binding sites  
On DNA origami 
18 binding sites  
A26 tag01  142 56  48  47  
A17 tag03  13.3 32.5 39  45 
An15 tag02  0.8 1.5 5.1 6.2 
An16 tag04  2.3  4.6  9.2  10.5  
 
From this analysis it is evicted that the ATP binding affinity of covalent RNPs is retained after 
hybridization on DNA origami. Moreover a change in the KD behavior is noticeable when the cRNP 
receptors are hybridized on DNA origami.  A similar tendency could be underlined for An16tag04, 
An15tag02 and A17tag03. A26tag01, on the contrary, shows an opposite behavior. In order to acquire a 
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deeper understanding of the cluster effect on cRNPs receptors on DNA origami, a kinetic study was 
performed.  
3.5.6. Kinetic measurements on DNA origami 
Kinetic studies were carried out on A26tag01 and An16tag04 cRNPs evaluating the kinetics of the 
ligand binding event upon ATP titration in bulk conditions, on DNA origami 18 binding sites, 12 
binding sites and 6 binding sites. The experiments were performed on a microplate reader; after 30 
minutes incubation at room temperature, ATP was added and immediately the spectra recorded at 
525nm (λMAX). The obtained saturation curves show that the ligand-binding event is a slow process that 
reaches saturation around 1 hour (from Figure 33 to Figure 42). 
 
 
 
 
 
 
 
 
Figure 33: Fluorescence intensity change spectra upon ATP titration on An16tag04 in bulk conditions (ATP concentration range: 0 µM; 
0.1 µM; 0.5 µM; 1 µM; 5 µM; 10 µM; 25 µM ). Kd evaluated at the saturation point.  
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Figure 34: Fluorescence intensity change spectra upon ATP titration on An16tag04 on DNA origami 6 binding sites (ATP concentration 
range: 0 µM; 0.1 µM; 0.5 µM; 1 µM; 5 µM; 10 µM; 25 µM ). Kd evaluated at the saturation point.  
 
 
 
 
 
 
 
 
 
Figure 35: Fluorescence intensity change spectra upon ATP titration on An16tag04 on DNA origami 12 binding sites (ATP concentration 
range: 0 µM; 0.1 µM; 0.5 µM; 1 µM; 5 µM; 10 µM; 25 µM ). Kd evaluated at the saturation point.  
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Figure 36: Fluorescence intensity change spectra upon ATP titration on An16tag04 on DNA origami 18 binding sites (ATP concentration 
range: 0 µM; 0.1 µM; 0.5 µM; 1 µM; 5 µM; 10 µM; 25 µM ). Kd evaluated at the saturation point.  
 
 
Figure 37: Total KD evaluation on An16tag04. Respectively, red circles (bulk conditions); green ribbons (6 binding sites);  blue triangles 
(12 binding sites); purple squares (18 binding sites). 
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Figure 38: Fluorescence intensity change spectra upon ATP titration on A26tag01 bulk conditions (ATP concentration range: 0 µM; 10 
µM; 25 µM; 50 µM; 100 µM; 150 µM; 200 µM; 300 µM; 500 µM). Kd evaluated at the saturation point.  
 
 
 
 
 
 
 
 
 
Figure 39: Fluorescence intensity change spectra upon ATP titration on A26tag01 on 6 binding sites (ATP concentration range: 0 µM; 10 
µM; 25 µM; 50 µM; 100 µM; 150 µM; 200 µM; 300 µM; 500 µM). Kd evaluated at the saturation point.  
 
 
 
 
 
230 
 
 
 
 
 
 
 
 
Figure 40: Fluorescence intensity change spectra upon ATP titration on A26tag01 on 12 binding sites (ATP concentration range: 0 µM; 
10 µM; 25 µM; 50 µM; 100 µM; 150 µM; 200 µM; 300 µM; 500 µM). Kd evaluated at the saturation point.  
 
 
 
 
 
 
 
 
Figure 41: Fluorescence intensity change spectra upon ATP titration on A26tag01 on 18 binding sites (ATP concentration range: 0 µM; 
10 µM; 25 µM; 50 µM; 100 µM; 150 µM; 200 µM; 300 µM; 500 µM). Kd evaluated at the saturation point.  
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Figure 42: Total KD evaluation on A26tag01. Respectively, red circles (bulk conditions); green ribbons (6 binding sites);  blue triangles 
(12 binding sites); purple squares (18 binding sites). 
 
The KD values, obtained from the data at the saturation point (3600 seconds), are consistent with the 
results achieved from the ATP titrations previously performed after incubation at 4 degree Celsius.  
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3.6. Conclusions 
As discussed in chapter 2, stepwise manner constructed covalently linked RNP receptors allowed ATP 
detection at low concentration. In this work we designed molecular switchboards with programmable 
placement of multiple ATP-binding biosensors at defined locations on DNA origami by using sequence 
specific tags as adaptors. The structure of molecular switchboard was confirmed by AFM analyses and 
the tag specificity was evaluated trough gel image studies. The fluorescent responses of the ATP-
binding molecular switchboards revealed that the cRNP receptors maintain their activity once 
hybridized with DNA origami. Moreover, varying the receptors density a change in the sensitivity 
towards the target was observed. Receptors localization and clustering may have a dramatic influence 
on signaling. This phenomenon aroused a huge interesting in scientific environments but unfortunately, 
nowadays, the availability of in vitro models for studying receptors cluster effect are very limited. 
Molecular switchboard based on DNA origami may represent a convenient tool for analyzing receptors 
clusters outside the cell. In order to acquire a deeper understanding of the cluster effect on cRNP 
receptors on DNA origami, a kinetic study will be performed. Furthermore, a future development of 
this project considers the combination of receptors presenting different sensitivity towards the target on 
the same switchboard with the purpose to analyze how this might affect the target binding curve.  
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3.7. Materials and methods 
3.7.1. Materials 
DNA templates, respectively, A26tag01, An15tag02, A17tag03, An16tag04, and primers (for-A26ta01; 
for-An15tag02; for-A17tag03; for-An16tag04; Rev-S2) were purchased from Sigma Aldrich. The DNA 
amplification kit (5X Prime Star buffer (Mg
2+ 
plus); 25mM dNTP mixture; Prime Star HS DNA 
Polymerase enzyme 250U 2.5U/µl) was bought from TaKaRa. T7-Scribe Standard RNA NT Kit which 
consists of 10X T7-Scribe transcription buffer; RNase-free water; RNase-free DNase 1 enzyme 1u/µL; 
T7-Scribe enzyme; 100mM Dithiothreitol and 25mM rNTP mixture, was purchased from CellScript. 
INC. Nacalai Tesque provided 1mol/L Tris-HCl buffer solution (pH 7.60); EtOH 99.5%; Isopropanol; 
0.5M EDTA pH 8.00. TBE buffer components: Ethylenediaminetetraacetic Acid (Edetic Acid, EDTA); 
Boric Acid (Nuclease and Protease tested);Tris(hydroxymethyl)aminomethane (Neclease and Protease 
tested) and APS (Aminoperoxysufate) were obtained from Nacalai Tesque. Urea was bought from 
Wako. Sigma Aldrich supplied Oligo DNA strands for DNA origami; M13mp ss DNA was acquired 
from New England BioLabs. 
 
3.7.2. DNA amplification  
DNA template amplification solution consists of : 
30 µl 5x Prime Star buffer (Mg
2+
plus); 
12 µl 25 µM dNTP mixture; 
15 µl 20 µM for-primer; 
15 µl 20 µM Rev-S2 primer; 
73.5 µl dH2O; 
3 µl 0.2 µM  template cDNA;       
1.5 µl Prime Star HS DNA Polymerase enzyme 250U 2.5U/µl. 
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The solution was then tripartited into PCR microtubes (50µL each) In order to assess the optimum 
cycle number for DNA template amplification, a PCR cycle check was performed: protocol applied: 
98ºC 10sec→55ºC 30sec→72 ºC 30sec; 24 cycles. In the example reported in Figure 43, 16 cycles 
were selected for obtaining the pure desired DNA sequences. 
                      
            Figure 43: PCR cycle check on An16tag04 and A26tag01 DNA template. The numbers in red correspond to the cycle number. 
 
Amplified DNA was precipitate by EtOH 2.5 eq. +10% AcONa pH 5.2 (samples centrifuged for 20 
minutes at 150x100rpm); successively washed with 70% EtOH (centrifuged 15minutes at 150x100rpm) 
dried up  under vacuum and redissolved in 20µl TE buffer. The sample purity was checked by nature 
8% gel bisacrylamide gel as shown representatively in Figure 44. 
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                                                            Figure 44: DNA gel purity check 
 
3.7.3. DNA transcription 
RNA transcription mixture for 1µg DNA: 
10 µl 10xT7 reaction buffer; 
30 µl 25mM rNTP mixture; 
10 µl 100mM dtt; 
40 µl  RNase water + Template DNA; 
2.5 µl T7 enzime. 
The samples were left at 37 ºC for 3 hours and then stored at 4 ºC , to stop the reaction 1µl DNase was 
added (20min 37 ºC). RNA was extracted using a phenol/chloroform solution and then precipitated 
using EtOH. Purification was accomplished using 8% urea (6M) gel. Pure RNA was extracted using 
500µl TE buffer and centrifuged for 45min at 150x100rpm. It was, subsequently, precipitated using 2-
isopropanol and gel-filtrated on a Micro Bio-Spin 6 Chromatography Column (4 min 10x100G). The 
purity was confirmed by gel check (Figure 45). 
236 
 
 
 
 
 
 
 
 
                                                     Figure 45: RNA purity check by 8% denatured bis-acrylamide gel. 
 
3.7.4. DNA origami preparation 
DNA origami preparation procedure was amply described at page 104-105; in this chapter I will focus 
on the gel size exclusion purification step optimization. With the aim of obtaining the highest DNA 
origami purity without detrimental effects on the yield, columns presenting filters of several materials 
and different pour size were compared by 1% agarose gel image as shown in Figure 46 and Figure 47.  
  
 
 
 
 
 
 
 
                                Figure 46: 1% agarose gel image (ETBr staining) of DNA origami pre and post gel purification step 
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                          Figure 47: 1% agarose gel image (ETBr staining) of DNA origami pre and post gel purification step 
   
In a second time also the gel media was analyzed. In Figure 48 are reported three media having 
increasing porosity ranges. 
                              
                      Figure 48: 1% agarose gel image (ETBr staining) of DNA origami pre and post gel purification step 
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It could be observed that the results are almost all comparable; in this optic we decided to use the 
combination that gave us the best yield/purity ratio: S400 gel and PVDF 0.65µm column. 
 
3.7.5. ATP titration on cRNPs : KD measurement 
Covalently linked RNPs were analyzed both in bulk and on DNA origami surface in DNA origami 
buffer conditions (40mM Tris-HCl, 20mM acetic acid, 12.5mM MgCl2 +0.005%Tween 20) at pH 7.60. 
The successful hybridization event and the approximate yield were evaluated from volume analyses on 
gel image and AFM analyses. Recovered cRNPs were then incubated at 4ºC with increasing 
concentration of ATP neutralized with NaOH on a microplate platform (30µL each sample). The 
fluorescence change measurements were carried out using Tecan Infinite Pro 200 plate-reader exciting 
the samples at 470nm; The Emission spectrum was scanned  in a range from 500 to750nm at 4°C 
degree (Figure 49). 
 
 
 
 
 
 
                   Figure 49: Schematic representation of  the ATP titration experiments conducted on a microplate reader fluorimeter. 
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3.7.6.  Dissociation constant calculation 
 
The dissociation constant was achieved using Igor software, applying the following one-to-one binding 
fitting equation: 
Function Kd (w,x) : FitFunc 
 Wave w 
 Variable x 
f(x) = v_0+ v_2*(((v_3+x+v_1)-((v_3+x+v_1)
^2
-4*v_3*x)
^0.5
)/(2*v_3)) 
 
where v_0 is the initial point at 0μM ATP addition (usually considered 1 in the I/I0 plotting); v_2 
corresponds to the expected KD of the complex; v_3 is the intensity change during the titration and v_4 
represents the substrate concentration. The results in bulk conditions are consistent with the results 
previously obtained.  
 
3.7.7. Kinetics measurement  
Experimental conditions: 
- Instrument: Tecan Infinite pro 200; 
- cRNP concentration: 60nM; 
- DNA origami concentration: 10nM; 
- Gain 80; 
- Sample volume 100µl; 
- Room temperature; 
- Incubation time at room temperature: 30 minutes before adding ATP; 
- Shaking: 10sec, amplitude 2mm (orbital); 
- Fluorescent intensity measured every 30sec; 
- Exc. Wv.: 470nm; 
- Emission Wv: 525nm (λMAX); 
 
As for the KD measurements, an ATP titration was performed on Tecan microplate reader. In order to 
compare bulk conditions with 12, 18 and 4 binding sites, sample concentration was fixed at 60nM 
cRNP (corresponding to the full binding of the 6 binding sites DNA origami). Sample concentration 
was evaluated from gel image volume analyses (Figure 50). After ATP addition fluorescence changes 
measurements were immediately carried out (every 30 second for 1hour) and successively plotted 
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against ATP concentration. The ATP range scanned is 0 µM; 0.1 µM; 0.5 µM; 1 µM; 5 µM; 10 µM; 25 
µM (An16tag04) and 0 µM; 10 µM; 25 µM; 50 µM; 100 µM; 150 µM; 200 µM; 300 µM; 500 µM 
(A26tag01). 
An16tag04 18 b.s. A26tag01 18 b.s. 
 
 
 
 
 
 
 
M: marker; 
1, 4: DNA origami without cRNP; 
2,5: DNA origami with cRNP 
Before purification; 
3,6: DNA origami with cRNP after 
purification.  
Yield: An16: 81%;  A26: 87% 
 
Figure 50: Gel image analyses of An16tag04 and A26tag01 on DNA origami 18 binding sites. From the top: EtBr staining (left side); 
fluorescence image (right side) and overlaid image (on the bottom).    
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